инспиноны висач

#### INTERNATIONAL A CATION PUBLISHED UNDER THE I

### NT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/52, C12P 17/18, 17/10, C12N 9/00, 1/21, 15/70, C12Q 1/68

A1

(11) International Fablication Number:

WO 98/07868

(43) International Publication Date: 26 February 1998 (26.02.98)

EP

(21) International Application Number:

PCT/EP97/04495

(22) International Filing Date:

18 August 1997 (18.08.97)

(30) Priority Data:

20 August 1996 (20.08.96) 96810551.0

(34) Countries for which the regional or international application was filed:

DE et al.

(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): SCHUPP. Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). TOUPET, Christiane [FR/FR]; 12/5, rue de l'Ours, F-68200 Mulhouse (FR). ENGEL, Nathalie [FR/FR]; 29, rue de la Doller, F-68260 Kingersheim (FR).
- (74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR. LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH. KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR. GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

### (54) Title: RIFAMYCIN BIOSYNTHESIS GENE CLUSTER

#### (57) Abstract

The present invention primarily relates to a DNA fragment which is obtainable from the gene cluster responsible for rifamycin biosynthesis within the genome of Amycolatopsis mediterranci, and comprises at least one gene or a part of a gene which codes for a polypeptide which is directly or indirectly involved in the biosynthesis of rifamycin, and to a method for preparing said DNA fragment. The present invention furthermore relates to recombinant DNA molecules which comprise one of the DNA fragments according to the invention, and to the plasmids and vectors derived therefrom. Host organisms transformed with said plasmid or vector DNA are likewise embraced.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Słovenia	
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia	
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal	
AU	Australia	GA	Gabon	LV	Latvis	SZ	Swaziland	•
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad	
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo	
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan	
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan	
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey	
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago	
BJ	Benip	IE.	ireland	MN	Mongolia	UA	Ukraine	
BR	Brazil	IL	Israel	MR	Mauritania	UĢ	Uganda	
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America	٠
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan	
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam	
CG	Congo	KE	Кепув	NL	Netherlands	YU	Yugoslavia	
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe	
CI	Côte d'Ivoire	KP	Democratic People's	NZ.	New Zealand			
CM.	Cameroon		Republic of Korea	PL	Poland			
CN	China	KR	Republic of Korea	PT	Portugal			
CU	Cuba	ΚZ	Kazakstan	RO	Romania			
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation			
DE	Germany	LI	Liechtenstein	SD	Sudan			
DK	Denmark	LK	Sri Lanka	SE	Sweden			
EE	Estonia	LR	Liberia	SG	Singapore			



Rifamycins form an important group of macrocyclic antibiotics (Wehrli, Topics in Current Chemistry (1971), 72, 21-49). They consist of a naphthoquinone chromophore which is spanned by a long aliphatic bridge. Rifamycins belong to the class of ansamycin antibiotics which are produced by several Gram-positive soil bacteria of the actinomycetes group and a few plants.

Ansamycins are characterized by a flat aromatic nucleus spanned by a long aliphatic bridge joining opposite positions of the nucleus. Two different groups of ansamycins can be distinguished by the structure of the aromatic nucleus. One group has a naphthoquinoid chromophore, with the typical representatives being rifamycin, streptovaricin, tolypomycin and naphthomycin. The second group, which has a benzoquinoid chromophore, is characterized by geldanamycin, maytansines and ansamitocines (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). In contrast to antibiotics of the macrolide type, the ansamycins contain in the aliphatic ring system not a factone linkage but an amide linkage which forms the connection to the chromophore.

The discovery of the rifamycins produced by the microorganism Streptomyces mediterranei (as the organism was called at that time, see below) was described for the first time in 1959 (Sensi et al., Farmaco Ed. Sci. (1959) 14, 146-147). Extraction with ethyl acetate of th acidified cultures of Streptomyces mediterranei resulted in isolation of a mixture of antibiotically active components, the rifamycins A, B, C, D and E. Rifamycin B, the most stable component, was separated from the other components and isolated on the basis of its strongly acidic properties and ease of salt formation.

Rifamycin B has the structure of the formula (1)

$$\begin{array}{c} CH_3COO \\ CH_3O \\ CH_3 \\ OH \\ OH \\ OH \\ OH_3 \\ OH \\ OH_3 \\ OH \\ OH_3 \\ O$$

Rifamycin B is the main component of the fermentation when barbiturate is added to the fermentation medium and/or improved producer mutants of *Streptomyces mediterranei* are used.

The rifamycin producer strain was originally classified as Streptomyces mediterranei (Sensi et al., Farmaco Ed. Sci. (1959) 14, 146-147). Analysis of the cell wall of Streptomyces mediterranei by Thiemann et al. later revealed that this strain has a cell wall typical of Nocardia, and the strain was reclassified as Nocardia mediterranei (Thieman et al. Arch. Microbiol. (1969), 67 147-151). Nocardia mediterranei has been reclassified again on the basis of more recent accurate morphological and biochemical criteria. Based on the exact composition of the cell wall, the absence of mycolic acid and the insensitivity to Nocardia and Rhodococcus phages, the strain has been assigned to the new genus Amycolatopsis as Amycolatopsis mediterranei (Lechevalier et al., Int. J. Syst. Bacteriol. (1986), 36, 29).

Rifamycins have a strong antibiotic activity mainly against Gram-positive bacteria such as mycobacteria, neisserias and staphylococci. The bactericidal effect of rifamycins derives from specific inhibition of the bacterial DNA-dependent RNA polymerase, which interrupts RNA biosynthesis (Wehrli and Staehelin, Bacteriol. Rev. (1971), 35, 290-309). The semisynthetic rifamycin B derivative rifampin (rifampicin) is widely used clinically as antibiotic against the agent causing tuberculosis, *Mycobacterium tuberculosis*.

The naphthoquinoid ansamycins of the streptovaricin and tolypomycin group show, like rifamycin, an antibacterial effect by inhibiting bacterial RNA polymerase. By contrast, naphthomycin has an antibacterial effect without inhibiting bacterial RNA polymerase. The

benzoquinoid ansamycins show no inhibition of bacterial RNA polymerase, and they therefore have only relatively weak antibacterial activity, if any. On the other hand, some representatives of this class of substances have an effect on eukaryotic cells. Thus, antifungal, antiprotozoal and antitumour properties have been described for geldanamycin. On the other hand, antimitotic (antitubilin), antileukaemic and antitumour properties are ascribed to the maytansines. Some rifamycins also show antitumour and antiviral activity, but only at high concentrations. This biological effect thus appears to be nonspecific.

Despite the great structural variety of the ansamycins, their biosynthesis appears to take place by a metabolic pathway which contains many common elements (Ghisalba et al. Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). The aromatic nucleus for all ansamycins is probably built up starting from 3-amino-5-hydroxybenzoic acid. Starting from this molecule, which is presumably activated as coenzyme A, the entire aliphatic bridge is synthesized by a multifunctional polyketide synthase. The length of the bridge and the processing of the keto groups, which are initially formed by the condensation steps, are controlled by the polyketide synthase. To build up the complete aliphatic bridge for rifamycins, 10 condensation steps, 2 with acetate and 8 with propionate as building blocks, are necessary. The sequence of these individual condensation steps is likewise determined by the polyketide synthase. Structural comparisons and studies with incorporation of radioactive acetate and propionate have shown that the sequence of acetate and propionate incorporation for the various ansamycins takes place in accordance with a scheme which appears to be identical or verv similar in the first condensation steps. Thus, from a common synthesis scheme of the ansamycin polyketide synthases (the rifamycin synthesis scheme), the syntheses of the various ansamycins sooner or later branch off, in accordance with their structural difference from the rifamycin structure, into side branches of the synthesis (Ghisalba et al.. Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327).

Because of the great structural variety of the rifamycins and their specific and interesting biological effect, there is great interest in understanding the genetic basis of their synthesis in order to create the possibility of specifically influencing it. This is particularly desirable because, as explained above, there is much in common between the synthesis of rifamycins and that of other ansamycins. This similarity in the biosynthesis, which probably derives from a common evolutionary origin of this metabolic pathway, naturally has a genetic basis.

The genetic basis of secondary metabolite biosynthesis essentially exists in the genes which code for the individual biosynthetic enzymes, and in the regulatory elements which control the expression of the biosynthesis genes. The secondary metabolite synthesis genes of actinomycetes have hitherto been found as clusters of adjacent genes in all the systems investigated. The size of such antibiotic gene clusters extends from about 10 kilobases (kb) up to more than 100 kb. The clusters often contain specific regulator genes and genes for resistance of the producer organism to its own antibiotic (Chater, Ciba Found, Symp. (1992), 171, 144-162).

The invention described herein has now succeeded, by identifying and cloning genes of rifamycin biosynthesis, in creating the genetic basis for synthesizing by genetic method: rifamycin analogues or novel ansamycins which combine structural elements from rifamycin with other ansamycins. This also creates the basis for preparing novel collections of substances based on the rifamycin biosynthesis gene cluster by combinatorial biosynthesis.

It was possible in a first step to identify and clone a DNA fragment from the genome of A. mediterranei, which shows homology with known polyketides synthase genes. After obtaining the sequence information from this DNA fragment which confirmed a typical sequence for polyketide synthases it was possible to screen a cosmid library of A. mediterranei with specific DNA probes derived from this fragment in a screening program for further DNA fragments which are involved in the rifamycin gene cluster. As a result, the complete rifamycin polyketide synthase gene cluster was identified and subjected to sequence determination (see SEQ ID NO 3). The gene cluster comprises six open reading frames, which are referred to hereinafter as ORF A, B, C, D, E and F and which code for the proteins and polypeptides depicted in SEQ ID NOS 4 to 9.

The gene cluster isolated and characterized in this way represents the basis, for example, for targeted optimization of the production of rifamycin, ansamycins or analogues thereof. Examples of techniques and possible areas of application available in this connection are as follows:

- Overexpression of individual genes in producer strains with plasmid vectors or by incorporation into the chromosome.
- Study of the expression and transcriptional regulation of the gene cluster during fermentation with various producer strains and optimization thereof through physiological paramet rs and appropriate ferm intation conditions.

- Identification of regulatory genes and of the DNA binding sites of the corresponding regulatory proteins in the gene cluster. Characterization of the effect of these regulatory elements on the production of rifamycins or ansamycins; and influencing them by specific mutation in these genes or the DNA binding sites.
- Duplication of the complete gene cluster or parts thereof in producer strains.

Besides these applications of the gene cluster to improve production by fermentation as described above, it can likewise be employed for the biosynthetic preparation of novel rifamycin analogues or novel ansamycins or ansamycin-like compounds in which the aliphatic bridge is connected at only one end to the aromatic nucleus. The following possibilities come into consideration here, for example:

- Inactivation of individual steps in the biosynthesis, for example by gene disruption.
- Mutation of individual steps in the biosynthesis, for example by gene replacement.
- Use of the cluster or fragments thereof as DNA probe in order to isolate other natural microorganisms which produce metabolites similar to rifamycin or ansamycins.
- Exchange of individual elements in this gene cluster by those from other gene clusters.
- Use of modified polyketide synthases for setting up libraries of various rifamycin analogues or ansamycins, which are then tested for their activity (Jackie & Khosla, Chemistry & Biology, (1995), 2, 355-362).
- Construction of mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted, and can thus be used for expressing genetically modified gene clusters.
- Exchange of individual elements within the gene cluster.

### Detailed description of the invention

The invention relates to a DNA fragment from the genome of *Amycolatopsis mediterranei*, which comprises a DNA region which is involved directly or indirectly in the gene cluster responsible for rifamycin synthesis; and the adjacent DNA regions; and functional constituents or domains thereof.

The DNA fragments according to the invention may moreover comprise regulatory sequences such as promoters, repressor or activator binding sites, repressor or activator genes, terminators; or structural genes. Likewise part of the invention are any combinations of these DNA fragments with one another or with other DNA fragments, for example combinations of promoters, repressor or activator binding sites and/or repressor or activator genes from an ansamycin gene cluster, in particular from the rifamycin gene cluster, with

foreign structural genes or combinations of structural genes from the ansamycin gen cluster, especially the rifamycin gene cluster, with foreign promoters; and combinations of structural genes with one another or with gene fragments which code for nzymatically active domains and are from various ansamycin biosynthesis systems. Foreign structural genes, and foreign gene fragments coding for enzymatically active domains, code, for example, for proteins involved in the biosynthesis of other ansamycins.

A preferred DNA fragment is one directly or indirectly involved in the gene cluster responsible for rifamycin synthesis.

The gene cluster or DNA region described above contains, for example, the genes which code for the individual enzymes involved in the biosynthesis of ansamycins and, in particular, of rifamycin, and the regulatory elements which control the expression of the biosynthesis genes. The size of such antibiotic gene clusters extends from about 10 kilobases (kb) up to over 100 kb. The gene clusters normally comprise specific regulatory genes and genes for resistance of the producer organism to its own antibiotic. Examples of what is meant by enzymes or enzymatically active domains involved in this biosynthesis are those necessary for synthesizing, starting from 3-amino-5-hydroxybenzoic acid, the ansamycins such as rifamycin, for example polyketide synthases, acyltransferases, dehydratases, ketoreductases, acyl carrier proteins or ketoacyl synthases.

Thus, the complete sequence of the gene cluster shown in SEQ ID NO 3, as well as DNA fragments which comprise sequence portions which code for a polyketide synthase or an enzymatically active domain thereof, are particularly preferred. Examples of such preferred DNA fragments are, for example, those which code for one or more of the proteins and polypeptides depicted in SEQ ID ID NOS 4, 5, 6, 7, 8 and 9, or functional derivativ s thereof, also including partial sequences thereof which comprise, for example, 15 or more consecutive nucleotides. Other preferred embodiments relate to DNA regions of the gene cluster according to the invention or fragments thereof, like those present in the deposited clones pNE95, pRi44-2 and pNE112, or derived therefrom. Further preferred DNA fragments are those comprising sequence portions which display homologies with the sequences comprised by the clones pNE95, pRi44-2 and/or pNE112 or with SEQ ID ID NOS 1 and/or 3, and therefore can be used as hybridization probe within a genomic gene bank of an ansamycin-, in particular, rifamycin-producing organism for finding constituents

of the corresponding gene cluster. The DNA fragment may moreover, for example, comprise exclusively genomic DNA. A particularly preferred DNA fragment is one which comprises the nucleotide sequence depicted in SEQ ID NO 1 or 3, or partial sequences thereof, which, by reason of homologies, can be regarded as structural or functional equivalent to said sequence or partial sequence therefrom, and which therefore are able to hybridize with this sequence.

The DNA fragments according to the invention comprise, for example, sequence portions which comprise homologies with the above-described enzymes, enzyme domains or fragments thereof.

The term homologies and structural and/or functional equivalents refers primarily to DNA and amino acid sequences with few or minimal differences between the relevant sequences. These differences may have very diverse causes. Thus, for example, this may entail mutations or strain-specific differences which occur naturally or are artificially induced. Or the differences observed from the initial sequence are derived from a targeted modification, which can be introduced, for example, during a chemical synthesis.

Functional differences can be regarded as minimal if, for example, the nucleotide sequence coding for a polypeptide, or a protein sequence has essentially the same characteristic properties as the initial sequence, whether in respect of enzymatic activity, immunological reactivity or, in the case of a nucleotide sequence, gene regulation.

Structural differences can be regarded as minimal as long as there is a significant overlap or similarity between the various sequences, or they have at least similar physical properties. The latter include, for example, the electrophoretic mobility, chromatographic similarities, sedimentation coefficients, spectrophotometric properties etc.

In the case of nucleotide sequences, the agreement should be at least 70%, but preferably 80% and very particularly preferably 90% or more. In the case of the amino acid sequence, the corresponding figures are at least 50%, but preferably 60% and particularly preferably 70%. 90% agreement is very particularly preferred.

The invention furthermore relates to a method for id ntifying, isolating and cloning one of the DNA fragments described above. A preferr d method comprises, for example, the following steps:

- a) setting up of a genomic gene bank,
- b) screening of this gene bank with the assistance of the DNA sequences according to the invention, and
- c) isolation of the clones identified as positive.

A general method for identifying DNA fragments involved in the biosynthesis of ansamycins comprises, for example, the following steps

- 1) Cloning of a DNA fragment which shows homology with known polyketide synthas:
  - a) The presence of DNA fragments having homology with the polyketide synthase genes according to the invention is detected in the strains of the microorganism to be investigated by a Southern experiment with chromosomal DNA of this strain. The size of such homologous DNA fragments can be determined by digesting the DNA with a suitable restriction enzyme.
  - b) Production of a plasmid gene bank comprising the above digested chromosomal fragments. Normally, individual clones of this gene bank are tested once again for homology with the polyketide synthase genes according to the invention. Clones with recombinant plasmids comprising fragments having homology with the polyketide probe are then normally isolated on the basis of this homology.
- 2) Analysis of the cloned region
  - a) Restriction analysis of the isolated recombinant plasmids and checking of the identit of these cloned fragments with one another.
  - b) By a chromosomal Southern with DNA of the original microorganism and the isolated DNA fragment as probe it can be demonstrated that the cloned fragment is an original chromosomal DNA fragment from the original microorganism.
  - c) It is possible as an option to demonstrate a significant homology of the cloned DNA fragment with chromosomal DNA from other ansamycin producers (streptovaricin, tolypomycin, geldanamycin, ansamitocin). This would confirm that the cloned DNA is typical of gene clusters of ansamycin biosynthesis and thus also of rifamycin biosynthesis.



- d) DNA sequencing of an internal restriction fragment and demonstration by comparative sequence analysis that the cloned region is a typical DNA sequence of polyketide synthases, coding for the biosynthesis of polyketide antibiotics from actinomycetes.
- 3) Isolation and characterization of adjacent DNA regions
  - a) Construction of a cosmid gene bank from the original microorganism and analysis thereof for homology with the isolated fragments. Isolation of cosmids having homology with this fragment.
  - b) Demonstration by restriction analysis that the isolated cosmid clones comprise a DNA region of the original microorganism which overlaps with the original fragment.

As described above, the first step in the isolation of the DNA fragments according to the invention is normally the setting up of genomic gene banks from the organism of interest, which synthesize the required ansamycin, especially rifamycin.

Genomic DNA can be obtained from a host organism in various ways, for example by extraction from the nuclear fraction and purification of the extracted DNA by known methods.

The fragmentation, which is necessary for setting up a representative gene bank, of the genomic DNA to be cloned to a size which is suitable for insertion into a cloning vector can take place either by mechanical shearing or else, preferably, by cutting with suitable restriction enzymes.

Suitable cloning vectors, which are already in routine use for producing genomic gene libraries, comprise, for example, cosmid vectors, plasmid vectors or phage vectors.

It is then possible in a screening program to obtain suitable clones which comprise the required gene(s) or gene fragment(s) from the gene libraries produced in this way.

One possibility for identifying the required DNA region consists in, for example, using the gene bank described above to transform strains which, because of a blocked synthetic pathway, are unable to produce ansamycins, and identifying those clones which are again able after the transformation to produce ansamycin (revertants). The vectors which lead to revertants comprise a DNA fragment which is required in ansamycin synthesis.

Another possibility for id ntifying the required DNA region is based, for example, on using suitable probe mol cules (DNA probe) which are obtained for example as described above. Various standard methods are available for identifying suitable clones, such as differential colony hybridization or plaque hybridization.

It is possible to use as probe molecule a previously isolated DNA fragment from the same or a structurally related gene or gene cluster which, because of the homologies present, is able to hybridize with the corresponding sequence section within the required gene or gene cluster to be identified. Preferably used as probe molecule for the purpose of the present invention is a DNA fragment obtainable from a gene or a DNA sequence involved in the synthesis of polyketides such as ansamycins or soraphens.

If the nucleotide sequence of the gene to be isolated, or at least parts of this sequence, are known, it is possible in an alternative embodiment to use, based on this sequence information, a corresponding synthesized DNA sequence for the hybridizations or PCR amplifications.

In order to facilitate detectability of the required gene or else parts of a required gene, one of the DNA probe molecules described above can be labelled with a suitable, easily detectable group. A detectable group for the purpose of this invention means any material which has a particular, easily identifiable, physical or chemical property.

Particular mention may be made at this point of enzymatically active groups such as enzymes, enzyme substrates, coenzymes and enzyme inhibitors, furthermore fluorescent and luminescent agents, chromophores and radioisotopes such as <sup>3</sup>H, <sup>35</sup>S, <sup>32</sup>P, <sup>125</sup>I and <sup>14</sup>C. Easy detectability of these markers is based, on the one hand, on their intrinsic physical properties (for example fluorescent markers, chromophores, radioisotopes) or, on the other hand, on their reaction and binding properties (for example enzymes, substrates, coenzymes, inhibitors). Materials of these types are already widely used in particular in immunoassays and, in most cases, can also be used in the present application.

General methods relating to DNA hybridization are described, for example, by Maniatis T. et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (1982).

Those clones within the previously described gene libraries which are able to hybridize with a probe molecule and which can be identified by one of the abovementioned detection methods can then be further analysed in order to determine the extent and nature of the coding sequence in detail.

An alternative method for identifying cloned genes is based on constructing a gen—library consisting of plasmid or expression vectors. This entails, in analogy to the methods described previously, the genomic DNA comprising the required gene being initially isolated and then cloned into a suitable plasmid or expression vector. The gene libraries produced in this way can then be screened by suitable procedures, for example by us—of complementation studies, and those clones which comprise the required gene or else at least a part of this gene as insert can be selected.

It is thus possible with the aid of the methods described above to isolate a gene, several genes or a gene cluster which code for one or more particular gene products.

For further characterization, the DNA sequences purified and isolated in the manner described above are subjected to restriction analysis and sequence analysis.

For sequence analysis, the previously isolated DNA fragments are first fragmented using suitable restriction enzymes, and then cloned into suitable cloning vectors. In order to avoid mistakes in the sequencing, it is advantageous to sequence both DNA strands completely.

Various alternatives are available for analysing the cloned DNA fragment in respect of its function within ansamycin biosynthesis.

Thus, for example, it is possible in complementation experiments with defective mutants not only to establish involvement in principle of a gene or gene fragment in secondary metabolite biosynthesis, but also to verify specifically the synthetic step in which said DNA fragment is involved.

In an alternative type of analysis, evidence is obtained in exactly the opposite way. Transfer of plasmids which comprise DNA sections which have homologies with appropriate sections

on the genome results in integration of said homologous DNA sections via homologous recombination. If, as in the present case, the homologous DNA section is a region within an open reading frame of the gene cluster, plasmid integration results in inactivation of this gene by so-called gene disruption and, consequently, in an interruption in secondary metabolite production. It is assumed according to current knowledge that a homologous region which comprises at least 100 bp, but preferably more than 1000 bp, is sufficient to bring about the required recombination event.

However, a homologous region which extends over a range of from 0.3 to 4 kb, but in particular over a range of from 1 to 3 kb, is preferred.

To prepare suitable plasmids which have sufficient homology for integration via homologous recombination there is preferably provision of a subcloning step in which the previously isolated DNA is digested, and fragments of suitable size are isolated and subsequently cloned into a suitable plasmid. Examples of suitable plasmids are the plasmids generally used for genetic manipulations in streptomycetes or *E. coli*.

It is possible in principle to use for the preparation and multiplication of the previously described constructs all conventional cloning vectors such as plasmid or bacteriophage vectors as long as they have replication and control sequences derived from species compatible with the host cell.

The cloning vector usually has an origin of replication plus specific genes which result in phenotypical selection features in the transformed host cell, in particular resistances to antibiotics. The transformed vectors can be selected on the basis of these phenotypical markers after transformation in a host cell.

Selectable phenotypical markers which can be used for the purpose of this invention comprise, for example, without this representing a limitation of the subject-matter of the invention, resistances to thiostrepton, ampicillin, tetracycline, chloramphenicol, hygromycin, G418, kanamycin, neomycin and bleomycin. Another selectable marker can be, for example, prototrophy for particular amino acids.

Mainly preferred for the purpose of the present invention are streptomycetes and E. coli plasmids, for example the plasmids used for the purpose of the present invention.

Host cells primarily suitable for the previously described cloning for the purpos of this invention are prokaryotes, including bacterial hosts such as streptomycetes, actinomycetes, *E. coli* or pseudomonads.

E. coli hosts are particularly preferred, for example the E. coli strain HB101 or X-1 blue MR\* (Stratagene) or streptomyces such as the plasmid-free strains of Streptomyces lividans TK23 and TK24.

Competent cells of the *E. coli* strain HB101 are produced by the methods normally used for transforming *E. coli*. The transformation method of Hopwood *et al.* (Genetic manipulation of streptomyces a laboratory manual. The John Innes Foundation, Norwich (1985)) is normally used for streptomyces.

After transformation and subsequent incubation on a suitable medium, the resulting colonies are subjected to a differential screening by plating out on selective media. It is then possible to isolate the appropriate plasmid DNA from those colonies which comprise plasmids with DNA fragments cloned in.

The DNA fragment according to the invention, which comprises a DNA region which is involved directly or indirectly in the biosynthesis of ansamycin and can be obtained in the previously described manner from the ansamycin biosynthesis gene cluster, can also be used as starter clone for identifying and isolating other adjacent DNA regions overlapping therewith from said gene cluster.

This can be achieved, for example, by carrying out a so-called chromosome walking within a gene library consisting of DNA fragments with mutually overlapping DNA regions, using the previously isolated DNA fragment or else, in particular, the sequences located at its 5' and 3' margins. The procedures for chromosome walking are known to the person skilled in this art. Details can be found, for example, in the publications by Smith *et al.* (Methods

Enzymol (1987), 151, 461-489) and Wahl et al. (Proc Natl. Acad. Sci, USA (1987), 84, 2160-2164).

The prerequisite for chromosome walking is the presence of clones having coherent DNA fragments which are as long as possible and mutually overlap within a gene library, and a suitable starter clone which comprises a fragment which is located in the vicinity or els, preferably, within the region to be analysed. If the exact location of the starter clone is unknown, the walking is preferably carried out in both directions.

The actual walking step starts by using the identified and isolated starter clone as probe in one of the previously described hybridization reactions in order to detect adjacent clones which have regions overlapping with the starter clone. It is possible by hybridization analysis to establish which fragment projects furthest over the overlapping region. This is then used as starting clone for the 2nd walking step, in which case there is establishment of the fragment which overlaps with said 2nd clone in the same direction. Continuous progression in this manner on the chromosome results in a collection of overlapping DNA clones which cover a large DNA region. These can then, where appropriate after one or more subcloning steps, be ligated together by known methods to give a fragment which comprises parts or else, preferably all of the constituents essential for ansamycin biosynthesis.

The hybridization reaction to establish clones with overlapping marginal regions preferably makes use not of the very large and unwieldy complete fragment but, in its place, a partial fragment from the left or right marginal region, which can be obtained by a subcloning step. Because of the smaller size of said partial fragment, the hybridization reaction results in fewer positive hybridization signals, so that the analytical effort is distinctly less than on use of the complete fragment. It is furthermore advisable to characterize the partial fragment in detail in order to preclude its comprising larger amounts of repetitive sequences, which may be distributed over the entire genome and thus would greatly impede a targeted sequence of walking steps.

Since the gene cluster responsible for ansamycin biosynthesis covers a relatively large region of the genome, it may also be advantageous to carry out a so-called large-step walking or cosmid walking. It is possible in these cases, by using cosmid vectors which

permit the cloning of very large DNA fragments, to cover a very large DNA region, which may comprise up to 42 kb, in a single walking step.

In one possible embodiment of the present invention, for example, to construct a cosmid gene bank from streptomycetes or actinomycetes, complete DNA is isolated with the size of the DNA fragments being of the order of about 100 kb, and is subsequently partially digested with suitable restriction endonucleases.

The digested DNA is then extracted in a conventional way in order to remove endonuclease which is still present, and is precipitated and finally concentrated. The resulting fragment concentrate is then fractionated, for example by density gradient centrifugation, in accordance with the size of the individual fragments. After the fractions obtainable in this way have been dialysed they can be analysed on an agarose gel. The fractions which contain fragments of suitable size are pooled and concentrated for further processing. Fragments to be regarded as particularly suitable for the purpose of this invention have a size of the order of 30 kb to 42 kb, but preferably of 35 kb to 40 kb.

In parallel with the fragmentation described above, or later, for example a suitable cosmid vector pWE15\* (Stratagene) is completely digested with a suitable restriction enzyme, for example BamHI, for the subsequent ligase reaction.

Ligation of the cosmid DNA to the streptomyces or actinomycetes fragments which have been fractionated according to their size can be carried out using a T4 DNA ligase. The ligation mixture obtainable in this way is, after a sufficient incubation time, packaged into  $\lambda$  phages by generally known methods.

The resulting phage particles are then used to infect a suitable host strain. A recA E. colistrain is preferred, such as E. coli HB101 or X-1 Blue (Stratagene). Selection of transfected clones and isolation of the plasmid DNA can be carried out by generally known methods.

The screening of the gene bank for DNA fragments which are involved in ansamycin biosynthesis is carried out, for example, using a specific hybridization probe which is assumed (for example on the basis of DNA sequence or DNA homology or

complementation tests or gene disruption or the function thereof in other organisms) to comprise DNA regions from the 'ansamycin gene clust r'.

A plasmid which comprises an additional fragment of the required size or has been identified on the basis of hybridizations can then be isolated from the gel in the previously described manner. The identity of this additional fragment with the required fragment of the previously selected cosmid can then be confirmed by Southern transfer and hybridization.

Function analysis of the DNA fragments isolated in this way can be carried out in a gene disruption experiment as described above.

Another possible use of the DNA fragments according to the invention is to modify or inactivate enzymes or domains involved in ansamycin and, in particular, rifamycin biosynthesis, or to synthesize oligonucleotides which are then in turn used for finding homologous sequences in PCR amplification.

Besides the DNA fragments according to the invention as such, also claimed are their use firstly for producing rifamycin, rifamycin analogues or precursors thereof, and for the biosynthetic production of novel ansamycins or of precursors thereof. Included in this connection are those molecules in which the aliphatic bridge is connected only at one end to the aromatic nucleus.

The DNA fragments according to the invention permit, for example, by combination with DNA fragments from other biosynthetic pathways or by inactivation or modification thereof, the biosynthesis of novel hybrid compounds, in particular of novel ansamycins or rifamycin analogues. The steps necessary for this are generally known and are described, for example, in Hopwood, Current Opinion in Biotechnol. (1993), 4, 531-537.

The invention furthermore relates to the use of the DNA fragments according to the invention for carrying out the novel technology of combinatorial biosynthesis for the biosynthetic production of libraries of polyketide synthases based on the rifamycin and ansamycin biosynthesis genes. If, for example, several sets of modifications are produced, it is possible in this way to produce, by means of biosyntheses, a library of polyketides, for example ansamycins or rifamycin analogues, which then needs to be tested only for the

DEFENDANCE 1810 -------

activity of the compounds produced in this way. The st ps necessary for this are generally known and are described, for example, in Tsoi and Khosla, Chemistry & Biology (1995), 2, 355-362 and WO-9508548.

Besides the DNA fragment as such, also claimed is its use for the genetic construction of mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted, and which can thus be used for expressing genetically modified ansamycin or rifamycin biosynthesis gene clusters.

The invention furthermore relates to a hybrid vector which comprises at least one DNA fragment according to the invention, for example a promoter, a repressor or activator binding site, a repressor or activator gene, a structural gene, a terminator or a functional part thereof. The hybrid vector comprises, for example, an expression cassette which comprises a DNA fragment according to the invention which is able to express one or more proteins involved in ansamycin biosynthesis and, in particular in rifamycin biosynthesis, or a functional fragment thereof. The invention likewise relates to a host organism which comprises the hybrid vector described above.

Suitable vectors representing the starting point of the hybrid vectors according to the invention, and suitable host organisms such as bacteria or yeast cells are generally known.

The host organism can be transformed by generally customary methods such as by means of protoplasts, Ca<sup>2+</sup>, Cs<sup>+</sup>, polyethylene giycol, electroporation, viruses, lipid vesicles or a particle gun. The DNA fragments according to the invention may then be present both as extrachromosomal constituents in the host organism and integrated via suitable sequence sections into the chromosome of the host organism.

The invention likewise relates to polyketide synthases which comprise the DNA fragments according to the invention, in particular those from *Amycolatopsis mediterranei* which are involved directly or indirectly in rifamycin synthesis, and functional constituents thereof, for example enzymatically active domains.

Š

The invention furthermore relates to a hybridization probe comprising a DNA fragment according to the invention, and to the use thereof, in particular for identifying DNA fragments involved in the biosynthesis of ansamycins.

In order to obtain unambiguous signals in the hybridization, DNA bound to the filter (for example made of nylon or nitrocellulose) is normally washed at  $55-65^{\circ}$ C in  $0.2 \times SSC$  (1 × SSC = 0.15 M sodium chloride, 15 mM sodium citrate).

### **Examples**

### General

General molecular genetic techniques such as DNA isolation and purification, restriction digestion of DNA, agarose gel electrophoresis of DNA, ligation of restriction fragm nts, cultivation and transformation of *E. coli*, plasmid isolation from *E. coli*, are carried out as described in Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982).

Culture conditions and molecular genetic techniques with *A. mediterranei* and other *actinomycetes* are as described by Hopwood *et al.* (Genetic manipulation of streptomyces a laboratory manual, The John Innes Foundation, Norwich, 1985). All liquid cultures of *A. mediterranei* and other *actinomycetes* are carried out in Erlenmeyer flasks at 28°C on a shaker at 250 rpm.

### Nutrient media used:

- LB Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982)
- NL148 Schupp + Divers FEMS Microbiology Lett. 36, 159-162 (1986) (NL148 = NL148G without glycine)
- R2YE Hopwood et al. (Genetic manipulation of streptomyces a laboratory manual. The John Innes Foundation, Norwich, 1985)

٠.

TB: 12 g/l Bacto tryptone

24 g/l Bacto yeast extract

4 ml/l glycerol

## Example 1: Detection of chromosomal DNA fragments from A. mediterranei having homology with polyketide synthase genes of other bacteria

To obtain genomic DNA from *A. mediterranei*, cells of the strain *A. mediterranei* wt3136 (= LBGA 3136, ETH collection of strains) are cultivated in NL148 medium for 48 hours. 1 ml of this culture is then transferred into 50 ml of NL148 medium (+ 2.5 g/l glycine) in a 200 ml Erlenmeyer flask, and the culture is incubated for 48 h. The cells are removed from the medium by centrifugation at 3000 g for 10 min. and are resuspended in 5 ml of SET (75 mM NaCl, 25 mM EDTA, 20 mM Tris, pH 7.5). High molecular weight DNA is extracted by the method of Pospiech and Neumann (Trends in Genetics (1995), 11, 217-218).

In order to detect, by a Southern blot, individual fragments from the isolated *A. mediterranei* DNA which have homology with polyketide synthase genes, a radioactive DNA probe is prepared from a known polyketide synthase gene cluster. To do this, the Pvul fragment 3.8 kb in size is isolated from the recombinant plasmid p98/1 (Schupp et al. J. of Bacteriol. (1995), 177, 3673-3679), which comprises a DNA region, about 32 kb in size, from the polyketide synthase for the antibiotic soraphen A. About 0.5 µg of the isolated 3.8 kb Pvul DNA fragment is radiolabelled with <sup>32</sup>P-d-CTP by the nick translation system from Gibco/BRL (Basle) in accordance with the manufacturer's instructions.

For the Southern blot, about 2 µg of the genomic DNA isolated above from *A. mediterranei* are completely digested with the restriction enzyme BgIII (Böhringer, Mannheim), and the resulting fragments are fractionated on a 0.8% agarose gel. A Southern blot with this agarose gel and the DNA probe isolated above (3.8 kb Pvul fragment) detects a DNA BgIII-cut fragment which is about 13 kb in size from the genomic DNA of *A. mediterranei*, and which has homology with the DNA probe used. It can be concluded on the basis of this homology that the detected DNA fragment from *A. mediterranei* is a genetic region which codes for a polyketide synthase and thus is involved in the synthesis of a polyketide antibiotic.

## Example 2: Production of a specific recombinant plasmid collection comprising BgIIIdigest d chromosomal fragments from A. mediterranei 12-16 kb in size

Th *E. coli* positive selection vector plJ4642 (derivative of plJ666, Kieser & Melton, Gene (1988), 65, 83-91) developed at the John Innes Centre (Norwich, UK) is used to produce the plasmid gene bank. This plasmid is first cut with BamHI, and the two resulting fragments are fractionated on an agarose gel. The smaller of the two fragments is the filler fragment of the vector and the larger is the vector portion which, on self-ligation after deletion of the filler fragment, forms, owing to the flanking fd termination sequences, a perfect palindrome, which means that the plasmid cannot be obtained as such in *E. coli*. This vector portion 3.8 kb in size is isolated from the agarose gel by electroelution as described on page 164-165 of Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbo. Laboratory Press, Cold Spring Harbor NY (1982).

To prepare the BgIII-cut DNA fragments from *A. mediterranei*, the high molecular weight genomic DNA prepared in Example 1 is used. About 10 μg of this DNA are completely digested with the restriction enzyme BgIII and subsequently fractionated on a 0.8% agarose gel. DNA fragments with a size of about 12 - 16 kb are cut out of the gel and detached from the gel block by electroelution (see above). About 1 μg of the BgIII fragments isolated in this way is ligated to about 0.1 μg of the BamHI portion, isolated above, of the vector pIJ4642. The ligation mixture obtained in this way is then transformed into the *E. coli* strain HB101 (Stratagene). About 150 transformed colonies are selected from the transformation mixture on LB agar with 30 μg per ml chloramphenicol. These colonies contain recombinant plasmids with BgIII-cut genomic DNA fragments from *A. mediterranei* in the size range 12

# Example 3: Cloning and characterization of chromosomal A. mediterranei DNA fragments having homology with bacterial polyketide synthase genes

150 of the plasmid clones prepared in Example 2 are analysed by colony hybridization using a nitrocellulose filter (Schleicher & Schuell) as described on pages 318-319 of Maniatis et al., Molecular Cloning: A laboratory manual, 1st Edit. Cold Spring Harbor Laboratory Press, Cold Spring Harbor NY (1982). The DNA probe used is the 3.8 kb Pvul fragment, radiolabelled with <sup>32</sup>P-d-CTP and isolated in Example 1, of the plasmid p98/1. The plasmids are isolated from 5 plasmid clones which show a hybridization signal, and are characteriz d by two restriction digestions with the enzymes HindlH or Kpnl. HindlH cuts

twice in the vector portion of the clones, 0.3 kb to the right and left of the BamHI cleavage site into which th *A. mediterranei* DNA has been int grated. KpnI does not cut in th pIJ 4642 vector portion. This restriction analysis shows that the investigated clones comprise both identical HindIII fragments of about 14 and 3.1 kb and identical KpnI fragments approximately 11.4 kb and 5.7 kb in size. This shows that these clones comprise the same genomic BgIII fragment of *A. mediterranei*, and that the latter has a size of about 13 kb. It can additionally be concluded from this restriction analysis that this cloned BgIII fragment has no internal HindIII cleavage site, but has 2 KpnI cleavage sites which afford an internal KpnI fragment 5.7 kb in size.

The plasmid DNA of the above 5 clones with identical restriction fragments is further characterized by a Southern blot. For this purpose, the plasmids are cut with HindIII and KpnI, and the DNA probe used is the <sup>32</sup>P-radiolabelled 3.8 kb PvuI fragment of the plasmid p98/1 used above. This experiment confirms that the 5 plasmids contain identical A. mediterranei DNA fragments and that these have significant homology with the DNA probe which is characteristic of bacterial polyketide synthase genes. In addition, the Southern blot shows that the internal KpnI fragment 5.7 kb in size likewise has significant homology with the DNA probe used. The plasmid called pRi7-3 is selected from the 5 plasmids for further processing.

To demonstrate that the cloned BgIII fragment about 13 kb in size from *A. mediterranei* is an original chromosomal DNA fragment, another Southern blot is carried out. Chromosomal DNA from *A. mediterranei* which has been cut with BgIII, KpnI or BamHI is employed in this blot. Two BamHI fragments which are about 1.8 and 1.9 kb in size and are present in the 5.7 kb KpnI fragment of pRi7-3 are used as radiolabelled DNA probe. This experiment confirms that the BgIII DNA fragment about 13 kb in size cloned in the recombinant plasmid pRi7-3 is an authentic genomic DNA fragment from *A. mediterranei*. In addition, this experiment confirms that the cloned fragment comprises an internal KpnI fragment 5.7 kb in size and two BamHI fragments about 1.8 and 1.9 kb in size, and that these DNA fragments are likewise authentic genomic DNA fragments from *A. mediterranei*.

# Example 4: D monstration of a significant homology of the cloned genomic 13 kb Bglll fragment from A. mediterranei with chromosomal DNA from other actinomycetes which produce ansamycins

Demonstration of a significant homology between the cloned chromosomal DNA region of A. mediterranei and chromosomal DNA from other ansamycin-producing actinomycetes takes place by a Southern blot experiment. The following ansamycin-producing strains are employed for this purpose (the ansamycins produced by the strains are in parentheses): Streptomyces spectabilis (streptovaricins), Streptomyces tolypophorus (tolypomycins), Streptomyces hygroscopicus (geldanamycins), Nocardia species ATCC31281 (ansamitocins). Genomic DNA from these strains is isolated as described for A. mediterranei in Example 1 and digested with the restriction enzyme KpnI, and the restriction fragment obtained in this way are fractionated on an agarose gel for the Southern blot. Two BamHi fragments about 1.8 and 1.9 kb in size from A. mediterranei, which are used in Example 3 and are isolated from the plasmid pRi7-3, are used as radioactive probe. This exp riment shows that these ansamycin-producing strains have a significant DNA homology with the DNA probe used and thus with the cloned chromosomal region of A. mediterranei. It is to be observed in this connection that the homology in the case of producers of ansamycins with a naphthoquinoid ring system (streptovaricin, tolypomycin) is greater than in the case of those with a benzoquinoid ring system (geldanamycin, ansamitocin). This result suggests that the cloned chromosomal DNA region from A. mediterranei is typical of ansamycin biosynthesis gene clusters and, especially, of gene clusters for ansamycins with naphthoquinoid ring systems, corresponding to the ring system in rifamycins.

# Example 5: DNA sequence determination of the KpnI fragment 5.7 kb in size located within the cloned 13 kb BgllI fragment

For the sequencing, the 5.7 kb KpnI fragment is isolated from the plasmid pRi7-3 (DSM 11114) (Maniatis et. al. 1992) and subcloned into the KpnI cleavage site of the vector pBRKanf4, which is suitable for the DNA sequencing, affording the plasmids pTS004 and pTS005. The vector pBRKanf4 (derived from pBRKanf1; Bhat, Gene (1993) 134, 83-87) is suitable for introducing sequential deletions of Sau3A fragments in the cloned insert fragment, because this vector does not itself have a GATC nucleotide sequence. In addition, the BamHI fragments 1.9 and 1.8 kb in size present in the 5.7 kb KpnI fragment are subcloned into the BamHI cleavage site of pBRKanf4, r sulting the plasmids pTS006 and pTS007, and pTS008 and pTS009, respectively.

To prepare subclones sequentially truncated by Sau3A fragments for the DNA sequencing, the plasmids pTS004 to pTS009 are partially digested with Sau3A and completely digested with Xbal or HindllI (a cleavage site in the multiple cloning region of the vector). The DNA obtained in this way (consisting of the linearized vector with inserted DNA fragments truncated by Sau3A fragments) is filled in at the ends using Klenow polymerase (fragment of polymerase I, see Maniatis et al. pages 113-114), self-ligated with T4 DNA ligase and transformed into E. coli DH5a. The plasmid DNA which corresponds to the pTS004 to pTS009 plasmids, but has DNA regions, which are truncated from one side by Sau3A fragments, from the original integrated fragments of A. mediterranei, is isolated from individual transformed clones obtained in this way.

The DNA sequencing is carried out with the plasmids obtained in this way and with pTS004 to pTS009 using the reaction kit from Perkin-Elmer/Applied Biosystems with dye-labelled terminator reagents (Kit N° 402122) and a universal primer or a T7 primer. A standard cycle sequencing protocol with a thermocycler (MJ Research DNA Engine Thermocycler, Model 225) is used, and the sequencing reactions are analysed by the Applied Biosystems automatic DNA sequencer (Modell 373 or 377) in accordance with the manufacturer's instructions. To analyse the results, the following computer programs (software) are employed: Applied Biosystems DNA analysis software, Unix Solaris CDE software, DNA assembly and analysis package GAP licensed from R. Staden (Nucleic Acid Research (1995)23, 1406-1410) and Blast (NCBI).

The methods described above can be used to sequence completely both DNA strands of the 5.7 kb KpnI fragment from *A. mediterranei* strain wt3136. The DNA sequence of the 5.7 kb fragment with a length of 5676 base pairs is depicted in SEQ ID NO 1.

### Example 6: Analysis of the protein-encoding region (genes) on the 5.7 kb Konl fragment from A. mediterranei

The nucleotide sequence of the 5.7 kb Kpnl fragment is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that this fragment is over its whole length a protein-encoding region and thus forms part of a larger open reading frame (ORF). The codons used in this ORF are typical of

streptomycetes and actinomycetes genes. The amino acid sequence derived from the DNA sequence from this ORF is depicted in SEQ ID NO 2.

Polyketide synthases for macrolide antibiotics (such as erythromycin, rapamycin) are very large multifunctional proteins which comprise several enzymatically active domains which are now well characterized (Hopwood und Khosla, Ciba Foundation Symposium (1992), 171, 88-112; Donadio and Katz, Gene (1992), 111, 51-60; Schwecke et al., Proc. Natl. Acad. Sci. U.S.A. (1995) 92 (17), 7839-7843). Comparison of the amino acid sequence depicted in SEQ ID NO 2 with that of the very well-characterized erythromycin polyketide synthase, eryA ORF1 (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession NO M63676) gives the following results:

Region from SEQ ID NO 2: amino acids 2 - 325: is 40% identical to the acyltransferase domain of module 2 of the eryA locus of Saccharopolyspora erythraea.

Region from SEQ ID NO 2: amino acids 325 - 470: is 43% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea.

Region from SEQ ID NO 2: amino acids 762 - 940: is 48% identical to the ketoreductase domain of module 2 of the eryA locus of Saccharopolyspora erythraea.

Region from SEQ ID NO 2: amino acids 1024- 1109: is 57% identical to the acyl carrier protein domain of module 2 of the eryA locus of Saccharopolyspora erythraea.

Region from SEQ ID NO 2: amino acids 1126 - 1584: is 59% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

The very large similarities found in the amino acid sequence and in the size and arrangement of the enzymatic domains suggest that the cloned KpnI region 5.7 kb in size from *A. mediterranei* codes for part of a polyketide synthase which is typical of polyketides of the macrolide type.

### Example 7: Construction of a cosmid gene bank from A. mediterranei

The cosmid vector employed is the plasmid pWE15 which can be purchased (Stratagene, La Jolla, CA, USA). pWE15 is completely cut with the enzyme BamHI (Maniatis *et al.* 1989) and precipitated with ethanol. For ligation to the cosmid DNA, chromosomal DNA from *A. mediterranei* is isolated as described in Example 1 and partially digested with the restriction enzyme Sau3A (Böhringer, Mannheim) to form DNA fragments most of which have a size of 20 - 40 kb. The DNA pretreated in this way is fractionated by fragment size by centrifugation (83,000 g, 20°C) on a 10% to 40% sucrose density gradient for 18 h. The gradient is fractionated in 0.5 ml aliquots and dialysed, and samples of 10 µl are analysed on a 0.3% agarose gel with DNA size standard. Fractions with chromosomal DNA 25 - 40 kb in size are combined, precipitated with ethanol and resuspended in a small volume of water.

Ligation of the cosmid DNA to the *A. mediterranei* Sau3A fragments isolated according to their size (see above) takes place with the aid of a T4-DNA ligase. About 3 μg of each of the two DNA starting materials are employed in a reaction volume of 20 μl, and the ligation is carried out at 12°C for 15 h. 4 ml of this ligation mixture are packaged into lambda phages using the *in vitro* packaging kit which can be purchased from Stratagene (La Jolla, CA, USA) (in accordance with the manufacturer's instructions). The resulting phages are introduced by infection into the *E. coli* strain X-1BlueMR<sup>®</sup> (Stratagene). Titration of the phage material reveals about 20,000 phage particles per ml, analysis of 12 cosmid clones shows that all the clones contain plasmid DNA inserts 25 - 40 kb in size.

# Example 8: Identification, cloning and characterization of the chromosomal A. mediterranei DNA region which is adjacent to the cloned 5.7 kb Kpnl fragment

To identify and clone the chromosomal *A. mediterranei* DNA region which is adjacent to the 5.7 kb KpnI fragment described above in Examples 3 and 5, firstly a radioactive DNA probe is prepared from this 5.7 kb KpnI fragment. This is done by radiolabelling approximately 0.5 µg of the isolated DNA fragment with <sup>32</sup>P-d-CTP by the nick translation system of Gibco/BRL (Basle) in accordance with the manufacturer's instructions.

Infection of E. coli X-1 Blue MR (Stratagene) with an aliquot of the lambda phages packaged in vitro (see Example 7) r sults in more than 2000 clones on several LB + ampicillin (50 µg/ml) plates. These clones are tested by colony hybridization on nitrocellulose filters (see Example 3 for method). The DNA probe used is the 5.7 kb Kpnl DNA fragment from A. mediterranei which is radiolabelled with <sup>32</sup>P-d-CTP and was prepared above.

5 cosmid clones showing a significant signal with the DNA probe are found. The plasmid DNA of these cosmids is isolated (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), digested with KpnI and analysed in an agarose gel. Analysis reveals that all 5 plasmids have integrated chromosomal *A. mediterranei* DNA with a size of the order of about 25-35 kb, and all contain the 5.7 kb KpnI fragment.

To characterize the chromosomal *A. mediterranei* DNA region which is adjacent to the cloned KpnI fragment, the plasmid DNA of one of the 5 cosmid clones is subjected to restriction analysis. The selected plasmid of the cosmid clone has the number pNE112 and likewise comprises the 13 kb BglII fragment described in Example 3.

Digestion of the plasmid pNE112 with the restriction enzymes BamHI, BgIII, HindIII (singularly and in combination) allows a restriction map of the cloned region of A. mediterranei to be prepared, and this permits this region about 26 kb in size in the chromosome of A. mediterranei to be characterized. This region is characterized by the following restriction cleavage sites with the stated distance in kb from one end: BamHI in position 3.2 kb, HindIII in position 6.6 kb, BgIII in position 11.5 kb, BamHI in position 16.6 kb, BamHI in position 24 kb.

# Example 9: Determination of the sequence of the chromosomal A. mediterranei DNA region present in the plasmid pNE112 and overlapping with the cloned 5.7 kb Kpnl fragment

The plasmid pNE112 DNA is split up into fragments directly using an Aero-Mist nebulizer (CIS-US Inc., Bedford, MA, USA) under a nitrogen pressure of 8-12 pounds per square inch. These random DNA fragments are treated with T4 DNA polymerase, T4 DNA kinase and E. coli DNA polymerase in the presence of the 4 dNTPs in order to generate blunt ends

on the double-stranded DNA fragments (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The fragments are then fractionated in 0.8% low melting agarose (FMC SeaPlague Agarose. Catalogue N° 50113), and fragments 1.5-2 kb in size are extracted by hot phenol extraction (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989). The DNA fragments obtained in this way are then ligated with the aid of T4 DNA ligase to the plasmid vector pBRKanf4 (see Example 5) or pBlueScript KS+ (Stratagene, La Jolla, CA, USA), each of which is cut once with square ends by appropriate restriction digestion (Small for pBRKanf4 and EcoRV for pBlueScript KS+), and is dephosphorylated on the ends by a treatment with alkaline phosphatase (Böhringer, Mannheim). The ligation mixture is then transformed into E. coli DH5α, and the cells are incubated overnight on LB agar with the appropriate antibiotic (kanamycin 40 µg/ml for pBRKanf4, ampicillin 100 μg/ml for pBlueScript KS+). Grown colonies are transferred singly into 1.25 ml of liquid TB medium with antibiotic in 96-well plates with wells of a volume of 2 ml, and incubated at 37°C overnight. Template DNA for the sequencing is prepared directly from these cultures by alkaline lysis (Birnboim, Methods in Enzymology (1983) 100, 243-255). The DNA sequencing takes place using the Perkin Elmer/Appled Biosystems reaction kit with dye-labelled terminator reagents (Kit N° 402122) and universal M13 mp18/19 primers or T3, T7 primers, or with primers prepared by us which bind to internal sequences. A standard cycle sequencing protocol with 20 cycles is used with a thermocycler (MJ Research DNA Engine Thermocycler, Model 225). The sequencing reactions are precipitated with ethanol, resuspended in formamide loading buffer and fractionated and analysed by electrophoresis using the Applied Biosystems automatic DNA sequencer (Model 377) in accordance with the manufacturer's instructions. Sequence files are produced with the aid of the Applied Biosystems DNA Analysis Software computer program and transferred to a SUN UltraSpark computer for further analysis. The following computer programs (software) are employed for analysing the results: DNA assembly and analysis package GAP (Genetics Computer Group, University of Wisconsin, R. Staden, Cambridge University UK) and the four programs: Phred, Cross-match, Phrad and Consed (P. Green, University of Washington, B. Ewing and D. Gordon, Washington University in Saint Louis). After the original sequences have been connected together to give longer coherent sequences (contigs), missing DNA sections are specifically sequenced with the aid of new primers (binding to sequenced sections), or by longer sequencing or sequencing the other strand.

DEEDOCID, JUIO CONTROL

It is possible with the method described above to sequence the entire chromosomal DNA region 26 kb in size from A. mediterranei which is cloned in pNE112. The DNA sequence is depicted in SEQ ID NO 3 in the base pair 27801 - 53789 section. The DNA sequence of the 5.7 kb KpnI fragment described in Example 5 is present in pNE112, and is depicted in SEQ ID NO 3 in the base pair 43093 - 48768 region.

# Example 10: Identification and characterization of cosmid clones with chromosomal DNA fragments from A. mediterranei which overlap with one end of the 26 kb A. mediterranei region of pNE112

To identify cosmid clones which comprise chromosomal DNA fragments from A. mediterranei located directly in front of the 26 kb region of pNE112, the plasmid pNE112 is cut with the restriction enzyme BamHI, and the resulting BamHI fragment 3.2 kb in size is separated from the other BamHI fragments in an agarose gel and isolated from the gel. This BamHI fragment is located at one end of the incorporated A. mediterranei DNA in pNE112 (see Example 8) and can thus be used as DNA probe for finding the required cosmid clones. Approximately 0.5 µg of the isolated 3.2 kb BamHI DNA fragment is radiolabelled with <sup>32</sup>P-dCTP by the nick translation system from Gibco/BRL (Basel) in accordance with the manufacturer's instructions.

The cosmid gene bank from *A. mediterranei* described in Example 7 is then analysed by colony hybridization (Method of Example 3) using this 3.2 kb DNA probe for clones with overlaps. Two cosmid clones with a strong hybridization signal can be identified in this way and are given the numbers pNE95 and pRi44-2. It is possible by restriction analysis and Southern blot to confirm that the plasmids pNE95 and pRi44-2 comprise chromosomal DNA fragments from *A. mediterranei* which overlap with the 3.2 kb BamHI fragment from pNE112 and together cover a 35 kb chromosomal region of *A. mediterranei* which is directly adjacent to the 26 kb *A. mediterranei* fragment of pNE112 cloned in pNE112.

### Example 11: Restriction analysis of the chromosomal A. mediterranei DNA region cloned with the cosmid clones pNE112, pNE95 and pRi44-2

The chromosomal *A. mediterranei* DNA region cloned with the cosmid clones pNE112, pNE95 and pRi44-2 is characterized by carrying out a restriction analysis. Digestion of the plasmid DNA of the three cosmids with the restriction enzymes EcoRI, BgIII and HindIII (singly and in combination) produces a rough restriction map of the cloned region of *A. mediterranei*. Overlapping fragments of the three plasmids are in this case established and confirmed by Southern blot. This chromosomal region of *A. mediterranei* has a size of about 61 kb and is characterized by the following restriction cleavage sites with the stated distance in kb from one end: EcoRI in position 7.2 kb, HindIII in position 21 kb, BgIII in position 31 kb, HindIII in position 42 kb, BgIII in position 47 kb and BgIII in position 59 kb. In this region in the *A. mediterranei* chromosome, the plasmid pRi 44-2 covers a region from position 1 to approximately 37 kb, plasmid pNE95 covers a region of approximate position 9 kb - 51 kb and plasmid pNE 112 covers a region of approximate position 35 kb - 61 kb.

# Example 12: Determination of the sequence of the chromosomal A. mediterranei DNA region described in Example 11 from the EcoRI cleavage site in the 7.2 kb position up to the 61 kb end

Determination of the DNA sequence of the chromosomal region described in Example 11 from *A. mediterranei* (EcoRl cleavage site in the 7.2 kb position to 51 kb) is carried out with the plasmids pRi 44-2 and pNE95, using exactly the same method as described in Example 9. Analysis of the DNA sequence obtained in this way confirms the rough restriction map described in Example 11 and the overlaps of the cloned *A. mediterranei* fragments in the plasmids pNE112, pNE95 and pRi44-2.

The DNA sequence of the chromosomal *A. mediterranei* DNA region described in Example 11 from the EcoRI cleavage site in the 7.2 kb position up to the end at 61 kb is depicted in SEQ ID NO 3 (length 53789 base pairs).

## Example 13: Analysis of a first protein-encoding region (ORF A) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence shown in SEQ ID NO 3 is analysed with the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a very large open reading frame (ORF A) which codes for a protein is present in

the first third of the sequence (position 1825 - 15543 including stop codon in SEQ ID NO 3). The codons used in ORF A are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF A (SEQ ID NO 4, size 4572 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase of *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region from ORF A, SEQ ID NO 4: amino acids 370 - 451: is 50% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 469 - 889: is 65% identical to the ketoacy synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 982 - 1292: is 54% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 1324 - 1442: is 42% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 1664 - 1840: is 56% identical to the ketoreductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 1929 - 2000: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 2032 - 2453: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 2554 - 2865: is 37% identical to the acy transferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 2918 - 2991: is 54% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 3009 - 3431: is 65% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region from ORF A, SEQ ID NO 4: amino acids 3532 - 3847: is 53% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF A, SEQ ID NO 4: amino acids 4142 - 4307: is 43% identical to the ketoreductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF A, SEQ ID NO 4: amino acids 4405 - 4490: is 50% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

In addition to thes significant homologies with the eryA polyketide synthase of S. erythraea, the region of ORF A, SEQ ID NO 4: amino acids 1 - 356 is 53% identical to the postulated starter unit activation domain of the rapamycin polyketide synthase from Streptomyces hygroscopicus (Aparicio et al. GENE (1996) 169, 9-16)

The great similarities found in the amino acid sequence of the enzymatic domains suggest unambiguously that the protein-encoding region (ORF A) of the *A. mediterranai* chromosomal region depicted in SEQ ID NO 3 codes for a typical modular (type 1) polyketide synthase. This very large *A. mediterranei* polyketide synthase encoded by ORF A comprises three complete bioactive modules which are each responsible for condensation of a C2 unit in the macrolide ring of the molecule and correct modification of the initially formed β-keto groups. Because of the homology with activating domains of the rapamycin polyketide synthase, the first module described above very probably comprises an enzymatic domain for activating the aromatic starter unit of rifamycin biosynthesis, 3-amino-5-hydroxybenzoic acid (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327).

### Example 14: Analysis of a second protein encoding region (ORF B) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that another large open reading frame (ORF B) which codes for a protein is present in the middle region of the sequence (position 15550 - 30759 including stop codon in SEQ ID NO 3). The codons used in ORF B are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF B (SEQ ID NO 5, length 5069 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase of *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region of ORF B, SEQ ID NO 5; amino acids 44 - 468; is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 571 - 889: is 56% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 921 - 1055: is 47% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 1353 - 1525: is 49% identical to the ketoreductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 1621 - 1706: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 1726 - 2148: is 62% identical to the ketoacy synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 2251 - 2560: is 55% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 2961 - 3132: is 49% identical to the ketoreductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 3228 - 3313: is 52% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 3332 - 3755: is 63% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 3857 - 4173: is 52% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 4664 - 4799: is 47% identical to the keto reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea. Region of ORF B, SEQ ID NO 5: amino acids 4929 - 5014: is 52% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

## Example 15: Analysis of a third protein-encoding region (ORF C) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF C) which codes for a protein is present in the middle region of the sequence (position 30895 - 36060 including stop codon in SEQ ID NO 3). The codons used in ORF C are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF C (SEQ ID NO 6, length 1721 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

Region of ORF C, SEQ ID NO 6: amino acids 1 - 414: is 63% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF C, SEQ ID NO 6: amino acids 514 - 828: is 54% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF C, SEQ ID NO 6: amino acids 1290 - 1399: is 49% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF C, SEQ ID NO 6: amino acids 1563 - 1648: is 55% identical to the acyl

## Example 16: Analysis of a fourth protein-encoding region (ORF D) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF D) which codes for a protein is present in the middle region of the sequence (position 36259 - 41325 including stop codon in SEQ ID NO 3). The codons used in ORF D are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF D (SEQ ID NO 7, length 1688 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence genes/EMBL accession N° M63676) gives the following results:

Region of ORF D, SEQ ID NO 7: amino acids 1 - 418: is 64% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF D, SEQ ID NO 7: amino acids 524 - 841: is 54% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF D, SEQ ID NO 7: amino acids 1260 - 1432: is 51% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF D, SEQ ID NO 7: amino acids 1523 - 1608: is 53% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

# Example 17: Analysis of a fifth protein-encoding region (ORF E) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that a large open reading frame (ORF E) which codes for a protein is present in the rear region of the sequence (position 41373 - 51614 including stop codon in SEQ ID NO 3). The codons used in ORF E are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF E (SEQ ID NO 8, length 3413 amino acids) with other polyketide synthases and specifically with the very well characterized polyketide synthase from *Saccharopolyspora erythraea* (Donadio, Science, (1991) 252, 675-679, DNA sequence gene/EMBL accession N° M63676) gives the following results:

synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 555 - 874: is 37% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 907 - 1036: is 49% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 1336 - 1500: is 52% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 1598 - 1683: is 51% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 1598 - 1683: is 51% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E. SEQ ID NO 8: amino acids 1702 - 2124: is 62% identical to the ketoacyl synthase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 2229 - 2543: is 53% identical to the acyltransferase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 2573 - 2700: is 47% identical to the dehydratase domain of module 4 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 3054 - 3227: is 52% identical to the keto-reductase domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

Region of ORF E, SEQ ID NO 8: amino acids 3324 - 3405: is 51% identical to the acyl carrier protein domain of module 1 of the eryA locus of Saccharopolyspora erythraea.

# Example 18: Analysis of a sixth protein-encoding region (ORF F) of the cloned A. mediterranei chromosomal region depicted in SEQ ID NO 3

The nucleotide sequence in SEQ ID NO 3 is analysed using the Codonpreference computer program (Genetics Computer Group, University of Wisconsin, 1994). This analysis shows that an open reading frame (ORF F) which codes for a protein is present in the rear region of the sequence (position 51713 - 52393 including stop codon in SEQ ID NO 3). The codons used in ORF F are typical of actinomycetes genes with a high G+C content.

Comparison of the amino acid sequence of ORF F (SEQ ID NO 9, length 226 amino acids) with proteins from the EMBL databank (Heidelberg) shows a great similarity with the N-hydroxyarylamine O-acyltransferase from Salmonella typhimurium (29% identity over a region of 134 amino acids). There is also significant homology with arylamine acyltransferases from other organisms. It can be concluded from these agreements that the ORF F found in A. mediterranei in SEQ ID No 3 codes for an arylamine acyl transferase, and it can be assumed that this enzyme is responsible for the linkage of the long acyl chain produced by the polyketide synthase to the amino group on the starter molecule, 3-amino-5-hydroxybenzoic acid. This reaction would close the rifamycin ring system correctly after completion of the condensation steps by the polyketide synthase.

# Example 19: Summarizing assessment of the function of the proteins encoded by ORF A - F in SEQ ID NO 3, and their role in the biosynthesis of rifamycin

The five protein-encoding regions (ORF A-E), described in Examples 13 - 17, of SEQ ID NO 3 comprise proteins with very great similarity (in the amino acid sequence and the arrangement of the enzymatic domains) to polyketide synthases for polyketides of the macrolide type. Taken together, these five multifunctional enzymes comprise 10 polyketide

synthase modules which are each responsible for a condensation step in the polyketide synthesis. 10 such condensation steps are likewise necessary for rifamycin biosynthesis (Ghisalba et al., Biotechnology of Industrial Antibiotics Vandamme E. J. Ed., Decker Inc. New York, (1984) 281-327). The processing of the particular keto groups required by the enzymatic domains within the modules substantially corresponds to the activity required by the rifamycin molecule, if it is assumed that the polyketide synthesis takes place "colinearly" with the arrangement of the modules in the gene cluster of *A. mediterranei* (this is so for other macrolide antibiotics such as erythromycin and rapamycin). It may be added here that it is not certain whether transcription of the five ORFs results in five proteins; in particular, ORF C and ORF D might possibly be translated to a large protein.

An enzymatic domain which is very probably responsible for activating the starter molecule, 3-hydroxy-5-aminobenzoic acid, of rifamycin biosynthesis can be found at the N terminus of ORF A, the start of the polyketide synthase. Directly below the described rifamycin polyketide synthase gene cluster there is a gene (ORF F) which very probably determines a protein which brings about ring closure of the rifamycin molecule after completion of the condensation steps by the polyketide synthase.

It can be concluded on the basis of these findings that the *A. mediterranei* chromosomal region described in SEQ ID NO 3 is responsible for the ten condensation steps required for rifamycin polyketide synthesis, including activation of the starter molecule 3-hydroxy-5-aminobenzoic acid, and the concluding ring closure.

#### Deposited microorganisms

The following microorganisms and plasmids have been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Mascheroder Weg 1b, D-38124 Braunschweig, in accordance with the requirements of the Budapest Treaty.

Microorganism/Plasmid	Date of deposit	Deposit number		
E. coli with plasmid pRi7-3	10.08.96	DSM 11114		
E. coli with plasmid pNE112	14.07.97	DSM 11657		
E. coli with plasmid pNE95	14.07.97	DSM 11656		
E. coli with plasmid pRi44-2	14.07.97	DSM 11655		

\_...\_

#### SEQUENCE LISTING

### (1) GENERAL INFORMATION:

- (i) APPLICANT:
  - (A) NAME: Novartis AG
  - (B) STREET: Schwarzwaldallee 215
  - (C) CITY: Basel
  - (E) COUNTRY: Switzerland
  - (F) POSTAL CODE (ZIP): 4058
  - (G) TELEPHONE: +41 61 324 1111
  - (H) TELEFAX: + 41 51 322 75 32
- (ii) TITLE OF INVENTION: Rifamycin biosynthesis gene cluster
- (iii) NUMBER OF SEQUENCES: 9
- (iv) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGTACCCGGT	GTTCGCGACG	GCGTTCGACG	AGGCTTGCGA	GCAGCTGGAC	GTCTGTCTGG	60
CCGGCCGTGC	CGGGCACCGC	GTGCGGGACG	TCGTGCTCGG	CGAAGTGCCC	GCCGAAACCG	120
GGCTGCTGAA	CCAGACGGTC	TTCACCCAAG	CCGGGCTGTT	CGCGGTGGAG	AGCGCGCTGT	180
TCCGGCTCGC	CGAATCCTGG	GGTGTCCGGC	CGGACGTGGT	GCTCGGCCAC	TCCATCGGGG	240
AGATCACCGC	CGCGTATGCC	GCGGGCGTCT	TCTCGCTGCC	GGACGCCGCC	CGGATCGTCG	300
CGGCGCGCGG	CCGGCTGATG	CAGGCGCTGG	ceceeeee	GGCGATGGTC	GCCGTCGCCG	360
CCTCCGAAGC	CGAGGTGGCC	GAACTGCTCG	GCGACGCGT	GGAACTCGCC	GCCGTCAACG	420
GCCCTTCGGC	GGTAGTCCTT	TCCGGGGACG	CGGACGCGGT	CGTCGCGGCC	GCCGCCCGCA	480
TGCGCGAGCG	CGGGCACAAG	ACCAAGCAGC	TCAAGGTTTC	GCACGCGTTC	CACTCCGCGC	540
GGATGGCGCC	GATGCTGGCG	GAGTTCGCCG	CCGAGCTGGC	CGGCGTGACG	TGGCGCGAGC	600
CGGAGATCCC	: GGTGGTCTCC	AACGTGACCG	CCCGGTTCGC	CGAGCCCGGC	GAACTGACCG	660
AGCCGGGCTA	A CTGGGCCGAG	: CACGTGCGGC	: GGCCGGTGCG	GTTCGCCGAG	GGCGTCGCGG	720
CCGCGACGGI	A GICCGGCGGC	: TOGOTGTTCG	TGGAGCTCGG	; GCCGGGGGCG	GCGCTGACCG	780
CCCTCGTCG	A GGAGACGGC	GAGGTCACCI	r GCGTCGCGGG	CCTGCGGGAC	GACCGCCCGG	840
AGGTCACCG	C GCTGATCACO	C GCGGTCGCCC	G AGCTGTTCGT	r cccccccrr	r GCGGTCGATT	900
GGCCGGCCC	r gergeegee	GTCACCGGG	r TCGTCGACCI	r gccgaagta	C GCCTTCGACC	960
AGCAGCACT	a TTGGCTGCA	s ccceccece	C AGGCCACGG	A CGCGGCCTC	CTCGGGCAGG	1020

TCGCGGCCGA CCACCCGCTG CTGGGCGCGG TGGTCCGGCT GCCGCAGTCG GACGGCCTGG 1080 TCTTCACCTC GCGGCTGTCA TTGAAATCGC ACCCGTGGCT GGCCGACCAC GTCATCGGCG 1140 GGGTGGTGCT CGTCGCGGGC ACCGGGCTCG TCGAGCTGGC CGTCCGGGCC GGGGACGAGG 1200 CCGGCTGCCC GGTCCTCGAA GAACTCGTCA TCGAGGCTCC GCTGGTCGTC CCCGACCACG 1260 GCGGGGTCCG GATCCAGGTC GTCGTGGGGG CACCGGGGGA GACCGGTTCG CGCGCGGTCG 1320 AGGTGTACTC CCTGCGCGAG GACGCCGGTG CCGAAGTGTG GGCCCGGCAC GCCACCGGGT 1380 TCCTGGCTGC GACGCCGTCG CAGCACAAGC CGTTCGACTT CACCGCCTGG CCGCCCCCG 1440 GCGTCGAGCG CGTCGACGTC GAGGACTTCT ACGACGGCTT CGTCGACCGC GGGTACGCCT 1500 ACGGCCGTC GTTCCGGGCC CTGCGGGCGG TGTGGCGGCG CGGCGACGAA GTGTTCGCCG 1560 AGGTCGCCCT GGCCGAGGAC GACCGCGGGG ACGCGGCCCG GTTCGGCATC CACCCCGGCC 1620 TGCTGGACGC CGCCCTGCAC GCGGGCATGG CCGGTGCCAC CACCACGGAA GAGCCCGGCC 1680 GGCCGGTGCT GCCGTTCGCC TGGAACGGCC TGGTGCTGCA CGCGGCCGGG GCGTCCGCGC 1740 TGCGGGTCCG GCTCGCCCCG AGCGGTCCGG ACGCCCTGTC GGTCGAGGCC GCGGACGAGG 1800 1860 CCGCCGCTCT CGTTGTGACG GCGGACTCGC TGGTCTCCCG GCCGGTGTCG GCCGAACAGC TGGGCGCGC GGCGAACCAC GACGCGTTGT TCCGCGTGGA GTGGACCGAG ATTTCCTCGG 1920 CTGGAGACGT TCCGGCGGAC CACGTCGAAG TGCTCGAAGC CGTCGGCGAG GATCCCCTGG 1980 AACTGACCGG CCGGGTCCTG GAGGCCGTGC AGACCTGGCT CGCCGACGCA GCCGACGACG 2040 CTCGCCTGGT CGTGGTGACC CGCGGCGCCG TCCACGAGGT GACTGACCCG GCCGGTGCCG 2100 CGGTGTGGGG CCTGATCCGG GCCGCGCAGG CGGAAAACCC GGACCGGATC GTGCTGCTGG 2160

ACACCGACGG TGAAGTGCCG CTAGGCCGGG TGCTGGCCAC CGGCGAGCCC CAAACAGCCG 2220 TCCGAGGCGC CACGCTGTTC GCCCCGCGC TGGCCCGCGC CGAGGCCGCG GAGGCACCGG 2280 CAGTGACCGG CGGGACGGTC CTGATCTCGG GCGCCGCCTC GCTGGGCGCG CTCACCGCCC 2340 GGCALCTGGT CGCCCGGCAC GGAGTCCGGC GGCTGGTGCT CGTCAGCCGC CGTGGCCCCG 2400 ACGCCGACGG CATGGCCGAA CTGACCGCTG AACTCATCGC TCAGGGCGCC GAGGTCGCCG 2460 TAGTOGOTTG CGACCTGGCC GACCGGGACC AGGTCCGGGT ACTGCTGGCC GAGCACCGCC 2520 CGAACGCCGT CGTCCACACG GCCGGTGTTC TCGACGACGG CGTCTTCGAG TCGCTGACGC 2580 GGGAGCGGCT GGCCAAGGTC TTCGCGCCCA AAGTTACTGC TGCCAATCAC CTCGACGAGC 2640 TGACCCGCGA ACTGGATCTT CGCGCGTTCG TCGTGTTCTC CTCCGCCTCC GGGGTCTTCG 2700 GCTCCGCCGG GCAGGGCAAC TACGCCGCTG CCAACGCCTA CCTGGACGCC GTGGTCGCCA 2760 ACCGCCGGGC CGCGGGCCTG CCCGGCACAT CGCTGGCCTG GGGCCTGTGG GAACAGACCG 2820 ACGGGATGAC CGCGCACCTC GGCGACGCCG ACCAGGCGCG GGCGAGTCGC GGCGGGGTCC 2880 TCGCCATCTC ACCCGCCGAA GGCATGGAGC TGTTCGACGC AGCGCCGGAC GGGCTCGTCG 2940 3000 TCCCGGTCAA GCTGGACCTG CGCAAGACCC GCGCCGGCGG GACGGTGCCG CACCTGCTGC GCGGCCTGGT CCGCCCGGGA CGGCAGCAGG CCCGTCCGGC GTCCACTGTG GACAACGGAC 3060 TGGCCGGGCG ACTCGCCGGG CTCGCGCCGG CGGAGCAGGA GGCGCTGCTG CTCGACGTCG 3120 TCCGCACGCA GGTCGCGCTG GTCCTCGGGC ACGCCGGGCC GGAGGCCGTC CGCGCGGACA 3180 CGGCGTTCAA GGACACCGGC TTCGACTCGC TGACGTCGGT GGAACTGCGC AACCGGCTGC 3240

GCGAGGCGAG CGGCTGAAG CTGCCCGCGA CGCTCGTCTT CGACTACCCG ACGCCGGTCG 3300 CGCTGGCCG CTACCTGCGT GACGAATTCG GCGACACGGT GGCAACAACT CCGGTGGCCA 3360 CCGCGGCCGC AGCGGACGCC GGCGAGCCGA TCGCCATCGT CGGCATGGCG TGCCGGCTGC 3420 CGGGCGGGT CACCGATCCC GAAGGCCTGT GGCGCCTGGT GCGCGACGGC CTCGAAGGGC 3480 TGTCTCCCTT CCCCGAGGAC CGGGGCTGGG ACCTGGAGAA CCTGTTCGAC GACGACCCCG 3540 ACCGCTCCGG CACGACGTAC ACCAGCCGGG GCGGGTTCCT CGACGGCGCC GGCCTGTTCG 3600 ACGCGGCTT CTTCGGGATT TCGCCGCGC AGGCGCTGGC CATGGACCCG CAGCAGCGGC 3660 TGCTGCTCGA GGCGGCCTGG GAAGCCCTCG AAGGCACCGG TGTCGACCCG GGCTCGTTGA 3720 AGGGCGCCGA CGTCGGGGTG TTCGCCGGGG TGTCCAACCA GGGCTATGGG ATGGGCGCGG 3780 ATCCGGCCGA ACTGGCGGGG TACGCGAGCA CGGCGGGCGC TTCGAGCGTC GTCTCGGGCC 3840 GAGTCTCGTA CGTCTTCGGG TTCGAAGGAC CGGCGGTCAC GATCGACACG GCTTGCTCGT 3900 CGTCGCTGGT GGCGATGCAC CTGGCCGGGC AGGCGCTGCG GCAGGGCGAG TGCTCGATGG 3960 CCCTGGCCGG TGGCGTCACG GTGATGGGGA CGCCCGGCAC GTTCGTGGAG TTCGCGAAGC 4020 AGCGCGCCT GGCCGCCAC GGCCGTGCA AGGCCTACGC CGAAGGCCGC GACGCCACGG 4080 SCTGGGCCGA GGGCGTCGGG GTCGTCGTGC TGGAGCGCGT GTCGGTGGCG CGCGAGCGCG 4140 GGCACCGGT GCTGGCCGTG CTGCGCGGCA GCGCGGTCAA CTCCGACGGC GCGTCCAACG 4200 GCCTGACCGC CCCCAACGGG CCGTCGCAGC AACGGGTGAT CCGCCGGGCC CTGGCCGCCG 4260 CCGGCCTCGA ACCGTCCGAT GTGGACATCG TGGAAGGGCA CGGCACCGGG ACGGCGCTGG 4320 GCGACCCGAT CGAGGCGCAG GCCCTGCTGG CCACCTACGG CAAGGACCGC GACCCGGAGA 4380

CGCCGTTGTG GCTGGGGTCG GTGAAGTCGA ACTTCGGCCA CACGCAGTCC GCGGCCGGCG TEGCCEGEGT GATCAAGATG GTECAGECEC TECECCACEG CETCATECCE CCCACCCTEC 4500 ACGTGGACCG GCCCACCAGC CAGGTCGACT GGTCCGCGGG GGCCGTCGAA GTGCTGACCG 4560 AGGCACGGGA GTGGCCGCGG AACGGCCGTC CGCGCCGGGC CGGGGTGTCC TCGTTCGGGA 4620 TCAGCGGCAC GAACGCCCAC CTGATCATCG AAGAAGCACC GGCCGAGCCA CAGCTTGCCG 4680 GACCACCGCC GGACGCCGT GTGGTGCCGC TGGTCGTCTC GGCTCGCAGC CCCGGTGCCC 4740 TGGCCGGTCA GGCGCGTCGG CTGGCCACGT TCCTCGGCGA CGGGCCCCTT TCCGACGTCG 4800 CCGGTGCGCT GACGAGCCGC GCCCTGTTCG GCGAGCGCGC GGTCGTCGTG GCGGATTCGG 4860 CCGAGGAAGC CCGCCCGGT CTGGGCGCAC TGGCCCGCGG CGAAGACGCG CCGGGCCTGG 4920 TCCGCGGCCG GGTGCCCGCG TCCGGCCTGC CGGGCAAGCT CGTGTGGGTG TTCCCCGGGC 4980 AGGGGACGCA GTGGGTGGGC ATGGGCCGCG AACTCCTCGA AGAGTCTCCG GTGTTCGCCG 5040 AGCGGATCGC CGAGTGTGCG GCCGCGCTGG AGCCGTGGAT CGGCTGGTCG CTGTTCGACG 5100 TCCTCCGTGG CGACGGTGAC CTCGATCGGG TCGATGTGCT GCAGCCCGCG TGCTTTGCGG 5160 TGATGGTCGG CTTGGCCGCG GTGTGGTCCT CGGCCGGGGT GGTCCCCGAT GCGGTGCTCG 5220 GCCACTCCCA GGGTGAGATC GCCGCGCGT GCGTGTCGGG TGCGTTGTCG CTGGAGGATG 5280 CGCCGAAGGT GGTTGCCCTG CGCAGCCAGG CCATCGCCGC GAAGCTCTCC GGCCGCGGCG 5340 GGATGGCTTC GGTCGCCTTG GGCGAAGCCG ATGTGGTGTC GCGGCTGGCG GACGGGGTCG 5400 AGGTGGCTGC CGTCAACGGT CCGGCGTCCG TGGTGATCGC GGGGGATGCC CAGGCCCTCG 5460

ACGAAACGCT	GGAAGCGCTG	TCCGGTGCGG	GAATCCGGGC	TCGGCGGGTG	GCGGTGGACT	5520
ACGCCTCGCA	CACCCGGCAC	GTCGAAGACA	TCGAAGACAC	CCTCGCCGAA	GCGCTGGCCG	5580
GGATCGACGC	CCGGGCGCCG	CTGGTGCCGT	TCCTCTCCAC	CCTCACCGGC	GAGTGGATCC	5640
GGGACGAGGG	CGTCGTGGAC	GGCGGCTACT	GGTACC			5676

- (2) INFORMATION FOR SEQ ID NO: 2:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1891 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Tyr Pro Val Phe Ala Thr Ala Phe Asp Glu Ala Cys Glu Gln Leu Asp 1 5 10 15

Val Cys Leu Ala Gly Arg Ala Gly His Arg Val Arg Asp Val Val Leu 20 25 30

Gly Glu Val Pro Ala Glu Thr Gly Leu Leu Asn Gln Thr Val Phe Thr 35 40 45

Gln Ala Gly Leu Phe Ala Val Glu Ser Ala Leu Phe Arg Leu Ala Glu 50 55 60

Ser Trp Gly Val Arg Pro Asp Val Val Leu Gly His Ser Ile Gly Glu 65 70 75 80

- Ile Thr Ala Ala Tyr Ala Ala Gly Val Phe Ser Leu Pro Asp Ala Ala 85 90 95
- Arg Ile Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu Ala Pro Gly
  100 105 110
- Gly Ala Met Val Ala Val Ala Ala Ser Glu Ala Glu Val Ala Glu Leu 115 120 125
- Leu Gly Asp Gly Val Glu Leu Ala Ala Val Asn Gly Pro Ser Ala Val
  130 135 140
- Val Leu Ser Gly Asp Ala Asp Ala Val Val Ala Ala Ala Ala Arg Met 145 150 155 160
- Arg Glu Arg Gly His Lys Thr Lys Gln Leu Lys Val Ser His Ala Phe 165 170 175
- His Ser Ala Arg Met Ala Pro Met Leu Ala Glu Phe Ala Ala Glu Leu 190 185 190
- Ala Gly Val Thr Trp Arg Glu Pro Glu Ile Pro Val Val Ser Asn Val 195 200 205
- Thr Gly Arg Phe Ala Glu Pro Gly Glu Leu Thr Glu Pro Gly Tyr Trp
  210 215 220
- Ala Glu His Val Arg Pro Val Arg Phe Ala Glu Gly Val Ala Ala 225 230 235 240
- Ala Thr Glu Ser Gly Gly Ser Leu Phe Val Glu Leu Gly Pro Gly Ala 245 250 255
- Ala Leu Thr Ala Leu Val Glu Glu Thr Ala Glu Val Thr Cys Val Ala
  260 265 270

-----

Ala Leu Arg Asp Asp Arg Pro Glu Val Thr Ala Leu Ile Thr Ala Val 275 280 285

Ala Glu Leu Phe Val Arg Gly Val Ala Val Asp Trp Pro Ala Leu Leu 290 295 300

Pro Pro Val Thr Gly Phe Val Asp Leu Pro Lys Tyr Ala Phe Asp Gln 305 310 315 320

Gln His Tyr Trp Leu Gln Pro Ala Ala Gln Ala Thr Asp Ala Ala Ser 325 330 535

Leu Gly Gln Val Ala Ala Asp His Pro Leu Leu Gly Ala Val Val Arg 340 345 350

Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys 355 360 365

Ser His Pro Trp Leu Ala Asp His Val Ile Gly Gly Val Val Leu Val 370 375 380

Ala Gly Thr Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala 335 390 395 400

Gly Cys Pro Val Leu Glu Glu Leu Val Ile Glu Ala Pro Leu Val Val
405 410 415

Pro Asp His Gly Gly Val Arg Ile Gln Val Val Val Gly Ala Pro Gly
420 425 430

Glu Thr Gly Ser Arg Ala Val Glu Val Tyr Ser Leu Arg Glu Asp Ala 435 440 445

Gly Ala Glu Val Trp Ala Arg His Ala Thr Gly Phe Leu Ala Ala Thr 450 455 460

Pro Ser Gln His Lys Pro Phe Asp Phe Thr Ala Trp Pro Pro Pro Gly

Val Glu Arg Val Asp Val Glu Asp Phe Tyr Asp Gly Phe Val Asp Arg Gly Tyr Ala Tyr Gly Pro Ser Phe Arg Gly Leu Arg Ala Val Trp Arg Arg Gly Asp Glu Val Phe Ala Glu Val Ala Leu Ala Glu Asp Asp Arg Ala Asp Ala Ala Arg Phe Gly Ile His Pro Gly Leu Leu Asp Ala Ala Leu His Ala Gly Met Ala Gly Ala Thr Thr Thr Glu Glu Pro Gly Arg Pro Val Leu Pro Phe Ala Trp Asn Gly Leu Val Leu His Ala Ala Gly Ala Ser Ala Leu Arg Val Arg Leu Ala Pro Ser Gly Pro Asp Ala Leu Ser Val Glu Ala Ala Asp Glu Ala Gly Gly Leu Val Val Thr Ala Asp . 595 Ser Leu Val Ser Arg Pro Val Ser Ala Glu Gln Leu Gly Ala Ala Ala Asn His Asp Ala Leu Phe Arg Val Glu Trp Thr Glu Ile Ser Ser Ala Gly Asp Val Pro Ala Asp His Val Glu Val Leu Glu Ala Val Gly Glu Asp Pro Leu Glu Leu Thr Gly Arg Val Leu Glu Ala Val Gln Thr Trp

6€5

WO 98/07868



Leu Ala Asp Ala Ala Asp Asp Ala Arg Leu Val Val Thr Arg Gly
675 680 685

Ala Val His Glu Val Thr Asp Pro Ala Gly Ala Ala Val Trp Gly Leu 690 695 700

Ile Arg Ala Ala Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu Asp 705 710 715 720

Thr Asp Gly Glu Val Pro Leu Gly Arg Val Leu Ala Thr Gly Glu Pro
725 730 735

Gln Thr Ala Val Arg Gly Ala Thr Leu Phe Ala Pro Arg Leu Ala Arg
740 745 750

Ala Glu Ala Ala Glu Ala Pro Ala Val Thr Gly Gly Thr Val Leu Ile
755 760 765

Ser Gly Ala Gly Ser Leu Gly Ala Leu Thr Ala Arg His Leu Val Ala 770 775 780

Arg His Gly Val Arg Arg Leu Val Leu Val Ser Arg Arg Gly Pro Asp
785 790 795 800

Ala Asp Gly Met Ala Glu Leu Thr Ala Glu Leu Ile Ala Gln Gly Ala 805 810 815

Glu Val Ala Val Val Ala Cys Asp Leu Ala Asp Arg Asp Gln Val Arg 820 825 830

Val Leu Leu Ala Glu His Arg Pro Asn Ala Val Val His Thr Ala Gly 835 840 845

Val Leu Asp Asp Gly Val Phe Glu Ser Leu Thr Arg Glu Arg Leu Ala 850 855 860



- Lys Val Phe Ala Pro Lys Val Thr Ala Ala Asn His Leu Asp Glu Leu 865 870 875 880
- Thr Arg Glu Leu Asp Leu Arg Ala Phe Val Val Phe Ser Ser Ala Ser 885 890 895
- Gly Val Phe Gly Ser Ala Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala 900 905 910
- Tyr Leu Asp Ala Val Val Ala Asn Arg Arg Ala Ala Gly Leu Pro Gly 915 920 925
- Thr Ser Leu Ala Trp Gly Leu Trp Glu Gln Thr Asp Gly Met Thr Ala 930 935 940
- His Leu Gly Asp Ala Asp Gln Ala Arg Ala Ser Arg Gly Gly Val Leu 945 950 955 960
- Ala Ile Ser Pro Ala Glu Gly Met Glu Leu Phe Asp Ala Ala Pro Asp 965 970 975
- Gly Leu Val Val Pro Val Lys Leu Asp Leu Arg Lys Thr Arg Ala Gly 980 985 990
- Gly Thr Val Pro His Leu Leu Arg Gly Leu Val Arg Pro Gly Arg Gln 995 1000 1005
- Gln Ala Arg Pro Ala Ser Thr Val Asp Asn Gly Leu Ala Gly Arg Leu 1010 1015 1020
- Ala Gly Leu Ala Pro Ala Glu Gln Glu Ala Leu Leu Leu Asp Val Val 1025 1030 1035 1040
- Arg Thr Gln Val Ala Leu Val Leu Gly His Ala Gly Pro Glu Ala Val 1045 1050 1355
- Arg Ala Asp Thr Ala Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr Ser



1060 1065 1070

Val Glu Leu Arg Asn Arg Leu Arg Glu Ala Ser Gly Leu Lys Leu Pro 1075 1080 1085

Ala Thr Leu Val Phe Asp Tyr Pro Thr Pro Val Ala Leu Ala Arg Tyr 1090 1095 1100

Leu Arg Asp Glu Phe Gly Asp Thr Val Ala Thr Thr Pro Val Ala Thr 1105 1110 1115 1120

Ala Ala Ala Asp Ala Gly Glu Pro Ile Ala Ile Val Gly Met Ala 1125 1130 1135

Cys Arg Leu Pro Gly Gly Val Thr Asp Pro Glu Gly Leu Trp Arg Leu 1140 1145 1150

Val Arg Asp Gly Leu Glu Gly Leu Ser Pro Phe Pro Glu Asp Arg Gly 1155 1160 1165

Trp Asp Leu Glu Asn Leu Phe Asp Asp Asp Pro Asp Arg Ser Gly Thr 1170 1180

Thr Tyr Thr Ser Arg Gly Gly Phe Leu Asp Gly Ala Gly Leu Phe Asp 1185 1190 1195 1200

Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro 1205 1210 1215

Gln Gln Arg Leu Leu Glu Ala Ala Trp Glu Ala Leu Glu Gly Thr 1220 1225 1230

Gly Val Asp Pro Gly Ser Leu Lys Gly Ala Asp Val Gly Val Phe Ala 1235 1240 1245

Gly Val Ser Asn Gln Gly Tyr Gly Met Gly Ala Asp Pro Ala Glu Leu 1250 1255 1260



Ala Gly Tyr Ala Ser Thr Ala Gly Ala Ser Ser Val Val Ser Gly Arg 1265 1270 1275 1280

Val Ser Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Thr 1285 1290 1295

Ala Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Gly Gln Ala Leu 1300 1305 1310

Arg Gln Gly Glu Cys Ser Met Ala Leu Ala Gly Gly Val Thr Val Met 1315 1320 1325

Gly Thr Pro Gly Thr Phe Val Glu Phe Ala Lys Gln Arg Gly Leu Ala 1330 1335 1340

Gly Asp Gly Arg Cys Lys Ala Tyr Ala Glu Gly Ala Asp Gly Thr Gly
1345 1350 1355 1360

Trp Ala Glu Gly Val Gly Val Val Leu Glu Arg Leu Ser Val Ala 1365 1370 1375

Arg Glu Arg Gly His Arg Val Leu Ala Val Leu Arg Gly Ser Ala Val 1380 1385 1390

Asn Ser Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser 1395 1400 1405

Gln Gln Arg Val Ile Arg Arg Ala Leu Ala Gly Ala Gly Leu Glu Pro 1410 1415 1420

Ser Asp Val Asp Ile Val Glu Gly His Gly Thr Gly Thr Ala Leu Gly
1425 1430 1435 1440

Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Lys Asp Arg 1445 1450 1455



Asp Pro Glu Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly 1460 1465 1470

His Thr Gln Ser Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln 1475 1480 1485

Ala Leu Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Arg Pro 1490 1495 1500

Thr Ser Gln Val Asp Trp Ser Ala Gly Ala Val Glu Val Leu Thr Glu 1505 1510 1515 1520

Ala Arg Glu Trp Pro Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser 1525 1530 1535

Ser Phe Gly Ile Ser Gly Thr Asn Ala His Leu Ile Ile Glu Glu Ala 1540 1545 1550

Pro Ala Glu Pro Gln Leu Ala Gly Pro Pro Pro Asp Gly Gly Val Val 1555 1560 1565

Pro Leu Val Val Ser Ala Arg Ser Pro Gly Ala Leu Ala Gly Gln Ala 1570 1575 1580

Arg Arg Leu Ala Thr Phe Leu Gly Asp Gly Pro Leu Ser Asp Val Ala 1585 1590 1595 1600

Gly Ala Leu Thr Ser Arg Ala Leu Phe Gly Glu Arg Ala Val Val 1605 1610 1615

Ala Asp Ser Ala Glu Glu Ala Arg Ala Gly Leu Gly Ala Leu Ala Arg 1620 1625 1630

Gly Glu Asp Ala Pro Gly Leu Val Arg Gly Arg Val Pro Ala Ser Gly 1635 1640 1645

Leu Pro Gly Lys Leu Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp

- 52 **-**

1650

1655

1660

Val Gly Met Gly Arg Glu Leu Leu Glu Glu Ser Pro Val Phe Ala Glu 1665 1670 1675 1680

Arg Ile Ala Glu Cys Ala Ala Ala Leu Glu Pro Trp Ile Gly Trp Ser 1685 1690 1695

Leu Phe Asp Val Leu Arg Gly Asp Gly Asp Leu Asp Arg Val Asp Val 1700 1705 1710

Leu Gln Pro Ala Cys Phe Ala Val Met Val Gly Leu Ala Ala Val Trp 1715 1720 1725

Ser Ser Ala Gly Val Val Pro Asp Ala Val Leu Gly His Ser Gln Gly 1730 1735 1740

Glu Ile Ala Ala Cys Val Ser Gly Ala Leu Ser Leu Glu Asp Ala 1745 1750 1755 1760

Ala Lys Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Lys Leu Ser 1765 1770 1775

Gly Arg Gly Gly Met Ala Ser Val Ala Leu Gly Glu Ala Asp Val Val 1780 1785 1790

Ser Arg Leu Ala Asp Gly Val Glu Val Ala Ala Val Asn Gly Pro Ala 1795 1800 1805

Ser Val Val Ile Ala Gly Asp Ala Gln Ala Leu Asp Glu Thr Leu Glu 1810 1825 1820

Ala Leu Ser Gly Ala Gly Ile Arg Ala Arg Arg Val Ala Val Asp Tyr 1825 1830 1835 1840

Ala Ser His Thr Arg His Val Glu Asp Ile Glu Asp Thr Leu Ala Glu 1845 1850 1855



Ala Leu Ala Gly Ile Asp Ala Arg Ala Pro Leu Val Pro Phe Leu Ser 1860 1865 1870

Thr Leu Thr Gly Glu Trp Ile Arg Asp Glu Gly Val Val Asp Gly Gly 1875 1880 1885

Tyr Trp Tyr 1890

### (2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 53789 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

#### (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAATTCCAGG	CCGTCGACGG	CTGCGACATC	GCGGTCTTCC	GGTGGTCGCA	CCGCACGAAG	60
ATCGCCGAAT	AAGAATTTCC	GGATCTCCCA	CGGGAAAGGT	TTCCATGACC	GACGCAATAT	120
CCTTCGAGGT	GCCGTGGGAC	CGGACCGACA	AGTTCGACCC	GCCCGCGGTG	TTCGACTCTC	180
TGCGCGAAGA	ACGTCCGCTC	GCGAAGATGG	TTTACCCGGA	TGGGCACGTC	GGCTGGATCG	240
TTTCCAGCTA	CGAGCTGGTC	CGCGAGGTCC	TCAGCGACCT	GCGGTTCAGC	CACAGCTGCG	300
AAGTCGGCCA	CTTCCCGGTG	ACCCACCAGG	GCCAGGTCAT	CCCGACCCAC	CCGCTGATCC	360

CCGGCATGTT CATCCACATG GACCCGCCCG AGCACACGCG CTACCGCAAG CTGCTGACCG 420 GCGAGTTCAC CGTCCGCCGC GCCAGCAGGC TGATCCCGCG GGCCGAGGCC GTGGCCGCCG 480 AGCAGATCGA GGTCATGCGG GCCAAGGGCG CCCCCGCGGA CGTGGTCATG GACTTCGCCA 540 AGCCGCTGGT GCTGCGGATG CTGGGCGAGC TCGTCGGCCT GCCCTACGAG GAACGCGACC 600 GGTACGTGCC CGCGGTGACC CTCCTGCACG ACGCCGAAGC GGACCCGGCC GAGGCCGCGG 660 CCGCCTACGA GGTGGCCGGG AAGTTCTTCG ACGAGGTCAT CGAGCGCCGC CGGCAGCGGC 720 CCCAGGACGA CCTCATCAGC TCGCTCGTCA CCGAGGACCT GACCCAGGAG GAGCTGCGCA 780 ACATCGTCAC CCTGCTGCTG TTCGCCGGGT ACGAGACCAC CGAGGGCGCG CTCGCCACCG 840 GCGTCTTCGC GCTGCTGCAC CACACCGATC AGCTGGCGGC ACTGCGCGCG GAGCCGGAAA 900 AGCTCGACGC CGCGATCGAA GAGCTGCTGC GCTACCTGAC CGTCAACCAG TACCACACCT 960 ACCGCACCGC GCTGGAGGAC GTGAAGCTGG AGGGCGAGCT GATCAAGAAG GGCGACACGG 1020 TGACGGTGTC GCTGCCCGCG GCCAACCGCG ACCCGGCCAA GTTCGGCTGT CCCGCGGAGC 1080 TCGACATCGA GCGGGACACC TCCGGCCACG TCGCGTTCGG CTTCGGCATC CACCAGTGCC 1140 TGGGCCAGAA CCTGGCGCGC ATCGAGCTGC GGGCCGCTT CACGGCGCTC CTGCGGGCGT 1200 TCCCCGAGCT CCGGCTGGCC GTCCCGGCCG ACGAGGTTCC GCTGCGGCTG AAGGGTTCCG 1260 TCTTCTCGGT GAAGAAGCTG CCCGTCTCCT GGTGAGCGTT CTTCCCCTCG AACACCCGAA 1320 AGGATCTGCG GCACAGTGCG CACCGATCTC ATCAAGCCAC TTCACGTCGC ACTCCTGGAG 1380 AACGCGACCC GCTTCGCCGG CAAGCCGGCC TTCGCCGACG ACCACCGGAC GGTCACCTAC 1440 GGCGACCTCG AGGCGCGGAC GCGCCGGCTG GCCGGGCACC TGGCCGGCCT CGGTGTCCGG 1500

- 54 -



CACGGCGACC GGGTGCCGAT CTGCCTCGGC AACCGGGTGT CCACTGTGGA GAGTTACTTC 1560 GCGATCCTGC GCGCGGTGC CGTCGGCGTG CCGCTCAACC CCGGTTCGGC GACGGCCGAG 1620 CTCGAGCACC CGCTGACCGA CAGCGGCGCC ACGGTGGTCG TCACCGACGC CGCCCAGGCG 1680 CCCCGCTCC GCCTCGCGC GCACGTCGAG CTGCTGGTGA CCGGCGACGA CGTCCCGGAG 1740 GGCGCCCACT CCTACGACGA ACTCGCCCTC AGCGAACCGG CCGAGCCCGC CGCGGACGAC 1800 CTCGAGCTCG ACGAGCCGGC GTGGATGTTC TACACGTCGG GCACGACCGG GCGGCCCAAG 1860 GECGTCGTGT CCACGCAGCG CAACTGCCTC TGGTCCGTCG CTTCCTGCTA CGTGCCGTTC 1920 CCCGGGTTGT CGGACCAGGA CCGGGTGCTC TGGCCGCTCC CGCTGTTCCA CAGCCTTTCG 1980 CACATCGCCT GCGTCCTGTC CGCCACCGTG GTCGGGGCCA GCGTCCGGAT CGCCGACGGC 2040 AGCTCCGCCG ACGACGTGAT GCGGCTGATC GAGGCGGAGA GCTCGACCTT CCTGGCCGGC 2100 GTGCCGACCA CCTACCACCA CCTGGTGCGG GCCGCCCGGC AGCGCGGTTT CTCCGCGCCG 2160 ASCCTSCGGA TCGGCCTGGC CGGGGCGCG GTCCTCGGCG CCGGGCTGCG AAGCGAGTTC 2220 GAAGAGACCT TCGGCGTCCC GCTGATCGAC GCCTACGGCA GCACCGAGAC CTGCGGGGCG 2280 ATCACCATGA ACCCGCCGGA CGGCGCCCGC GTCGAGGGCT CGTGCGGCTT GGCCGTGCCG 2340 GGCGTCGACG TGCGGGTCGT CGACCCCGAC ACCGGGCTCG ACGTCCCCGC CGGCGAGGAG 2400 GGCGAGGTCT GGGTCAGCGG GCCGAACGTC ATGCTCGGCT ACCACAACAG CCCGGAGGCG 2460 ACCGCCGCG CGATGCGGGA CGGCTGGTTC CGGACCGGGG ACCTGGCCCG CCGCGACGAC 2520 GCCGGTTACT TCACCATCTG CGGCCGGATC AAGGAACTCA TCATCCGCGG CGGCGCGAAC 2580

\_\_\_\_

- 56 -



ATCCACCCC GCGAGGTCGA GGCGGTCCTG CGCACGGTCG ACGGCGTCGC GGACGCGGCG 2640 GTCGGCGGTG TGCCGCACGA CACGCTCGGC GAGGTGCCGG TCGCCTACGT CATCCCCGGA 2700 CCGACCGGTT TCGATCCTGC GGCGTTGATC GAGAAGTGCC GCGAACAGCT GTCCGCCTAC 2760 AAGGTGCCGG ACCGGATCCT CGAGGTCGCC CACATTCCCC GGACCGCGTC GGGCAAGATC 2820 CGGCGCGGC TGCTGACCGA CGAGCCCGCG CAGCTGCGGT ACGCCGCGAC CGAACACGAG 2880 GAACAGTCCC GGCACGCCGA CGAGTCCGTC GCGGCGCGCC TGCGCGCGCG ACTGTCCGGT 2940 3000 TTGGACGAAC GCGCCCAGTG CGAGCTCCTG GAAGACCTCG TCCGCACCCA GGCGGCCGAC GTGCTGGGGC AGCCGGTCCC GGACGGGCGT GCGTTCCGCG ACCTCGGCTT CACGTCGCTG 3060 GCCATCGTGG AGCTGCGCAA CCGGCTGACC GAGCACACCG GGCTCTGGCT GCCCGCCAGC 3120 GCCGTCTTCG ACCACCCCAC GCCGCGGCG CTGGCCGCCC GCGTCCGGGC TGAGCTCCTC 3180 GGGATCACGC AGGCCGTCGC GGAGCCGGTC GTCGCGGCCG ACCCGGGCGA GCCGATCGCG 3240 3300 CTGGTGGCCG AGCGCGTCGA CGCCGTTTCG GAGTTCCCCG GCGACCGCGG CTGGGACCTG 3360 GACAGCCTGA TCGACCCGGA CCGGGAGCGC GCCGGGACGT CGTACGTCGG CCAGGGCGGA 3420 TTCCTGCACG ACGCCGCCGA GTTCGACGCC GGGTTCTTCG GGATCTCGCC GCGTGAGGCC 3480 GTCGCGATGG ACCCGCAGCA GCGGTTGCTG CTGGAGACGT CGTGGGAGGC CCTCGAAAAC 3540 GCCGGAGTCG ACCCGATCGC GTTGAAGGGC ACCGACACCG GCGTGTTCTC CGGCCTCATG 3600 GGCCAGGGGT ACGGGTCCGG CGCGGTGGCG CCGGAGCTCG AAGGTTTCGT CACCACCGGG 3660 GTCGCGTCGA GCGTGGCCTC GGGCCGGGTG TCGTACGTGC TGGGACTGGA AGGCCCGGCG 3720



GTCACCGTGG ACACCGCGTG TTCGTCGTCG CTGGTCGCGA TGCACCTGGC CGCGCAGGCC 3780 CTGCGGCAGG GCGAATGCTC GATGGCGCTC GCCGGCGGGG TCACGGTGAT GGCCACGCCG 3840 3900 GGCTCGTTCG TCGAGTTCTC CCGCCAGCGG GCCCTGGCGC CCGACGGGCG CTGCAAGGCC TTCGCGGCGG CGCCCGACGG GACCGGCTGG TCCGAGGGTG TCGGCGTGGT CGTCCTCGAG 3960 CGGCTGTCCG TGGCGCGCGA GCGGGGCCAC CGGATCCTGG CCGTTTTGCG TGGCAGCGCG 4020 CTCAACCAGG ACGGCGCGTC CAACGGGCTC ACCGCGCCGA ACGGCCTCTC GCAGCAGCGG 4080 GTCATCCGCC GCGCGCTGGC CGCGCCGGG CTGGCACCGT CCGATGTGGA CGTCGTCGAG 4140 GCGCACGGCA CCGGGACCAC GCTGGGTGAC CCGATCGAGG CGCAGGCCCT GCTGGCGACC 4200 TACGGCCAGG AGCGGAAGCA GCCGTTGTGG CTCGGTTCGC TCAAGTCGAA CATCGGCCAC 4260 CCGCAGGCGG CCGCGGCGT TGCGGGCGTC ATCAAGATGG TGCAGGCGCT GCGGCACGAG 4320 ACCTTGCCGC CGACGCTGCA TGTCGACAAG CCGACTCTTG AGGTGGACTG GTCCGCCGGT 4380 GCCATTGAAC TGCTGACGGA GGCCCGTGCG TGGCCGCGCA ACGGCCGTCC GCGCCGGGCC 4440 GGGGTGTCGT CGTTCGGCGT CAGCGGGACC AACGCGCACC TGATCCTGGA GGAGGCGCCG 4500 GCCGAGGAGC CGGTCGCTGC CCCGGAACTG CCGGTGGTGC CCCTGGTGGT GTCGGCGCGG 4560 AGCACGGAGT CGCTGTCCGG GCAGGCCGAG CGGCTGGCGT CCCTCCTCGA AGGGGACGTC 4620 TOGOTGACOG AGGTGGCOGG GGCGCTGGTG TCCCGCCGGG CGGTGCTGGA CGAGCGGGCC 4680 GTCGTCGTGG CCGGTTCGCG CGAGGAAGCC GTGACCGGGC TGCGGGCGCT GAACACGGCC 4740 GGTTCGGGGA CGCCGGGCAA GGTCGTGTGG GTGTTCCCGG GGCAGGGGAC GCAGTGGGCC 4800

- 58 -



GGGATGGGCC GTGAGCTGCT GGCCGAGTCC CCGGTGTTCG CCGAGCGGAT CGCCGAGTGC 4860 GCGGCCGCGT TGGCGCCGTG GATCGACTGG TCGCTCGTCG ACGTCCTGCG CGGCGAGGGC 4920 GACCTGGGTC GGGTCGATGT GCTGCAGCCG GCCTGTTTCG CGGTGATGGT CGGGCTGGCT 4980 GCCGTCTGGG AGTCCGTGGG GGTCCGGCCG GACGCCGTCG TCGGGCACTC GCAGGGTGAG 5040 ATCGCGGCTG CCTGCGTTTC GGGGGCGTTG TCCCTCGAGG ACGCGGCGAA GGTGGTGGCC 5100 CTGCGCAGCC AGGCCATCGC GGCGGAACTG TCCGGCCGCG GCGGGATGGC GTCGGTCGCC 5160 CTGGGCGAGG ACGACGTCGT TTCGCGGCTG GTGGACGGGG TCGAGGTCGC CGCCGTCAAC 5220 GGCCCGTCGT CGGTGGTGAT CGCCGGGGAT GCCCATGCCC TCGACGCGAC CCTGGAAATC 5280 TTGTCCGGGG AAGGCATCCG GGTTCGGCGG GTGGCGGTGG ACTACGCCTC GCACACCCGG 5340 CATCTCGAGG ACATCCGCGA CACTCTTGCC GAAACCTTGG CCGGGATCAG TGCGCAGGCG 5400 CCGGCTGTGC CGTTCTACTC CACCGTCACG AGCGAGTGGG TGCGCGACGC GGGGGTGCTG 5460 GACGGCGCT ACTGGTACCG GAACCTGCGC AACCAGGTCC GGTTCGGAGC GGCCGCGACG 5520 GCCCTGCTCG AGCAGGCCA CACGGTGTTC GTCGAGGTCA GTGCGCACCC GGTGACGGTC 5580 CAGCCCTTGA CCGAGCTCAC CGGGGACGCG ATCGGGACAT TGCGGCGTGA AGACGGTGGC 5640 5700 CTGCGGCGGT TGCTGGCTTC GATGGGTGAG CTGTTCGTCC GCGGCATCGA CGTGGACTGG ACGGCGATGG TGCCCGCGGC CGGCTGGGTC GACTTGCCGA CCTACGCGTT CGAACACCGG 5760 CACTACTGGC TCGAGCCCGC CGAGCCCGCT TCGGCCGGAG ACCCGCTGCT GGGCACAGTC 5820 GTCAGCACTC CCGGTTCGGA CCGACTCACC GCCGTGGCGC AGTGGTCGCG CCGGGCGCAG 5880 CCCTGGGCGG TGGACGGCCT GGTGCCGAAC GCGGCCCTGG TCGAGGCGGC CATCCGGCTC 5940

GGCGACCTGG CCGGCACCCC CGTCGTCGGC GAACTGGTCG TCGACGCGCC GGTGGTGCTG 6000 CCGCGGCGCG GCAGCCGCGA GGTCCAGCTG ATCGTCGGCG AGCCCGGCGA GCAGCGGCGG 6060 CGTCCGATCG AGGTCTTTTC CCGGGAAGCC GACGAGCCGT GGACGCGGCA CGCGCACGGC 6120 ACACTOGOTO COGCOGOGO TGOGGTGCCA GAACCGGOGG CGGCGGAGA CGCCACCGAC 6180 GTCACCGTGG CCGGCCTGCG CGACGCGGAC CGGTACGGGA TCCACCCCGC GCTGCTGGAC 6240 GCCGCCGTCC GCACGGTCGT CGGCGACGAC CTGCTCCCGT CGGTGTGGAC CGGCGTGTCC 6300 CTGCTGGCCT CCGGGGCCAC GGCCGTGACC GTGACGCCGA CGGCGACCGG CCTGCGGCTG 6360 ACCGACCCGG CCGGGCAGCC CGTCCTGACC GTCGAATCCG TGCGCGGCAC GCCGTTCGTC 6420 GCCGAGCAGG GGACCACCGA CGCGCTCTTC CGCGTCGACT GGCCGGAAAT CCCGCTGCCC 6480 ACCGCCGAAA CCGCGGACTT CCTGCCGTAC GAAGCCACGT CGGCCGAGGC GACCCTCTCC 6540 GCGCTCCAGG CCTGGCTGGC AGACCCCGCG GAAACCCGGC TGGCCGTGGT CACCGGGGAC 6600 TGCACCGAAC CCGGCGCGC CGCGATCTGG GGCCTGGTGC GCTCGGCGCA GTCCGAACAC 6660 CCCGGCCGGA TCGTGCTGGC CGACCTCGAC GACCCCGCCG TGCTGCCCGC CGTGGTGGCG 6720 AGCGGCGAAC CGCAGGTGCG GGTGCGCAAC GGCGTCGCCT CGGTGCCGCG CTTGACCCGG 6780 GTTACTCCCC GGCAGGACGC GCGGCCGCTC GACCCCGAGG GCACCGTCCT GATCACCGGC 6840 GGCACCGGCA CGCTCGGTGC GCTGACCGCC CGGCACCTCG TCACCGCGCA CGGCGTCCGG 6900 CACCTGGTGC TGGTCAGCCG CCGCGGTGAG GCTCCCGAGC TGCAGGAAGA ACTGACCGCA 6960 7020 CTGGGGGCAT CCGTCGCCAT CGCCGCCTGC GACGTGGCAG ACCGGGCGCA GCTCGAAGCC



GTCTTGCGCG CGATCCCGGC CGAGCACCCG CTCACCGCCG TGATCCACAC CGCGGGGGTC 7080 CTCGACGACG GCGTCGTCAC CGAGCTGACC CCGGACCGGC TCGCCACCGT GCGGCGGCCG 7140 AAGGTCGACG CCGCCCGGCT CCTGGACGAG CTCACCCGGG AGGCCGATCT CGCCGCGTTC 7200 GTGCTGTTCT CCTCGGCGGC GGGTGTGCTG GGCAACCCCG GCCAGGCCGG GTACGCCGCC 7260 GCCAACGCCG AGCTGGATGC GTTGGCGCGC CAGCGGAACA GCCTCGACCT GCCCGCGGTG 7320 TCCATCGCAT GGGGCTACTG GGCGACGGTC AGCGGGATGA CCGAGCACCT GGGCGACGCC 7380 GACCTGCGGC GCAACCAGCG GATCGGCATG TCCGGGCTTC CCGCCGACGA GGGCATGGCG 7440 CTGCTGGACG CCGCCATCGC CACCGGTGGC ACGCTGGTCG CGGCCAAGTT CGACGTCGCC 7500 GCGCTGCGGG CGACGGCGAA GGCCGGCGGC CCGGTGCCGC CGCTGCTGCG TGGCCTGGCC 7560 CCGCTGCCGC GCCGGGCGC GGCCAAGACC GCGTCGCTGA CCGAACGCCT CGCCGGGCTG 7620 GCCGAGACCG AGCAGGCCGC GGCCCTGCTC GACCTGGTCC GGCGGCACGC CGCCGAGGTG 7680 CTCGGGCACA GCGGCGCCGA ATCCGTCCAT TCAGGACGGA CGTTCAAGGA CGCCGGCTTC .7740 GACTCGCTGA CCGCGGTGGA ACTGCGGAAC CGCCTCGCGG CCGCGACCGG GCTCACCCTG 7800 TCCCCGGCGA TGATCTTCGA CTACCCGAAG CCCCCGGCGC TCGCGGACCA CCTGCGCGCC 7860 AAGCTCTTCG GATCGCCGC GAACCGCCCG GCCGAGATCG GCACCGCCGC GGCCGAGGAG 7920 CCGATCGCGA TCGTCGCGAT GGCGTGCCGC TTCCCCGGTG GCGTGCACAG CCCCGAGGAC 7980 CTGTGGGGGC TGGTCGCCGA CGGCGCCGAC GCCGTCACCG AGTTCCCCGC CGACCGCGGC 8040 TGGGACACCG ACCGGCTCTA CCACGAAGAC CCCGACCACG AAGGCACGAC GTACGTCCGG 8100 CACGGCGCCT TCCTCGACGA CGCCGCGGG TTCGACGCCG CCTTCTTCGG CATCTCGCCG 8160

- 60 -



AACGAGGCGC TCGCCATGGA CCCGCAGCAG CGGCTGCTGC TGGAGACGTC CTGGGAGCTG 8220 TTCGAGCGGG CCGCGATCGA CCCGACCACG CTGGCCGGCC AGGACATCGG CGTCTTCGCC 8280 GGCGTCAACA GCCACGACTA CAGCATGCGG ATGCACCGGG CCGCCGGTGT CGAGGGCTTC 8340 CGGCTCACCG GCGGTTCGGC CAGCGTGCTC TCCGGCCGCG TCGCCTACCA CTTCGGCGTC 8400 GAAGGCCCGG CCGTCACGGT CGACACGGCC TGCTCGTCTT CGCTGGTCGC GCTGCACATG 8460 GCGGTGCAGG CCCTGCAGCG CGGCGAGTGC TCCATGGCGC TCGCGGGCGG CGTGATGGTG 8520 ATGEGEACGG TEGAGACETT CETEGAGTTE TEGEGGEAGE GEGGGETGGE CECEGACGGE 8580 CGCTGCAAGG CGTTCGCCGA CGGCGCGGAC GGCACCGGCT GGTCCGAGGG CGTCGGGCTG 8640 CTCCTGGTGG AGCGGCTGTC CGAGGCTCAG CGTCGCGGGC ACCAGGTCCT CGCCGTGGTC 8700 CGCGGGTCGG CGGTCAACTC CGACGGCGCG TCGAACGGCT TGACGGCCCC GAACGGCCCG 8760 TCCCAGCAGC GCGTGATCCG CAAGGCACTG GCCGCCGCCG GACTGTCCAC ATCGGACGTC 8820 GACGCGGTGG AGGCGCACGG CACCGGGACG ACCCTGGGCG ACCCGATCGA GGCCGAGGCG 8880 CTGCTGGCCA CCTACGGCCA GAACCGGGAA ACGCCGCTGT GGCTCGGGTC GGTGAAGTCG 8940 AACCTCGGGC ACACGCAGGC GGCTGCGGGT GTCGCAGGCG TGATCAAGAT GGTCATGGCC 9000 ATGCGCCACG GCGTCCTGCC CCGGACGCTG CACGTCGACC GGCCGTCGTC CTATGTGGAC 9060 TGGTCGGCCG GTGCGGTCGA GCTGCTGACC GAGGCACGGG ACTGGGTGAG CAACGGCCAC 9120 CCGCGCCGCG CGGGCGTGTC GTCGTTCGGC ATCGGCGGCA CCAACGCGCA CGTCGTCCTC 9180 GAAGAGGTTG CCGCACCGAT CACCACGCCG CAGCCTGAGC CGGCCGAGTT CCTGGTGCCG 9240

- 62 -



GTGCTCGTCT CCGCGCGGAC GGCGGCGGGT CTGCGCGGGCC AGGCCGGACG GCTCGCCGCG 9300 TTCCTCGGCG ACCGGACCGA CGTCCGCGTC CCCGATGCCG CCTACGCACT GGCCACCACG 9360 CGCGCCCAGC TCGACCACCG GGCCGTCGTC CTGGCCTCCG ACCGGGCACA GCTCTGCGCG 9420 GACCTTGCCG CGTTCGGCTC CGGCGTCGTG ACCGGAACGC CGGTTGACGG CAAGCTGGCC 9480 GTGCTCTTCA CCGGCCAGGG CAGCCAGTGG GCCGGGATGG GCCGTGAACT CGCCGAGACG 9540 TTCCCGGTCT TCCGCGACGC CTTCGAGGCC GCGTGCGAGG CCGTGGACAC GCACCTGCGT 9600 GAGCGTCCGC TGCGCGAGGT CGTGTTCGAC GACAGCGCGC TGCTCGACCA GACGATGTAC 9660 ACCCAGGGG CCCTGTTCGC CGTGGAGACC GCGTTGTTCC GGCTCTTCGA GTCCTGGGGT 9720 GTGCGGCCGG GTCTCCTCGC CGGTCACTCG ATCGGCGAGC TCGCCGCCGC GCACGTGTCC 9780 GGCGTGCTGG ACCTGGCCGA CGCGGGCGAG CTGGTCGCCG CGCGGGCCG GCTGATGCAG 9840 GCCCTGCCCG CGGGCGGCGC GATGGTCGCC GTCCAGGCGA CCGAGGACGA AGTCGCGCCC 9900 CTGCTCGACG GCACGGTCTG CGTCGCCGCG GTCAACGGTC CGGACTCGGT GGTGCTCTCC 9960 GGCACCGAAG CCGCCGTGCT CGCCGTCGCG GATGAACTGG CTGGTCGCGG CCGTAAGACC 10020 CEACGGCTGG CCGTGAGCCA CGCCTTCCAC TCGCCGCTCA TGGAACCGAT GCTCGACGAC 10080 TTCCGCGCGG TCGCCGAACG CCTGACGTAC CGGGCCGGTT CGCTGCCCGT CGTCTCGACG 10140 CTGACCGGGG AACTCGCGGC GCTCGACAGC CCGGACTACT GGGTCGGCCA GGTGCGCAAC 10200 GCCGTGCGGT TCAGCGACGC CGTCACCGCG CTGGGCGCCC AAGGCGCGTC GACGTTCCTC 10260 GAGCTCGCCC CGGGCGGTGC GCTCGCCGCG ATGGCGCTCG GCACGCTCGG CGGACCCGAG 10320 CAGAGCTGCG TCGCGACCCT GCGCAAGAAC GGCGCCGAGG TGCCCGACGT CCTCACCGCG 10380



CTCGCCGAAC TGCACGTCCG GGGCGTGGGC GTCGACTGGA CGACCGTGCT CGACGAACCG 10440 GCCACGGGG TCGGGACCGT CCTGCCCACC TACGCGTTCC AGCACCAGCG CTTCTGGGTC 10500 GACGTCGACG AAACAGCGGC CGTCAGCGTC ACCCCGCCGC CGGCGGAGCC GATCGTGGAC 10560 CGGCCGGTGC AGGACGTGCT GGAGCTGGTC CGGGAGAGCG CCGCGGTGGT GCTCGGGCAC 10620 CGGGACGCCG GCAGTTTCGA CCTCGACCGG TCCTTCAAGG ACCACGGCTT CGACTCGCTC 10680 AGCGCGGTCA AGCTGCGCAA CCGTCTGCGC GACTTCACCG GCGTGGAGCT GCCCAGCACC 10740 CTGATCTTCG ACTACCCGAA CCCGGCCGTC CTCGCGGACC ACCTGCGGGC CGAACTGCTC 10800 GGCGAGCGCC CGGCCGCGCC GGCCCCGGTG ACGAGGGACG TCTCCGACGA GCCGATCGCG 10860 ATCGTCGCCA TGAGCACCCG GCTGCCGGGT GGCGCCGACA GCCCCGAAGA GCTGTGGAAG 10920 CTCGTCGCGG AGGGACGGGA CGCCGTGTCC GGCTTCCCCG TCGACCGCGG CTGGGACCTC 10980 GACGGCCTCT ACCACCCGGA CCCCGCCCAC GCCGGGACGA GCTACACGCG TTCGGGCGGC 11040 TTCCTGCACG ACGCGGCCCA GTTCGACGCC GGGCTCTTCG GGATCTCACC GCGTGAGGCC 11100 CTGGCCATGG ACCCGCAGCA GCGGCTGCTG CTGGAGACGT CGTGGGAAGC CTTGGAGCGC 11160 GCGGGGTCG ACCCGCTGTC CGCCCGCGGC AGCGACGTCG GCGTCTTCAC CGGGATCGTC 11220 CACCACGACT ACGTGACGCG GCTGCGCGAA GTGCCCGAAG ACGTCCAGGG CTACACGATG 11280 ACCGGCACGG CTTCGAGCGT GGCGTCGGGC CGGGTGGCGT ACGTCTTCGG CTTCGAGGGC 11340 CCGGCGGTCA CCGTGGACAC CGCGTGTTCG TCGTCGCTGG TCGCGATGCA CCTGGCGGCG 11400 CAGGCGCTGC GGCAGGGGGA GTGCTCGATG GCCCTGGCCG GCGGCGCGAC CGTGATGGCC 11460



AGCCCGGACG CCTTCCTCGA GTTCTCCCGC CAGCGCGGCC TGTCCGCGGA CGGCCGGTGC 11520 AAGGCGTACG CGGAAGGCGC GGACGGCACG GGCTGGGCCG AGGGCGTCGG TGTCGTCGTC 11580 CTCGAACGC TTTCGGTGGC ACGCGAACGT GGCCACCGGG TGCTGGCGGT CCTGCGCGGC 11640 AGCGCGGTGA ACCAGGACGG TGCTTCCAAC GGCCTGACCG CCCCGAACGG GCCGTCGCAG 11700 CAGCGGGTGA TCCGCGGCGC GCTGGCGAGC GCCGGGCTGG CACCGTCCGA TGTGGACGTC 11760 GTGGAGGGCC ACGGGACCGG GACCGCGCTG GGTGACCCGA TCGAGGTCCA GGCGCTGCTG 11820 GCCACCTACG GGCAGGAGCG GGAACAGCCG TTGTGGCTCG GCTCGCTGAA GTCGAACCTC 11880 GGGCACACGC AGGCCGCGC CGGGGTCGTG GGCGTGATCA AGATGATCAT GGCCATGCGC 11940 12000 CACGGCGTCA TGCCGGCCAC GCTGCACGTC GACGAGCGCA CGAGCCAGGT CGACTGGTCG GCCGGCCGCA TCGAGGTGTT GACCGAGGCC CGGGAGTGGC CGCGCACCGG ACGTCCGCGC 12060 CGGGCCGGGG TGTCCTCCTT CGGCGCCAGC GGCACCAACG CGCACCTGAT CATCGAGGAA 12120 GGTCCCGCCG AAGAGGCCGT GGACGAAGAG GTGGCCTCCG TGGTGCCGCT GGTCGTCTCC 12180 GCCCGCAGCG CCGGTTCGCT GGCCGGGCAG GCCGGGCGCC TGGCCGCGGT CCTCGAGAAC 12240 GAATCGTTGG CCGGGGTGGC CGGTGCCCTG GTTTCCGGCC GCGCGACGCT GAACGAGCGC 12300 GCGGTCGTCA TCGCGGGCTC CCGCGACGAG GCCCAGGACG GCCTGCAGGC ACTGGCCCGC 12360 GGCGAGAACG CGCCCGGCGT CGTGACCGGG ACGGCGGCCA AGCCGGGCAA GGTCGTCTGG 12420 GTCTTCCCCG GCCAGGGCTC GCAGTGGATG GGCATGGGCC GGGACCTCCT GGACTCCTCG 12480 CCGGTGTTCG CCGCGCGGAT CAAGGAATGC GCTGCGGCAC TGGAACAGTG GACCGACTGG 12540 TOGOTGOTGG ACGTGCTGCG CGGCGACGCC GACCTGCTGG ACCGGGTCGA CGTGGTGCAG 12600



CCGGCCAGCT TCGCGATGAT GGTCGGGCTC GCCGCGGTGT GGACCTCGCT GGGGGTGACC 12660 CCGGATGCGG TGCTCGGCCA CTCCCAGGGC GAGATCGCCG CGGCGTGCGT GTCCGGCGCG 12720 CTGTCGCTGG ACGACGCGGC GAAGGTGGTC GCGTTGCGCA GCCAGGCGAT CGCGGGGGAG 12780 CTGGCGGGCC GCGGCGGGAT GGCGTCGGTC GCACTGAGCG AAGAGGACGC AGTCGCGCGG 12840 CTGACGCCGT GGGCGAACCG GGTCGAGGTG GCCGCGGTCA ACAGCCCGTC CTCGGTCGTC 12900 ATCGCGGGAG ACGCGCAGGC CCTCGACGAA GCCCTCGAAG CCCTGGCCGG CGACGGTGTC 12960 CGGGTCCGGC GGGTCGCGGT GGACTACGCC TCCCACACCC GGCACGTCGA GGCGATCGCC 13020 GAAACCCTGG CCAAGACCTT GGCCGGGATC GACGCGCGGG TTCCGGCGAT TCCGTTCTAT 13080 TCCACCGTCC TGGGCACGTG GATCGAGCAG GCCGTCGTCG ACGCGGGCTA CTGGTACCGG 13140 AACCTGCGC AGCAGGTGCG GTTCGGCCCC TCGGTGGCGG ACCTGGCCGG GCTGGGGCAC 13200 ACGGTGTTCG TGGAGATCAG CGCCCACCCG GTGCTGGTCC AGCCGCTGAG CGAGATCAGC 13260 GACGACGCG TGGTGACCGG GTCGCTGCGG CGGGACGACG GGGGACTGCG GCGCCTGCTG 13320 GCGTCGCCG CCGAACTGTA CGTCCGGGC GTGGCCGTGG ACTGGACGGC GGCCGTGCCC 13380 GCGGCCGCT GGGTGGACCT GCCGACGTAC GCCTTCGACC GCCGCCACTT CTGGCTGCAC 13440 GAAGCCGAGA CCGCCGAAGC CGCCGAGGGC ATGGACGGCG AGTTCTGGAC GGCGATCGAA 13500 CAGTCCGATC TGGACACCTT GCCCGACCTG CTCGACCTGG TGCCGGAGCA GCGCGGGGCG 13560 CTCASCACCG TCGTGCCCGT GCTGCCGCAG TGGCGGGACC GGCGCGCGA GCGCTCGACC 13620 GCGGAGAAGC TGCGCTACCA GGTCACCTGG CAGCCCCTGG AGCGCGAAGC CGCCGGCGTG 13680

CCGGGCGGC GCTGGCTGGC CGTCGTCCCG GCCGGCACCA CCGACGCGCT CCTGAAGGAG 13740 CTGACCGGCC AGGGACTCGA CATCGTCCGG CTGGAGATCG AGGAAGCTTC GCGGGCACAG 13800 CTCGCCGAGC AGCTGCGGAA CGTCCTGGCG GAGCACGACC TCACCGGCGT GCTGTCGCTG 13860 CTCGCTCTCG ACGCGCCCC CGCGGACGCG GCCGAGATCA CCGCGTCGAC GCTCGCGCTG 13920 GTCCAGGCCC TGGGCGACAC CACCACGTCC GCGCCGCTGT GGTGCCTCAC TTCCGGCGCG 13980 GTGAACATCG GCATCCAGGA CGCCGTGACC GCACCGGCCC AGGCGGCCGT GTGGGGGCTC 14040 GGCCGGCCG TCGCGCTGGA GCGCCTCGAC CGGTGGGGCG GCCTGGTCGA CTTGCCCGCC 14100 GCGATCGACG CCCGCACGGC TCAGGCCCTG CTCGGCGTCC TGAACGGCGC CGCCGGGGAA 14160 GACCAGCTCG CGGTCCGGCG CTCGGGCGTC TACCGCAGGC GGCTGGTCCG CAAGCCCGTG 14220 CCGGAGTCCG CGACGAGCCG GTGGGAACCC CGCGGCACGG TCCTGGTGAC CGGTGGGGCC 14280 GAAGGACTCG GCCGGCACGC CTCGGTCTGG CTCGCGCAGT CCGGCGCCGA ACGGCTCATC 14340 GTCACCGGCA CCGACGGCGT CGACGAACTG ACGGCCGAGC TGGCCGAGTT CGGCACCACG 14400 GTCGAGTTCT GCGCCGACAC CGACCGGGAC GCGATCGCGC AGCTGGTGGC GGACTCGGAG 14460 GTCACCGCCG TGGTGCACGC CGCGGACATC GCGCAGACCA GCTCCGTCGA CGACACCGGC 14520 GTGGCCGACC TCGACGAGGT GTTCGCCGCG AAGGTGACCA CCGCGGTGTG GCTGGACCAG 14580 CTGTTCGAGG ACACCCCGCT CGACGCGTTC GTCGTGTTCT CCTCGATCGC CGGCATCTGG 14640 GGCGGTGGCG GGCAGGGCCC GGCGGGTGCG GCGAACGCCG TCCTCGACGC CCTGGTCGAA 14700 TGGCGCCGGG CCCGCGCCT CAAGGCGACG TCGATCGCCT GGGGCGCGCT CGACCAGATC 14760 GGCATCGGCA TGGACGAGGC CGCCCTCGCC CAGCTGCGCC GCCGCGGTGT CATCCCGATG 14820

- 66 -



GCGCCGCCGC TGGCGGTCAC CGCGATGGTG CAGGCGGTCG CCGGCAACGA GAAGGCCGTG 14880 GCGGTGGCCG ACATGGACTG GGCCGCCTTC ATCCCGGCGT TCACCTCGGT CCGGCCCAGC 14940 CCGCTGTTCG CCGATCTGCC CGAGGCGAAG GCCATCCTCC GGGCGGCGCA GGACGACGGC 15000 GAAGACGCCG ACACCGCGTC GTCGCTCGCG GACTCCCTGC GCGCGGTCCC CGACGCCGAG 15060 CAGAACCGCA TCCTGCTGAA GCTGGTCCGC GGCCACGCTT CGACGGTGCT CGGCCACAGC 15120 GGCGCCGAAG GCATCGGCCC GCGCCAGGCG TTCCAGGAGG TCGGCTTCGA CTCGCTGGCC 15180 GCGGTCAACC TCCGCAACAG CCTGCACGCG GCCACCGGGC TGCGGCTGCC CGCGACGCTG 15240 ATCTTCGACT ACCCCACCC GGAGGCGCTG GTCGGCTACC TGCGCGTCGA ACTCCTGCGG 15300 GAGGCCGACG ACGGCCTGGA CGGGCGGGAA GACGACCTCC GGCGAGTCCT CGCGGCCGTG 15360 CCGTTCGCCC GGTTCAAGGA GGCGGGCGTG CTGGACACGC TGCTCGGCCT CGCCGACACC 15420 GGCACCGAAC CGGGCACGGA CGCCGAGACC ACCGAAGCGG CCCCGGCCGC CGACGACGCA 15480 GAACTGATCG ACGCACTGGA CATCTCCGGT CTCGTGCAAC GAGCCCTCGG GCAGACGAGC 15540 TGACCGCCGA TGGCGAACCA ATCGTGGAGG AAGAACATGT CCGCGCCGAA CGAGCAGATC 15600 GTTGACGCAC TGCGCGCGTC GCTGAAGGAG AACGTCCGGC TTCAGCAGGA GAACAGCGCG 15660 CTCGCCGCG CCGCCGCGGA GCCCGTCGCG ATCGTCTCCA TGGCCTGCCG CTACGCGGGC 15720 GGGATCCGCG GCCCGGAGGA CTTCTGGCGG GTGGTGTCGG AAGGCGCCGA CGTCTACACC 15780 GGCTTCCCCG AGGACCGCGG CTGGGACGTC GAAGGCCTCT ACCACCCGGA CCCCGACAAC 15840 CCCGCCACGA CGTACGTGCG GGAGGGCGCC TTCCTGCAGG ACGCGCCCCA GTTCGACGCC 15900

- 68 -



GGGTTCTTCG GCATCTCGCC GCGCGAGGCG CTGGCCATGG ACCCCCAGCA GCGGCAGCTC 15960 CTGGAGGTGT CCTGGGAGAC CTTGGAACGG GCCGGCATCG ACCCGCATTC GGTGCGGGGC 16020 AGCGACATCG GCGTCTACGC CGGGGTCGTG CACCAGGACT ACGCCCCCGA CCTCAGCGGG 16080 TTCGAAGGCT TCATGAGCCT GGAGCGCGCC CTGGGCACCG CGGGCGGTGT CGCCTCCGGC 16140 CGGGTCGCCT ACACGCTCGG GCTCGAAGGC CCCGCCGTCA CCGTCGACAC GATGTGCTCG 16200 TOGTOGOTGG TGGCGATTCA COTTGCCGCG CAAGCTCTTC GCCGTGGTGA GTGCTCGATG 16260 GCCCTCGCGG GCGGCTCGAC CGTGATGGCG ACCCCGGGCG GGTTCGTCGG CTTCGCGCGT 16320 CAGCGGGCGT TGGCCTTCGA CGGGGGCTGC AAGTCCTACG CCGCGGCCGC CGACGGTTCC 16380 GECTGGCCG AGGCGTCGG CGTGCTGCTG CTGGAGCGGC TGTCGGTGGC GCGCGAGCGC 16440 GGGCACCAGG TGCTGGCCGT CATCCGCGGC AGCGCGGTCA ACCAGGACGG CGCTTCCAAC 16500 GGCCTGACCG CGCCCAACGG CCCGGCGCAG CAGCGGGTCA TCCGCAAGGC ACTGGCGAGC 16560 GCCGGGCTGA CACCGTCCGA TGTGGACACC GTGGAGGGCC ACGGCACCGG CACCGTCCTC 16620 GGCGACCCGA TCGAGGTCCA GGCGCTGCTG GCCACCTACG GCCAGGGCCG CGACCCGCAG 16680 CAACCGCTGT GGCTGGGCTC GGTCAAGTCC GTCGTCGGGC ACACGCAGGC GGCATCCGGT 16740 GTGGCCGGCG TGATCAAGAT GGTCCAGTCG CTGCGGCACG GGCAGCTCCC GGCGACCCAG 16800 CACGTCGACG CGCCCACGCC GCAAGTGGAC TGGTCGGCCG GAGCGATCGA GCTGCTGGCC 16860 GAGGGCCGGG AGTGGCCGCG CAACGGCCAC CCGCGCCGGG GCGGCATCTC GTCGTTCGGG 16920 GCCAGCGGCA CGAACGCGCA CATGATCCTC GAAGAAGCGC CCGAGGACGA GCCGGTGACC 16980 GAAGCGCCGG CGCCCACGGG TGTCGTACCG CTGGTGGTGT CGGCGGCGAC CGCTGCTTCC 17040





CTGGCCGCCC AGGCCGGTCG GCTGGCGGAG GTCGGCGACG TCTCCCTGGC GGATGTCGCC 17100 GGGACGCTGG TGTCCGGCCG CGCGATGCTC AGCGAGCGCG CGGTCGTCGT GGCCGGCTCC CACGAAGAAG CCGTGACCGG GCTGCGGGCG CTGGCCCGCG GCGAGAGCGC GCCCGGCCTG 17220 CTTTCCGGCC GCGCTCGGG GGTCCCGGGC AAGGTCGTCT GGGTGTTCCC CGGCCAGGGC 17280 ACGCAGTGGG CCGCCATGGG CCGCGAGCTG CTGGACTCCT CGGAGGTGTT CGCCGCGCGG 17340 ATCGCCGAGT GCGAGACCGC GCTCGGGCGG TGGGTCGACT GGTCGCTGAC CGACGTGCTG 17400 CGCGGCGAGG CCGACCTGCT GGACCGGGTC GACGTGGTGC AACCGGCGAG CTTCGCCGTG 17460 ATGCTCGGGC TTGCCGCCGT CTGGGCCTCC CTCGGCGTCG AGCCCGAGGC CGTGGTGGGC 17520 CACTCGCAGG GCGAGATCGC GGCCGCATGC GTGTCCGGGG CACTGTCCCT GGAGGACGCG 17580 GCGAAGGTGG TGGCGTTGCG CAGCCAGGCG ATCGCCGCCT CGCTGGCCGG CCGGGGCGGC 17640 ATGCCTTCGC TCCCGTTGAG CCAAGAAGAC GCGACCGCGC GGCTCGAGCC GTGGGCGGGC 17700 CGCCTGGAGG TCGCCGCCGT CAACGGGCCG ACGTCCGTGG TGATCGCCGG GGACGCCGAG 17760 GCGCTGGACG AAGCCCTCGA CGCGCTCGAC GACCAAGGCG TCCGGATCCG GCGGGTGGCG 17820 GTGGACTACG CCTCCCACAC CCGGCACGTC GAAGCCGCGC GCGACGCACT GGCCGAGATG 17850 CTGGGCGGA TCCGCGCGCA GCCGCGGAA GTGCCGTTCT ACTCGACCGT GACCGGCGGC 17940 TGGGTCGAAG ACGCCGCGT GCTCGACGGC GGCTACTGGT ACCGGAACCT CCGCCGTCAG 18000 GTGCGGTTCG GCCCGGCGGT GGCCGAGCTG ATCGAGCAGG GCCACCGGGT GTTCGTCGAG 18060 GTCAGCGCGC ATCCCGTGCT GGTTCAGCCG ATCAACGAAC TCGTCGACGA CACCGAAGCC 18120



GTGGTCACCG GGACGCTGCG GCGCGAGGAC GGCGCCTCC GGCGCCTGCT GGCCTCGGCG 18180 GCCGAGCTCT TCGTCCGCGG CGTGACCGTG GACTGGTCCG GTGTGCTGCC ACCGTCCCGC 18240 CGGGTCGAGC TGCCGACGTA CGCCTTCGAC CACCAGCACT ACTGGCTGCA GATGGGCGGG 18300 TOGGCCACCG ACCCCGTGTC GCTGGGCCTG GCCGGCGCG ACCACCCGCT GCTGGGCGCG 18360 GTCGTCCCGC TGCCGCAGTC CGACGGGCTC GTCTTCACCT CGCGGCTGTC GCTGAAGTCG 18420 CACCCGTGGC TGGCCGGGCA CGCGATCGGC GGGGTCGTGC TCATTCCGGG CACGGTGTAC 18480 GTCGACCTCG CGCTGCGCGC CGGCGACGAG CTCGGCTTCG GCGTCCTGGA AGAGCTCGTG 18540 ATCGAGGCAC CGCTGGTGCT GGGCGAGCGC GGCGGCGTTC GCGTGCAGGT CGCCGTGAGC 18600 GGGCCGAACG AGACCGGCTC GCGTGCGGTG GACGTCTTCT CCATGCGGGA AGACGGCGAC 18660 GAATGCACCC GGCACGCGAC CGGTCTCCTC GGGGCGTCGA CGTCCCGGGA ACCGAGCCGC 18720 TTCGACTTCG CCGCCTGGCC GCCGGCCGGG GCGGAGCCGA TCGACGTCGA AAACTTCTAC 18780 ACCGACCTCA CCGAGCGCGG GTACGCCTAC AGCGGCGCCT TCCAGGGCAT GCGGGCGTC 18840 TGGCGGCGCG GTGACGAGGT CTTCGCCGAG GTCGCGCTGC CTGACGACCA CCGCGAGGAC 18900 GCCGGCAAGT TCGGCCTCCA CCCCGCCCTC CTCGACGCCG CTCTGCACAC GAACGCCTTC 18960 GCGAACCCGG ACGACGACCG CAGTGTGCTG CCGTTCGCGT GGAACGGCCT GGTCCTGCAC 19020 GCCGTGGGCG CGTCGGCGCT GCGGGTGCGG GTGGCGCCGG GCGGTCCGGA CGCGCTGACG 19080 TTCCAGGCCG CCGACGAGAC CGGTGGCCTG GTCGTCACCA TGGATTCGCT GGTGTCCCGC 19140 CAGGTGTCGG CCGCGCAGCT GGAGACGGCG GCGGGGGAAG AGCGCGACTC GCTGTTCCAG 19200 GTGGACTGGA TCGAGGTCCC CGCGACCGAG ACCGCGGCCA CCGAGCACGC CGAGGTGCTC 19260



GAAGCCTTCG GCGAGGCAGC GCCCCTCGAG CTGACCAGCC GGGTGCTGGA GGCCGTGCAG 19320 TCCTGGCTCG CCGACGCGGC CGACGAAGCA CGGTTGGTCG TGGTGACCCG TGGCGCCGTG 19380 CGCGAGGTGA CGGACCCGGC CGGTGCCGCC GTGTGGGGTT TGGTGCGAGC CGCCCAGGCG 19440 GAGAACCCGG GCCGGATCAT CCTCGTCGAC ACCGACGCG ACGTCCCGCT GGGTGCGGTG 19500 CTGGCCAGTG GTGAGCCGCA GCTCGCCGTG CGCGGCAACG CTTTCTCCGT CCCGCGCCTC 19560 CCCCGGCCA CCGCGAGGT GCCGGAGGCC CCCGCGGTGT TCAGTCCGGA AGGGACGGTC 19620 CTGCTCACCG GCGCACCGG CTCGCTGGGC GGTCTGGTGG CCAAGCACCT GGTTGCCCGG 19680 CACGGCGTCC GGCGGCTGGT GCTCGCCAGC CGCCGAGGCG TGGCCGCGGA AGACCTCGTC 19740 ACCGAGCTGA CCGAGCAGGG CGCGACGGTG TCCGTGGTGG CTTGCGACGT CTCCGACCGC 19800 GACCAGGTGG CCGCGTTGCT GGCCGAACAC CGCCCGACCG GCATCGTGCA CCTGGCCGGC 19860 CTGCTGGACG ACGGCGTCAT CGGAGCCCTG AACCGGGAGC GGCTGGCCGG GGTGTTCGCG 19920 CCCAAGGTCG ATGCCGTCCA GCACCTCGAC GAACTGACCC GCGACCTCGG CCTCGACGCG 19980 TTCGTCGTGT TCTCGTCCGC AGCCGCGCTC ATGGGCTCCG CCGGCCAGGG CAACTACGCG 20040 GCCGCCAACG CCTTCCTCGA CGGCTTGATG GCCGGGGGCC GCGCGGGGGG CCTGCCAGGC 20100 GTGTCCCTGG CGTGGGGCCT GTGGGAGCAG GCGGACGGCC TGACCGCGAA CCTCAGCGCC 20160 ACCGACCAGG CCCGGATGAG CCGCGGCGGC GTGCTGCCGA TGACACCGGC CGAGGCCCTG 20220 GACATCTTCG ACATCGGCCT GGCCGCGAG CAGGCCCTGC TGGTCCCGAT CAAGCTCGAC 20280 CTGCGGACGC TGCGCGGCCA GGCCACCGC GGCGGCGAGG TGCCGCACCT GCTGCGCGGC 20340



CTGGTCCGCG CGAGCCGCCG CGTGACCCGC ACGCCTGCCG CGAGTGGCGG CGGTGGCCTG 20400 GTCCACAGC TCGCCGGCCG GCCAGCCGAA GAGCAGGAAG CCGTGCTGCT GGGCATCGTC 20460 CAGGCGGAGG CGGCCGGGT GCTCGGCTTC AACGCCCCCG AGCTGGCCCA GGGCACCCGC 20520 GGGTTCAGCG ACCTCGGCTT CGACTCGCTG ACCGCGGTCG AGCTGCGGAA CCGGCTGAGC 20580 GCGGCGACCG GCGTCAAATT GCCCGCCACG CTCGTCTTCG ACTACCCGAC GCCGGTCGCG 20640 CTCGCCCGCC ACCTGCGCGA AGAGCTGGGC GAGACGGTGG CGGGTGCGCC GGCCACGCCG 20700 GTGACGACCG TCGCCGACGC GGGCGAGCCG ATCGCCATCG TCGGCATGGC GTGCCGCCTG 20760 CCGCGCGCGC TGATGAGCCC CGACGACCTC TGGCGGATGG TCGCCGAGGG CCGCGATGGG 20820 ATGTCGCCGT TCCCCGGAGA CCGCGGCTGG GACCTGGACG GCCTGTTCGA CTCGGACCCC 20880 GAGCGCCCGG GCACCGCCTA CATCCGCCAA GGCGGCTTCC TGCACGAGGC CGCGCTGTTC 20940 GACCCGGGCT TCTTCGGGAT CTCGCCGCGC GAAGCCCTGG CCATGGACCC GCAGCAGCGG 21000 CTGCTGCTCG AAGCCTCCTG GGAAGCCCTG GAGCGCGGG GCATCGACCC GACCAAGGCC 21060 CGCGGTGACG CCGTCGGCGT CTTCTCCGGC GTCTCCATCC ACGACTACCT CGAGTCCCTG 21120 🕟 🦠 21180 AGCAACATGC CCGCCGAGCT CGAAGGCTTC GTCACCACGG CCACGGCGGG CAGCGTCGCC TCGGGCCGGG TGTCCTACAC CTTCGGGTTC GAGGGCCCGG CGGTCACGGT GGACACGGCG 21240 TGCTCGTCGT CGCTGGTCGC GATCCACCTG GCCGCACAGG CACTGCGGCA GGGCGAGTGC 21300 ACGATGSCCC TGGCCGGCGG TGTCGCCGTG ATGGGCTCGC CGATCGGTGT CATCGGCATG TCGCGGCAGC GCGGCATGGC CGAGGACGGC CGGGTCAAGG CGTTCGCCGA CGGCGCGGAC 21420 GGCACCGTCC TGTCCGAAGG CGTCGGCATC GTCGTCCTCG AACGGCTTTC GGTGGCCCGC 21480





GAACGCGGGC ACCGGGTGCT CGCCGTGCTC CGCGGCAGCG CGGTCAACCA GGACGGCGCT 21540 TCGAACGCC TGACCGCCC CAACGGCCG TCGCAGCAGC GGGTGATCCG CAGCGCGCTG 21600 GCCGGGCCG GACTGCAACC GTCCGAAGTG GACGTCGTCG AAGCGCACGG CACCGGGACC 21660 GCGCTGGGCG AACCGATCGA AGCCCAGGCC CTGCTGGCCA CCTACGGCAA GAGCCGCGAG 21720 ACGCCGTTGT GGCTCGGGTC GCTGAAGTCG AACATCGGCC ACACCCAGGC GGCCGCGGC 21780 GTGGCGGCCG TGATCAAGAT GGTCCAGGCG CTGCGGCAGG ACACCCTGCC GCCGACCCTC 21840 CACGTGCAGG AACCCACCAA GCAGGTGGAC TGGTCCGCGG GTGCGGTCGA GCTGCTGACC 21900 GAAGGCCGG AGTGGGCCCG CAACGGCCAC CCGCGCGGG CCGGTGTCTC GTCGTTCGGC 21960 ATCAGCGGCA CCAACGCGCA CCTCATCCTG GAAGAGGCGC CCGCCGACGA CACCGCCGAG 22020 GCGGACGTGC CCGACGCCGT GGTGCCCGTG GTGATCTCCG CGCGCAGCAC CGGATCCCTG 22080 GCGGCCAGG CCGGACGCCT GGCGGCGTTC CTCGACGGAG ACGTCCCGCT GACCCGCGTG 22140 GCGGGTGCCC TGCTGTCGAC CCGGGCGACG CTGACCGACC GGGCCGTCGT CGTGGCGGGC 22200 TCGGCCGAGG AGGCCCGGC GGGGCTQACC GCGCTGGCCC GCGGCGAGAG CGCGAGCGGG 22260 CTTGTGACCG GTACCGCAGG GATGCCGGGC AAGACGGTCT GGGTGTTCCC CGGCCAGGGG 22320 ACGCAGTGGG CGGCATGGG CCGGGAGCTC CTCGAAGCGT CCCCGGTGTT CGCCGAGCGC 22380 ATTGAGGAAT GCGCGGCCGC GCTGCAGCCG TGGATCGACT GGTCGCTGCT GGACGTCCTC CGTGGCGAAG GTGAGCTGGA TCGGGTCGAC GTGCTGCAGC CGGCGTGTTT CGCGGTGATG 22500 GTGGGGCTGG CCGCCGTCTG GGCCTCGTC GGCGTCGTGC CGGACGCGGT CCTGGGCCAC 22560



TCCCAGGGG AGATTGCCGC CGCCTGCGTG TCGGGTGCAC TGTCCCTCGA GGACGCAGCC 22620 AAGGTCGTCG CGCTGCGCAG CCAGGCGATC GCGGGGGAGC TGTCGGGCCG CGGGGGCATG 22680 GCGTCGATCC AGCTGAGCCA CGACGAGGTG GCTGCCCGGC TCGCGCCGTG GGCGGCCGC 22740 GTCGAGATCG CCGCCGTCAA CGGTCCGGCC TCGGTCGTGA TCGCCGGTGA CGCCGAAGCG 22800 CTCACCGAGG CCGTCGAAGT CCTCGGCGGT CGGCGGGTGG CGGTGGACTA CGCGTCCCAC 22850 ACGCGGCACG TCGAGGACAT CCAGGACACC CTCGCCGAGA CTCTGGCCGG GATCGACGCG 22920 CAGGCCCCCG TGGTGCCCTT CTACTCCACG GTCGCCGGCG AGTGGATCAC CGATGCCGGG 22980 -23040 GTGGCCGAGC TCATCGAGCA GGGGCACGGG GTGTTCGTCG AGGTCAGTGC GCATCCGGTG 23100 CTGGTGCAGC CGATCAGCGA GCTCACCGAT GCGGTCGTCA CCGGGACGTT GCGGCGCGAC 23160 GACGGTGGGG TGCGGCGGCT GCTGACCTCG ATGGCCGAAC TGTTCGTCCG CGGTGTCCCG 23220 GTCGACTGGG CCACGATGGC GCCGCCCGCG CGCGTCGAGC TGCCGACCTA CGCCTTCGAC 23280 CACCAGCACT TCTGGCTCAG CCCGCCCGCC GTGGCGGACG CGCCCGCGCT CGGCCTGGCC 23340 GGCGCCGACC ACCCGCTGCT GGGGGCGGTT CTCCCGCTGC CGCAGTCCGA CGGCCTGGTG 23400 TTCACCTCGC GCCTGTCGGT GCGGACGCAT CCGTGGCTGG CCGACGGCGT CCCCGCCGCC 23460 GCCTTGGTGG AGCTGGCCGT GCGGGCCGGT GACGAAGCCG GTTGCCCGGT CCTCGCCGAC 23520 CTGACCGTCG AAAAGCTGCT GGTGCTGCCG GAGAGCGGTG GCCTGCGCGT CCAGGTGATC 23580 GTGAGCGGCG AGCGCACGGT CGAGGTGTAT TCGCAGCTCG AAGGCGCCGA AGACTGGATC 23640 CGGAACGCCA CCGGGCACCT GTCCGCCACG GCTCCGGCGC ACGAGGCCTT CGACTTCACC 23700



GCCTGGCCGC CCGCCGGAGC CCAGCAGGTC GACGGCCTCT GGCGGCGCGG CGACGAGATC 23760 TTCCCCGAGG TCGCCCTGCC GGAGGAGCTG GACGCCGGCG CGTTCGGCAT CCACCCCTTC 23820 CTGCTGGACG CGGCCGTGCA GCCGGTCCTC GCGGACGACG AGCAGCCGGC GGAGTGGCGC 23880 AGCCTGGTCC TGCACGCGC GGGTGCCTCG GCGCTGCGC TGCGGCTGGT GCCCGGCGGT 23940 GCCCTCCAAG CGGCGGACGA AACCGGCGGG CTGGTCCTCA CGGCGGATTC GGTGGCAGGC 24000 CGGGAACTCT CGGCCGGGAA GACCCGCGCC GGATCGCTGT ACCGGGTCGA CTGCACCGAA 24060 GTGTCCATTG CAGACAGTGC GGTGCCGGCC AACATCGAGG TCGTCGAAGC CTTCGGTGAA 24120 GAGCCCTGG AACTGACCGG CCGGGTCCTG GAGGCTGTGC AGACCTGGCT CGTCACCGCG 24180 GCCGACGATG CGCGGCTGGT CGTGGTGACC CGCGCGCGC TGCGCGAGGT GACCGACCCC 24240 GCCGGTGCGG CCGTGTGGGG CCTGGTCCGA GCCGCGCAGG CGGAGAACCC CGGTCGCATC 24300 TTCCTGATCG ACACCGACGG CGAGATCCCG GCCCTGACCG GTGACGAGCC CGAGATCGCG 24360 GTGCGCGCG GGAAGTTCTT CGTGCCCCGC ATCACTCGCG CGGAGCCGAG CGGGGCCGCC 24420 GTGTTCCGCC CGGACGGGAC AGTGCTGATC TCGGGCGCGG GTGCGCTCGG TGGCCTGGTG 24480 GCCCGGCGTC TCGTCGAACG CCACGGCGTG CGGAAGCTCG TGCTGGCGTC CCGGCGCGGC 24540 CGAGACCCG ACGCCTCGC GGACCTCGTC CCCGACCTCG CCGCGGACGT GTCCGTCGTG 24600 GCTTGCGACG TCTCCGATCG CGCCCAGGTG GCGGCCCTGC TCGACGAGCA CCGGCCGACC 24660 GCCGTCGTGC ACACCGCCGG CGTCATCGAC GCGGGCGTGA TCGAGACGCT GGACCGGGAC 24720 CGGCTGGCCA CGGTGTTCGC GCCGAAGGTC GACGCCGTGC GGCACCTCGA CGAGCTGACC **24780** 

BENCO - 1810 - 000700000



CGCGACCGCG ACCTCGACGC CTTCGTCGTC TACTCCTCGG TCTCGGCCGT GTTCATGGGC 24840 GCGGCAGCG GCAGTTACGC CGCGGCGAAC GCCTTCCTGG ACGGCCTGAT GGCGAACCGC 24900 CGGGCGGCGG GCCTGCCGGG CCTGTCGCTG GCGTGGGGCC TGTGGGACCA GAGCACCGGT 24960 ATGCCCCCC GCACCGACGA GCCCACCCGG GCGCGGATGA GCCGCCGGG TGGCCTGCAG 25020 ATCATGACGC AGGCCGAGGG CATGGACCTG TTCGACGCCG CGCTGTCGTC GGCCGAGTCG 25080 CTGCTGGTGC CCGCCAAGCT CGACCTGCGT GGGGTGCGCG CCGACGCCGC CGCGGGCGGG 25140 GTCGTGCCGC ACATGCTGCG TGGCCTGGTC CGCGCGGGCC GGGCGCAGGC CCGCGGGGCG 25200 TCCACTGTGG ACAACGGGCT GGCCGGACGG CTGGCCGGGC TCGCCCGGC GGACCAGGTC 25260 ACCCTGCTCC TGGACCTGGT CCGGGCGCAG GTCGCGGCCG TGCTCGGGCA CGCCGACGCG 25320 AGCGCCGTCC GCGTCGACAC GGCCTTCAAG GACGCCGGCT TCGACTCGCT GACCGCGGTC 25380 GAGCTGCGCA ACCGCATGCG GACCGCCACC GGCCTGAAGC TGCCCGCGAC GCTCGTCTTC 25440 GACTACCCGA ACCCCCAGGC GCTCGCCCGG CACCTGCGCG ACGAACTCGG TGGTGCGGCC 25500 CAGACGCCGG TGACCACAGC GGCCGCGAAG GCCGACCTCG ACGAGCCGAT CGCCATCGTC 25560 25620 GGGATGCCGT GCCGCTTGCC GGGCGGGGTC GCCGGGCCCG AGGACCTCTG GCGGCTGGTC 25680 GCCGAGGGC GGGACGCGT GTCGAGCTTC CCGACCGACC GCGGCTGGGA CACCGACAGC CTGTACGACC CCGATCCGGC CCGCCCGGGC AAGACCTACA CCCGGCACGG CGGCTTCCTG 25740 CACGAAGCCG GGCTCTTCGA CGCGGGCTTC TTCGGGATCT CGCCACGCGA GGCCGTCGCC 25800 ATGEACCCGC AGCAGCGGCT GCTGCTGGAG GCCTCCTGGG AGGCCATGGA AGACGCCGGG 25860 GTCGACCCAC TTTCGCTGAA GGGCAACGAC GTCGGCGTGT TCACCGGCAT GTTCGGCCAG 25920





CGTTACGTCG CTCCCGGGGA CAGCGTCGTC ACGCCGGAGC TGGAGGGTTT CGCGGGCACG GGCGGGTCGT CGAGTGTCGC GTCCGGCCGC GTGTCGTACG TGTTCGGGTT CGAAGGCCCG 26040 GCCGTGACGA TCGACTCGGC GTGCTCGTCC TCGCTGGTCG CGATGCACCT CGCCGCGCAG 26100 TCGCTGCGGC AGGGCGAGTG CTCGATGGCC TTGGCCGGCG GCGCGACGGT GATGGCGAAC 26160 CCCGCCCAT TCGTGGAGTT CTCGCGGCAG CGGGGCCTCG CCGTCGACGG TCGCTGCAAG 26220 GCGTTCGCCG CCGCGGCCGA CGGCACCGGC TGGGCCGAGG GCGTCGGTGT GGTCATCCTC 26280 GAGCGGCTGT CGGTGGCGCG GGAACGCGGC CACCGGATCC TGGCCGTGCT GCGCGGCAGC 26340 GCGCTCAACC AGGACGCGC CTCGAACGGC CTGACCGCGC CGAACGGGCC GTCGCAGCAG CGGCTGATCC CCCGGCGCCT GGTCAGCGCC GGGCTGGCAC CGTCCGATGT GGACGTCGTC 26460 GAGGCGCACG GCACCGGGAC CACGCTGGGT GACCCGATCG AGGCGCAAGC TCTGCTGGCT 26520 ACCTACGGCA AGGACCGCGA GTCGCCGCTG TGGCTCGGCT CGCTGAAGTC GAACATCGGC 26580 CACGCGCAGG CCGCCGCGG GGTCGCCGGC GTCATCAAGA TGGTCCAGGC GCTCCGGCAC 26640 GAAGTCCTGC CGCCGACGCT GCACGTCGAC CGGCCTACCC CCGAGGTCGA CTGGTCGGCC 26700 GGTGCCGTCG AACTGCTGAC GGAAGCCCGC GAGTGGCCGC GCAACGGGCG CCCGCGCCCGG 26760 GCCGGGGTCT CCGCGTTCGG CGTCAGCGGC ACGAACGCGC ACCTGATCCT GGAGGAGGCG 26820 CCCGCCGAG AGCCGGTGCC CACACCCGAG GTTCCCCTGG TGCCGGTCGT GGTCTCCGCG 26880 CGGAGCAGGG CGTCCCTGGC CGGTCAGGCC GGTCGCCTCG CCGGATTCGT GGCGGGTCAC 26940 GCGTCCTTGG CCGGTGTGGC CCGGGCGCTG GTGACGAACC GGGCCGCGCT GACCGAGCGC 27000

....



GCGGTCATGG TCGTGGGCTC TCGCGAAGAA GCCGTGACGA ACCTGGAAGC GCTGGCCCGC 27060 GGCGAAGACC CGGCCGCGT GGTCACCGGC CGGGCGGGTT CGCCGGGCAA GCTCGTCTGG 27120 GTCTTCCCCG GCCAGGGCTC GCAGTGGATC GGGATGGGCC GGGAACTCCT GGACTCTTCG 27180 CCGGTCTTCG CCGAGCGGGT CGCCGAATGC GCGGCCGCCC TGGAACCGTG GATCGATTGG 27240 TCACTGCTCG ACGTGCTGCG CGGGGAGTCC GACCTGCTGG ACCGGGTCGA CGTCGTGCAG 27300 CCCGCCAGCT TCGCGATGAT GGTCGGCCTG GCCGCGGTGT GGCAGTCGGT GGGTGTCCGC 27360 CCGGATGCCG TCGTCGCCCA CTCGCAGGGC GAGATCGCCG CCGCCTGCGT CTCGGGCGCG 27420 CTGTCGCTGC AGGACGCCGC GAAGGTGGTT GCCTTGCGCA GCCAGGCGAT CGCCACCCGG 27480 CTGGCCGGGC GCGCGGCAT GGCTTCCGTG GCGTTGAGCG AAGAAGACGC GACCGCGTGG 27540 CTGGCGCCGT GGGCCGACCG GGTCCAGGTG GCCGCGGTCA ACAGCCCTGC CTCCGTGGTG 27600 ATCGCCGGGG AAGCCCAGGC CCTCGACGAG GTCGTCGACG CGTTGTCCGG TCAGGAAGTC 27660 CGCGTCCGGC GGGTGGCCGT GGACTACGGG TCCCACACCA ACCAGGTCGA AGCCATCGAG 27720 GATCTGCTGG CCGAGACCTT GGCCGGCATC GAGGCGCAGG CCCCGAAGGT GCCCTTCTAC 27780 TCGACCCTGA TCGGTGACTG GATCCGTGAC GCCGGGATCG TCGACGGCGG CTACTGGTAC 27840 CGGAACCTGC GCAACCAGGT CGGGTTCGGT CCGGCCGTCG CGGAGCTCGT TCGCCAGGGC 27900 CACGGGGTGT TCGTCGAGGT CAGCGCGCAC CCGGTGCTGG TCCAGCCGCT CAGTGAACTC 27969 AGCGACGACG CGGTGGTGAC CGGGTCGCTG CGGCGCGAAG ACGGTGGCCT GCGCCGCCTG 28030 CTGACGTCGA TGGCCGAGCT GTACGTGCAG GGTGTCCCGC TCGACTGGAC CGCGGTCCTG 28080 CCGCGGACCG GCCGGGTCGA CCTGCCGAAG TACGCCTTCG ACCACCGGCA CTACTGGCTG 28140



CGGCCCGCCG AGTCCGCGAC CGACGCGGCT TCGCTGGGCC AGGCGGCGGC CGACCACCCG CTGCTGGGCG CGGTCGTCGA GCTGCCGCAG TCCGACGGCC TGGTGTTCAC CTCGCGGCTG 28260 TCCGTGCGGA CGCACCCGTG GCTGGCCGAC CACGCGGTCG GTGGCGTGGT CATCCTCCCC 28320 GGCTCCGGGC TGGCCGAACT GGCCGTCCGG GCCGGCGACG AAGCCGGGTG CACCGCCCTC 28380 GACGAGCTGA TCATCGAAGC TCCGCTGGTC GTGCCCGCCC AAGGCGCGGT CCGCGTCCAG 28440 GTCGCGTTGA GCGGCCCGGA CGAGACCGGC TCGCGCACGG TGGACCTCTA CTCCCAGCGC 28500 GACGGCGGCG CGGGGACGTG GACGCGGCAC GCCACCGGCG TGCTGTCGAC GGCCCCCGCT 28560 CAGGAACCCG AGTTCGACTT CCACGCCTGG CCGCCCGCGG ATGCCGAGCG GATCGACGTC 28620 GAGACCTTCT ACACCGACCT GGCCGAGCGT GGTTACGGCT ACGGGCCGGC GTTCCAGGGG 28680 CTGCAAGCGG TGTGGCGGCG TGACGGCGAC GTCTTCGCCG AGGTCGCCCT GCCCGAGGAC 28740 CTGCGCAAGG ACGCGGCCG GTTCGGCGTC CACCCGGCGC TGCTCGACGC GGCGCTGCAG 28800 CCCCCACGC CCGTGGCCGC CGACGAGCCC GGTCAGCCGG TGCTGGCGTT CGCGTGGAAC 28860 GGCCTGGTCC TGCACGCCGC GGGCGCGTCG GCCCTGCGGG TCCGGCTCGC GCCGAGCGGC 28920 CCGGACACGC TGTCCGTGGC AGCCGCCGAC GAAACCGGCG GCTTGGTCCT GACCATGGAA 28980 TCGCTGGTCT CCCGCCGGT TTCGGCCGAG CAGCTCGGCG CCGCGGCCGA CGCGGGCCAC 29040 GACGCGATGT TCCGCGTCGA CTGGACCGAG CTGCCTGCCG TGCCCCGCGC GGAACTGCCG 29100 CCGTGGGTGC GGATCGACAC CGCCGACGAC GTCGCGGCCT TGGCGGAGAA GGCGGACGCA 29160 CCACCGGTGG TGGTCTGGGA AGCCGCCGGG GGAGACCCGG CCCTGGCCGT GAGTTCCCGG 29220





GTGCTCGAGA TCATGCAGGC CTGGCTGGCC GCGCCCGCGT TCGAGGAGGC CCGGCTGGTC 29280 GTGACGACCC GCGGCGCGT ACCCGCCGGC GGTGACCACA CACTGACCGA CCCGGCCGCG 29340 GCCGCGGTGT GGGGCCTGGT CCGGTCCGCG CAGGCGGAAC ACCCGGACCG GGTCGTCCTG 29400 CTGGACACCG ACGGCGAAGT TCCGCTGGGC GCGGTGCTGG CCTCCGGTGA GCCGCAGCTC 29460 GCGGTGCGCG GAACGACGTT CTTCGTGCCC CGGCTGGCCC GCGCCACCCG GCTCTCGGAC 29520 GCGCCTCCTG CGTTCGACCC GGACGGGACC GTGCTGGTCT CGGGCGCCGG ATCGCTGGGC 29580 ACCTTGGTGG CCCGGCACCT GGTCACCCGG CACGGCGTGC GCCGGGTGGT GCTGGCCAGC 29640 CGCCAGGCCC GGGACGCCGA GGGCGCCCAG GACCTGATCA CCGAGCTCAC CGGCGAAGGC 29700 GCGGACGTGT CCTTCGTGGC CTGTGACGTC TCCGATCGCG ACCAGGTGGC CGCGCTGCTC 29760 GCGGGCCTCC CGGACCTGAC CGGGGTGGTG CACACCGCCG GCGTCTTCGA GGACGGCGTG 29820 ATCGAGGCGC TGACGCCCGA CCAGCTCGCG AACGTGTACG CGGCCAAGGT CACGGCCGCG 29880 ATGCACCTCG ACGAGCTCAC CCGCGACCGG GATCTCGGCG CGTTCGTCGT GTTCTCCTCC 29940 GTCGCGGGGG TGATGGGTGG TGGCGGTCAA GGCCCGTACG CGGCGGCGAA CGCCTTCCTG 30000 GACGCGGCGA TGGCGAGTCG TCAGGCCGCG GGCCTGCCGG GCCTGTCCCT GGCGTGGGGC 30060 CTCTGGGAAC GCAGCAGCGG CATGGCCGCC CACCTCAGCG AGGTCGACCA CGCGCGGGCG 30120 AGCCGCAACG GTGTCCTGGA ACTGACCCGG GCCGAGGGCC TGGCGCTGTT CGACCTCGGG 30180 CTGCGGATGG CCGAGTCGCT GCTCGTGCCG ATCAAGCTCG ACCTCGCCGC GATGCGGGCG 30240 AGCACGGTCC CGGTCCTGTT CCGCGGCCTG GTCCGGCCGA GCCGGACCCA GGCGCGCACG 30300 GCGTCCACTG TGGACCGGGG GCTGGCCGGG CGGCTCGCCG GGCTGCCGGT GGCCGAGCGG 30360

GCGGCGCTGC TGGTCGACCT GGTGCGCGGG CAGGTCGCGG TCGTGCTCGG CTACGACGGG 30420 CCGGAGGCCG TCCGCCCGGA CACGGCGTTC AAGGACACCG GGTTCGACTC GCTGACGTCG 30480 GTGGAACTGC GCAACCGGCT GCGCGAGGCG ACCGGGCTCA AGCTCCCCGC CACGCTCGTC 30540 TTCGACTACC CGAACCCCTT GGCGGTGGCG CGCTACCTGG GCGCGCGCT GGTCCCGGAC 30600 GGGACCGCGA ACGGCAACGG GAACGGGAAT GGGCACAGCG AAGACGACCG GCTGCGGCAC 30660 GCGCTGGCGG CCATCCCGGC CGAGGACGCG GGCGAGGAGC GGTCGATCGC CGACCTGGGC 30720 GTCGACGACC TCGTGCAACT GGCTTTCGGC GACGAGTGAT TGGGGCAAGT GGTGAGTGCG 30780 TCGTATGAAA AGGTCGTCGA GGCGCTGCGG AAGTCGCTCG AAGAGGTCGG CACGCTGAAG 30840 AAGCGGAACC GGCAGCTCGC CGACGCGGCC GGCGAGCCGA TCGCCATCGT CGGCATGGCC 30900 TGCCGGCTGC CCGGTGGCGT CACCGGGCCC GGTGACCTCT GGCGGCTGGT GGCCGAGGGC 30960 GGCGACGCCG TCTCGGGGTT CCCCACCGAC CGCTGCTGGG ACCTGGACAC CCTGTTCGAC 31020 CCGGATCCCG ACCACGCGG GACGTCGTAC ACCGACCAGG GCGGCTTCCT CCACGACGCG 31089 GCCCTGTTCG ACCCGGGCTT CTTCGGGGATT TCGCCGCGCG AGGCGCTGGC CATGGACCCG 31140 CAGCAGCGGT TGCTGCTGGA GGCGTCCTGG GAGGCGCTGG AAGGTGTCGG CCTCGACCCG 31200 GCTTCGTTGC AGGGCACCGA CGTCGGCGTG TTCACCGGCG CGGGCGGGTC GGGCTACGGC 31260 GGCGGCCTCA CCGGGCCGGA GATGCAGAGT TTCGCGGGCA CCGGGCTGGC CTCGAGCGTG 31320 GCTTCGGGCC GGGTGTCCTA CGTCTTCGGG TTCGAGGGAC CGGCGGTCAC GATCGACACG 31380 GCGTGCTCGT CGTCGCTGGT GGCGATGCAC CTCGCCGCGC AGGCCCTGCG CCAAGGCGAC 31440

TGCTCGATGG CACTGGCCGG CGGCGCGATG GTGATGTCGG GCCCCGACTC CTTCGTCGTC 31500 TTCTCCCGGC AGCGGGGCT GGCCACCGAC GGGCGTGCA AGGCGTTCGC GTCGGGCGCC 31560 GACGGCATGG TGCTCGCCGA GGGCATCAGC GTGGTCGTGC TGGAGCGGCT TTCGGTCGCG 31620 CGGGAACGCG GGCACCGGGT GCTGGCCGTG CTGCGCGGCA GCGCGGTGAA CCAGGATGGC 31680 31740 CTGGCCAACG CCGGAATCGG ACCGTCCGAT GTGGACCTCG TCGAGGCGCA CGGGACCGGG 31800 ACGAGCCTGG GTGATCCCAT CGAGGCGCAG GCCTTGCTGG CGACCTACGG CCAGGACCGG 31860 GAGACGCCGT TGTGGCTCGG CTCGCTGAAG TCGAACATCG GGCACACGCA GGCGCCGCG 31920 GCCGTGCCGA GCGTGATCAA GGTCGTGCAG GCCCTGCGGC ACGGCGTCAT GCCGCCGACC 31980 CTGCACGTCG ACGAGCCCAG CTCGCAGGTC GACTGGTCCG AAGGCGCGGT GGAACTGCTG 32040 ACCEGGAGCC GGGACTGGCC GCGCGGGGAC CGGCCGGGGCC GGGCCGGGGT GTCGTCGTTC 32100 GGCGTCAGCG GGACGAACGT GCACCTGATC ATCGAGGAAG CCCCCGAGGA GCCCGCTGCG 32160 GCCGTGCCGA CGTCCGCGGA CGTCGTGCCG CTGGTGGTTT CCGCACGCAG CACGGGTTCC CTGGCCGGTC AGGCCGACCG GCTGACCGAG GTGGACGTCC CCCTCGGACA CCTCGCCGGG 32280 GCGCTGGTGG CCGGGCGCGC GGTGCTCGAG GAACGCGCGG TCGTGGTCGC CGGTTCGGCC 32340 GAAGAAGCCC GCGCGGGCT GGGTGCGCTG GCTCGCGGTG AAGCCGCGCC CGGCGTCGTG 32400 ACCGGGACCG CGGCCAAGCC GGCCAAGGTC GTCTGGGTGT TCCCGGGACA GGGGACGCAG 32460 TGGGTGGGCA TGGGCCGGGA GCTCCTCGAC GCGTCCCCGG TGTTCGCCGA GCGGATCAAG 32520 GAGTGCGCGG CGGCACTGGA CCAGTGGACC GACTGGTCGC TGCTGGACGT CCTGCGTGGT 32580





GACGGTGACC TGGATTCTGT CGAGGTGCTG CAGCCCGCGT GCTTCGCGGT GATGGTGGGG 32640 CTGGCCGCGG TCTGGGAGTC GGCGGGGGTC CGGCCGGACG CCGTCGTCGG CCACTCGCAG 32700 GGCGAGATCG CCGCGGCCTG CGTGTCCGGC GCGCTCACCC TCGACGACGC CGCGAAGGTG 32760 GTGGCCCTGC GCAGCCAGGC GATCGCGGCG CGGCTGTCCG GCCGCGGCGG GATGGCGTCG 32820 GTCGCGTTGA GCGAGGACGA GGCGAACGCA CGGCTGGGTT TGTGGGACGG CCGGATCGAG 32880 GTGGCCGCGG TCAACGGCCC CGCCTCCGTG GTGATCGCGG GGGACGCCCA AGCCCTCGAC 32940 GAGGCTTTGG AGGTGCTGGC CGGGGACGGC GTCCGCGTCC GGCAGGTCGC GGTCGACTAC 33000 GCCTCCCACA CCCGGCACGT CGAGGACATC CGCGACACCC TCGCCGAGAC GCTGGCCGGG 33060 ATCACCGCGC AGGCCCCGGA CGTGCCGTTC CGCTCCACCG TCACCGGCGG CTGGGTGCGG 33120 GACGCCGACG TCCTGGACGG CGGGTACTGG TACCGCAACC TGCGCAACCA GGTCCGGTTC 33180 GGCCGGCCG TGGCCGAGCT GCTCGAGCAG GGCCACGGGG TGTTCGTCGA GGTCAGCGCC 33240 CACCCCGTGC TGGTGCAGCC GATCAGCGAG CTCACCGACG CGGTCGTCAC CGGGACGCTG 33300 CGGCGCGACG ACGCCGCCT GCGCCGCCTG CTGACGTCGA TGGCCGAGCT GTTCGTCCGC 33360 GGTGTTCGCG TCGACTGGGC CACGCTGGTG CCGCCCGCGC GCGTGGACCT CCCGACGTAC 33420 GCCTTCGACC ACCAGCACTT CTGGCTCCGG CCGGCCGCGC AGGCGGACGC CGTCTCGCTC 33480 GGCCAGGCCG CGGCGGAGCA CCCGCTGCTC GGCGCGGTCG TCCGGCTGCC GCAGTCGGAC 33540 GGCCTGGTCT TCACCTCGCG GCTGTCGCTG CGGACGCACC CGTGGCTGGC CGACCACACC 33600 ATCGGCGGCG TGGTGCTGTT CCCCGGCACC GGGCTGGTCG AACTGGCCGT GCGGGCCGGC 33660

BARDOCID- AND DECTOR



GACGAGGCCG GGTGCCCGGT CCTGGACGAA CTCGTGACCG AGGCGCCGCT GGTCGTGCCC 33720 GGGCAGGGCG CAGTGAACGT CCAGGTCACG GTGAGCGGCC CGGACCAGAA CGGCTTGCGC 33780 ACGCTGGACA TCCACTCCCA GCGCGACGAC GTGTGGACCC GGCACGCGAC CGGAACGGTC 33840 TCGCCGACCC CGGCGAGCAG CCCCGGCTTC GACTTCACCG CGTGGCCGCC GCCGGACGGG 33900 CAGCGCGTCG AGATCGCCGA CTTCTACGCC GACCTCGCCG AGCGCGGGTA CGCGTACGGG 33960 CCCTTGTTCC AGGGCGTGCG GGCGGTGTGG CAGCGCGCG AAGACGTGTT CGCCGAGGTC 34020 GCGCTGCCCG AAGACCGGCG GGAGGACGCC GCCCGGTTCG GCCTGCACCC GGCGTTGCTG 34080 GACGCGGCCC TGCAGACCGG GACGATCGCC GCGGCGCGT CCGGTCAGCC GGGCAAGTCC 34140 GTGATGCCGT TCTCGTGGAA CCGGCTGGCG CTGCACGCCG TCGGGGCCGC GGGCCTCCGG 34200 GTCCGCGTGG CCCCGGCGG ACCGGACGCG CTGACCGTCG AGGCCGCCGA CGAGACCGGC 34260 GCCCCGGTCC TCACCATGGA CTCGCTGATC CTGCGTGAAG TCGCCCTCGA CCAGCTGGAC 34320 ACTGCGCGCG CCGGCTCGCT CTACCGGGTG GACTGGACGC CACTGCCCAC TGTGGACAGT 34380 GCGGTGCCCG CTGGTCGGGC CGAGGTGCTG GAAGCTTTCG GCGAGGAGCC CCTGGACCTG 34440 . . . 34500 ACCGGCCGGG TGCTGGCCGC CCTGCAGGCG TGGCTTTCCG ACGCGGCGGA GGAAGCCCGC CTGGTCGTGG TGACCCGGGG TGCGGTGCCC GCCGGAGACG GTGTGGTGAG CGATCCGGCG 34560 GGTGCCGCGG TGTGGGGCCT GGTCCGGGCC GCGCAGGCGG AGAACCCGGA CCGGTTCGTC 34620 CTGCTCGACA CCGACGCGA GGTGCCGCTG GAAGCGGTGC TGGCGACCGG TGAGCCGCAG 34680 CTCGCGCTGC GCGCACGAC GTTCTCGGTG CCCCGGCTCG CCCGCGTCAC CGAACCGGCG 34740 GAAGCCCCGC TGACGTTCCG TCCGGACGGG ACGGTCCTGG TCTCCGGCGC CGGGACGCTG 34800





GGTGCGCTCG CCGCCCGCGA CCTCGTCACC CGGCACGGCG TCCGGCGGCT CGTGCTGGCC 34860 ACCCGCGCG GCCGGCCGC CGAGGGCATC GACGACCTCG TCGCCGAGCT GACCGGGCAC 34920 GGCGCCGAAG TGACGGTCGC CGCCTGCGAC GTCTCCGACC GCGACCAGGT GGCGGCGCTG 34980 CTCAAGGAAC ACGCGTGAC CGCGGTGGTG CACACGGGGG GCGTGTTCGA CGCCGGTGTC 35040 ACCGCCGCG TGACCCGGGA GCGCCTCGCC AAGGTGTTCG CGCCCAAGGT CGACGCGGCC 35100 AACCACCTCG ACGAGCTGAC CCGCGACCTG GACCTCGACG CGTTCATCGT CTACTCGTCC 35160 GCCTCCTCGA TCTTCATGGG CGCGGCAGC GGCGGGTACG CGCCGGCGAA CGCCTACCTC 35220 GACGCCTGA TGGCCGCCCG GCGCGGGCG GGCTGCCGG GGCTGTCGCT GGCCTGGGGC 35280 CCCTGGGAGC ACCTCACCGG CATGGCCGAC ACCATCGACG ACCTCACCCT GGCCCGGATG 35340 35400 TTCCACGCCG CGCTCGCGCC CGGCCAGGCG CTGCTGGTGC CGATCGAGCT CGACCTGCGC 35460 GAGGTGCGGG CCGACGCGGC CGGCGGCGC ACGTGCCGC ACCTGCTGCG CGGGCTGGTC 35520 35580 CTGGCCGGGC TCACCGTGGC CGAACAGGAA GCGCTGCTGC TCGACCTCGT CCGCGGTCAG 35640 GTCGCCGTCG TGCTCGGGCA CGCCGACAGC TCCGGCGTCC GCGCCGACGC GGCGTTCAAG 35700 GACGCCGCGT TCGACTCGCT GACGTCGGTG GAGCTGCGCA ACCGGCTGCG CGAGACGACC 35760 GGCCTGAAAC TGCCCGCGAC GCTGGTCTTC GACCATCCGA ACCCGCTGGC ACTGGCCCGG 35820 CACCTGCGGG CGGAACTCGC CGTCGACGAG GCATCCCCGG CCGATGCGGT GCTGGCCGGG 35880

¥ \_ '



CTCGCCGGGC TGGAGGCGGC CATCGCGGCC GCCGGCGCCC CGGACGGCGA CCGGATCACC 35940 GCGCGGCTGC GGGAACTGCT CAAGGCCGCC GAGGCGGCCG AGGCCCGGCC GGGCACCTCC 36000 GGCGATCTCG ACACGGCCAG CGACGAGGAA CTGTTCGCCC TCGTCGACGG GCTCGACTGA 36060 AACCGCTGTG ACATCCGGGG CTTCGCCACC CGGGCCCCGA AAAGCAAGCA CACGTGAGAG 36120 TTCTGGGACT TGAGTTCAGT GGCTGACGAG GGACAACTCC GCGACTACCT CAAGCGGGCC 36180 ATCGCCGACG CCCGCGACGC CCGCACGCGG CTGCGCGAGG TCGAGGAGCA GGCGCGGGAG 36240 CCGATCGCCA TCGTCGCCAT GGCGTGCCGG TACCCGGGCG GGGTGTCCTC GCCCGAGGAC 36300 CTGTGGCGC TGGTGGCCGA GGGGACCGAC GCCGTCTCCG CGTTCCCCGG CGACCGGGC 36360 TGGGACGTCG ACGGGCTCGT CGACCCGGAC CCCGACCGCC CGGGCACGAC GTACACGGAC 36420 CAGGGTGGCT TCCTCCACGA GGCCGGCCTC TTCGACGCGG GGTTCTTCGG GATCTCGCCG 36480 CGGGAGGCCG TCGCGATGGA CCCGCAGCAG CGGCTGCTGC TGGAGACGTC CTGGGAGGCCC 36540 ATCGAACGCA CCGCCACCGA CCCGCTTTCG CTGAAGGGCA GCGACATCGG CGTCTTCACC 36600 GCCGTCGCGA GCATGGCTTA CGGCGCCGGT GGCGGCGTGG TCGCGCCGGA GCTGGAGGGT 36660 TTCGTCGGCA CCGGTGCGGC GCCGTGCATC GCGTCCGGCC GGGTGTCGTA CGTCCTCGGC 36720 TTCGAAGGCC CGGCGGTCAC CGTCGACACC GGGTGTTCGT CGTCGCTGGT GGCGATGCAC 36780 CTCGCCGCG AGGCGCTGCG GCGGGGTGAG TGCTCGATGG CTCTGGCCGG CGGCGCGATG 36840 ETGATGECCC AGCCGGGTTC GTTCGTGTCC TTCTCGCGGC AACGCGGGCT CGCCCTGGAC 36900 GGGCGCTGCA AGGCGTTTTC GGACAGCGCC GACGGGATGG GACTGGCCGA GGGCGTCGGC 36960 GTCATCGCGC TGGAACGGCT GTCGGTCGCC CGTGAGCGTG GGCACCGGGT GCTGGCCGTG 37020

WO 98/07868 PCT/EP97/04495

-

87 -



CTGCGCGGTA TCGCGGTGAA CCAGGATGGC GCGTCGAACG GCTTGACCGC CCCGAACGGC 37080 CCGTCCCAGC AGCGGGTGAT CCGCGCCGCG CTGGCCGAAG CCGGGCTGTC GCCGTCCGAT 37140 37200 GCGTTGCTGG CCACCTACGG CAAGGGCCGG GACCCGGAGA AGCCGCTCTG GCTGGGCTCG 37260 GTGAAGTCGA ACCTCGGGCA CACGCAAGCG GCCGCGGGCG TGGCCAGCGT GATCAAGATG 37320 GTGCAGGCGC TGCGCCACGG CGTGCTGCCC CCGACGCTGC ACGTCGACCG GCCGTCCACC 37380 GAAGTCGACT GGTCGGCCGG TGCGGTCTCG CTGTTGACGG AGGCTCGGGA GTGGCCGCGC 37440 GAAGGCGGC CGCGCCGGGC CGGGGTGTCC TCGTTCGGGA TCAGCGGGGC CAACGCGCAC 37500 CTCATCCTGG AGGAAGCGCC CGAGGAGGAG CCGCCCGTCG CCGAAGCGCC TTCCGCCGGA 37560 GTGGTGCCCG TGGTGGTGTC GGCTCGTGGG GCCCTGGCGG GTCAGGCCGG CCGGCTGGCC 37620 GCGTTCCTCG AGGCGTCCGA CGAGCCGTTG GTGACCGTCG CCGGGGCGCT GATCTGCGGC 37680 CGGTCCCGT TCGGCGACCG GGCCGTCGTG GTGGCGGGCA CGCGCGCAGA GGCGACGGCC 37740 GGGCTGGCCG CGCTGGCCCG CGGCGAAAGC GCCGCCGACG TCGTGACCGG CACGGTCGCG 37800 GCCTCGGGCG TGCCGGGCAA GCTCGTGTGG GTGTTCCCGG GCCAGGGTTC GCAGTGGGTG 37860 GGCATGGGCC GGGAGCTCCT CGAAGCCTCG CCGGTGTTCG CCGCGCGGAT CGCGGAGTGC 37920 GCGGCTGCCC TCGAACCGTG GATCGACTGG TCGCTGCTGG ACGTCCTCCG TGGCGAGGGC 37980 GACCTCGACC GCGTCGACGT GGTGCAGCCC GCGAGTTTCG CGGTGATGGT CGGCCTGGCC 38040 GCGGTGTGGT CGTCCGTCGG GGTGGTGCCC GACGCGGTGC TCGGGCACTC GCAGGGGGAG 38100



ATCGCGCGG CGTGCGTGTC GGGGGGTTG TCGCTGCAGG ACGCGGCGAA GGTGGTCGCG 38160 TTGCGCAGCC AGGCGATCGC GCCGAAGCTG GCCGGCCGCG GCGGCATGGC CTCGGTCGCG 38220 CTGAGCGAGG AAGACGCGGT CGCGCGGTTG CGGCACTGGG CGGACCGGGT CGAGGTGGCC 38280 GCGGTCAACA GCCCGTCGTC GGTGGTGATC GCCGGCGACG CCGAAGCCCT CGACCAGGCC 38340 CTCGAAGCAC TGACCGGCCA GGACATCCGG GTCCGGCGGG TGGCGGTGGA CTACGCCTCG 38400 CACACCCGGC ACGTCGAAGA CATCCAGGAG CCCCTCGCCG AGGCACTGGC CGGGATCGAG 38460 GCGCACGCGC CGACCCTGCC GTTCTTCTCG ACCCTCACCG GTGACTGGAT TCGCGAAGCG 38520 38580 GCCGTCGTGG ACGCCGCTA CTGGTACCGG AACCTGCGCA ACCAGGTCGG TTTCGGCCCG GCGGTGCCG AGCTGCTCGG CCTCGGCCAC CGGGTGTTCG TCGAGGTCAG CGCGCACCCC 38640 GTGCTCGTCC AGGCGATCAG CGCGATTGCC GACGACACCG ACGCGGTCGT CACCGGCTCG 38700 CTGCGGCGCG AGGAGGCCGG CCTGCGGCGG CTGCTGACGT CGATGGCCGA GCTGTTCGTC 38760 CGCGGAGTCG ACGTGGACTG GGCCACGATG GTGCCGCCAG CGCGGGTCGA TTTGCCGACC TACGCCTTCG ACCACCAGCA CTACTGGCTG CGGTACGTCG AGACCGCGAC CGACGCGGCC 38880 🕐 🦎 GGTCCGGTGG TCCGGCTGCC GCAGACGGGC GGCCTGGTCT TCACCACCGA GTGGTCGCTG 38940 AAGTCACAGC CGTGGCTGGC CGAGCACACC CTGGAAGACC TGGTCGTCGT CCCCGGCGCG 39000 GCACTGGTCG AGCTGGCCGT CCGGGCCGGT GACGAGGCCG GGACCCCGGT GCTGGACGAA 39060 CTCGTCATCG AGACGCCCCT GGTCGTGCCG GAACGCGGCG CGATCCGGGT GCAGGTCACG 39120 GTGAGCGGAC CGGACGACG CACACGGACC CTGGAAGTGC ATTCCCAGCC CGAAGACGCC 39180 ACCGACGAAT GGACCCGGCA CGCCACCGGC ACGCTGTCGG CGACCCCGGA CGAAAGCAGC 39240



GGGTTCGACT TCACGGCCTG GCCGCCCCG GGCGCCCGGC AGCTCGACGG CGTTCCGGCG ATCTGGCGGG CCGGCGACGA GATCTTCGCC GAAGTCTCCC TGCCCGACGA TGCGGACGCC 39360 GAGGCATTCG GCATCCACCC CGCGCTCCTG GACGCGGCCC TGCACCCCGC CCTGCCCGGC 39420 GATGACGGTC TGACGCAGCC CATGGAATGG CGTGGCCTGA CGCTGCACGC CGCGGGGGCG 39480 TCCACGCTGC GGGTCCGGTT GGTGCCCGGC GGGTTCCTGG AAGCGGCCGA CGGCGCCGGC 39540 ASCCTGGTCG TCACGGCGAA GGAGGTTGCC CTCCGCCCGG TGACGATCGC GCGGTCGCGC 39600 ACCACCACC GAGACTCGCT GTTCCAGCTG AACTGGATCG AGCTGCCCGA GAGTGGCGTG 39660 GTGGCCGCG CAGACGACAC CGAGGTGCTG GAGGTGCCCG CGGGCGATTC CCCGCTGGCG 39720 GCGACCTCCC GAGTCTTGGA GCGGCTCCAG ACCTGGCTGA CCGAGCCCGA GGCGGAACAG 39780 CTGGTCGTCG TGACGCGCGG CGCGGTGCCC GCCGGGGACA CCCCGGTGAC CGACCCGGCC 39840 GCGGCGCGG TCTGGGGCCT GGTCCGGTCC GCGCAGGCGG AGAACCCGGA CCGGATCGTC 39900 39960 ETCGCGGTGC GCGCACGCC GCTGTACGTC CCGCGCCTGG CCCGCGCCGA CGCGGCCCG 40020 GTATCCGGTC TACATGGGAC GGTCCTCGTC TCCGGTGCCG GTGTGCTCGG CGAGATCGTG 40080 GCGCGCACC TGGTCACCCG CCACGGCGTG CGCAAGCTGG TGCTCGCCAG CCGCCGCGC 40140 CTGGACGCG ACGCGCGAA GGACCTCGTC ACCGACCTCA CCGGCGAGGG CGCGGACGTG 40200 TCCGTCGTCG CCTGCGACCT GGCCGATCGG AACCAGGTGG CCGCGCTGCT GGCCGACCAC 40260 CGCCCGGCGA GCGTCATCCA CACGGCGGC GTCCTCGACG ACGGCGTCAT CGGGACGCTG 40320





ACCCCGGAGC GGCTGGCCAA GGTGTTCGCG CCCAAGGTCG ACGCGGTCCG CCATCTCGAC 40380 GAGCTGACTC GCGACCTCGA CCTCGACGCG TTCGTCGTGT TCTCCTCCGG CTCCGGCGTG 40440 TICGGTTCGC CGGGGCAGGG CAACTACGCG GCGGCGAACG CGTTCCTGGA CGCGGCGATG 40500 GCGAGCCGCC GCGCGCGGG TCTTCCTGGT CTCTCGCTGG CGTGGGGCCT GTGGGAACAG 40560 GCCACCGGCA TGACCGCGCA CCTCGGCGGC ACCGACCAGG CCCGGATGAG CCGGGGCGGG 40620 GTGCGGCCGA TCACGCCCGA GGAAGGCATG GCCCTGTTCG ACACGGCACT GGGTGCGCAG 40680 CCCGCGCTGC TCGTGCCGGT CAAGCTCGAC CTGCGGGAGG TGCGGGCCGG CGGGGCCGTG 40740 CCGCACCTGC TGCGCGGGCT GGTCCGGGCC GGGCGGGGG AGGCCCAAGC CGCGTCCACA 40800 GTGGACAACC AGCTGCTGGG CCGGCTGGCC GGGCTGGGCG CGCCCGAGCA GGAGGCGCTG 40860 CTCGTCGACC TCGTGCGCGG CCAGGTCGCG GCGGTGCTCG GGCACGCCGG GCCGGACGCG 40920 GTCCGCGCCG ACACGCGTT CAAGGACGCC GGGTTCGACT CGCTCACCTC GGTCGACCTG 40980 CGCAACCGGC TGCGGGAGAG CACCGGGCTG AAGCTGCCCG CCACGCTCGC CTTCGACTAC 41040 CCGACCCCGC TGGTCCTCGC CCGGCACCTG CGTGACGAGC TCGGGGCCGG CGACGACGCG 41100 CTTTCGGTGG TGCACGCGCG GCTCGAAGAC GTCGAGGCGC TGCTCGGCGG GCTGCGCCTC 41160 GACGAATCCA CGAAGACCGG TCTCACCCTC CGGCTGCAGG GCCTGGTCGC CCGGTGCAAC 41220 GGCGTGAACG ACCAGACCGG CGGCGAAACG CTGGCGGACC GGCTCGAGGC CGCGTCCGCC 41280 GACGAAGTCC TCGACTTCAT CGACGAGGAG CTGGGTCTCA CCTGACCCCG GTTCGAGACC 41340 GACGTTCCAG CAACCCTTGT GAGGACCCGA GAATGGCCAC GGACGAGAAA CTCCTCAAAT 41400 ACCTCAAGCG CGTCACGGCG GAGCTGCACA GCCTGCGCAA GCAGGGTGCC CGGCACGCCG 41460





ACGAGCCGCT CGCCGTCGTC	GGGATGGCCT	GCCGGTTCCC	GGGTGGGGTG	TCCTCGCCCG	41520
AAGACCTGTG GCAGCTCGTG	GCCGGCGGGG	TCGACGCCCT	TTCGGACTTC	CCCGACGACC	41580
GGGGCTGGGA GCTGGACGGC	CTGTTCGACC	CGGACCCCGA	CCACCCCGG	ACGTCGTACA	41640
CCAGCCAGGG CGGCTTCCTG	CGTGGCGCCG	GGCTGTTCGA	CGCGGGCCTG	TTCGGCATCT	41700
CGCCGCGCGA GGCCCTCGTC	ATGGACCCGC	AGCAGCGGGT	GCTGCTGGAG	ACGTCGTGGG	41760
AGGCCCTCGA AGACGCCGGG	GTCGACCCGC	TTTCGCTGAA	GGGCAGCGAC	GTCGGCGTGT	41820
TCTCCGGCGT CTTCACCCAG	GGCTACGGCG	CCGGGGCGAT	CACGCCGGAC	CTCGAGGCGT	41880
TCGCGGGCAT CGGGGGGGG	TCGACCGTGG	CCTCGGGCCG	GGTGTCCTAC	GTCTTCGGGC	41940
TCGAAGGACC GGCGGTCACC	ATCGACACCG	CGTGTTCGTC	GTCGCTGGTG	GCCATCCACC	42000
TCGCCGCGCA GGCCCTGCGC	GCGGGCGAGT	GCTCGATGGC	GCTCGCCGGC	GGGCGACGG	42060
TGATGCCGAC GCCCGGCACC	TTCGTCGCGT	TCTCGCGGCA	GCGGGTGCTG	GCTGCCGACG	42120
GCCGGTCCAA GGCCTTCTCC	TCGACCGCGG	ACGCCACCGG	CTGGGCCGAG	GCCCCCGGG	42180
TGCTCGTCCT CGAACGGCTT	TCGGTCGCGC	AGGAGCGCGG	CCACCGGATT	CTCGCCGTGC	42240
TGCGCGGCAG CGCGGTCAAC	CAGGATGGCG	CCTCCAACGG	CCTGACCGCG	CCGAACGGGC	42300
CTTCGCAGCA GCGGGTGATC	CGCAAGGCGC	TCGCGGGCGC	CGGGCTGGTC	GCGTCCGATG	42360
TGGACGTCGT GGAGGCGCAC	GGCACGGGCA	CCGCGCTGGG	CGACCCGATC	GAAGCGCAGG.	42420
CGCTGCTGGC GACCTACGGC	CAGGGCCGTG	AGCGGCCGCT	GTGGCTGGGG	TCGGTCAAGT	42480
CGAACTTCGG GCACACGCAG	GCGGCCGCCG	GGGTCGCGGG	CGTGATCAAG	ATGGTCCAGG	42540



CCCTGCGGCA CGGCGCCATG CCGCCGACCC TGCACGTGGC CGAGCCGACG CCGGAGGTCG 42600 ACTGGTCGGC CGGTGCGGTG GAACTGCTGA CCGAGCCGCG CGAGTGGCCC GCCGGTGATC 42660 GCCGCGCG GCCGGGTG TCCGCGTTCG GGATCAGCGG GACGAACGCC CACCTGATCC 42720 TGEAGGAGGC GCCCCGGCC GACGCGGTCG CGGAAGAACC GGAGTTCAAG GGGCCGGTGC 42780 CGCTGGTCGT CTCGGCGGC AGCCCCACAT CTTTGGCGGC TCAGGCCGGC CGGCTCGCGG 42840 AGGTCCTGGC GTCCGGTGGT GTGTCCCGGG CCCGGCTGGC GAGCGGGCTG CTGTCGGGCC 42900 GGGCGCTGCT CGGTGACCGC GCGGTCGTGG TCGCGGGAAC GGACGAGGAC GCGGTGGCCG 42960 GGTTGCGTGC GCTGGCCCGC GGGGACCGCG CGCCCGGCGT GCTGACCGGT TCGGCCAAGC 43020 ACGCCAAGGT CGTCTACGTC TTCCCCGGCC AGGGTTCGCA GCGGCTCGGG ATGGGCCGCG 43080 AGCTCTACGA CCGGTACCCG GTGTTCGCGA CGGCGTTCGA CGAGGCTTGC GAGCAGCTGG 43140 ACGTCTGTCT GGCCGCCGT GCCGGGCACC GCGTGCGGGA CGTCGTGCTC GGCGAAGTGC 43200 CCGCCGAAAC CGGGCTGCTG AACCAGACGG TCTTCACCCA AGCCGGGCTG TTCGCGGTGG 43260 AGAGCGCGCT GTTCCGGCTC GCCGAATCCT GGGGTGTCCG GCCGGACGTG GTGCTCGGCC 43320 ACTCCATCGG GGAGATCACC GCCGCGTATG CCGCGGGCGT CTTCTCGCTG CCGGACGCCG 43380 CCCGGATCGT CGCGGCGCC GGCCGGCTCA TGCAGGCGCT GGCGCCGGGC GGGGCGATGG 43440 TOGCOGTOGO CGCCTCCGAA GCCGAGGTGG CCGAACTGCT CGGCGACGGC GTGGAACTCG 43500 CCGCCGTCAA CGGCCCTTCG GCGGTAGTCC TTTCCGGGGA CGCGGACGCG GTCGTCGCGG 43560 CCGCCGCCG CATGCGCGAG CGCGGGCACA AGACCAAGCA GCTCAAGGTT TCGCACGCGT 43620 TCCACTCCGC GCGGATGCCG CCGATGCTGG CGGAGTTCGC CGCCGAGCTG GCCGGCGTGA 43680

-----





CGTGGCGCGA GCCGGAGATC	CCGGTGGTCT	CCAACGTGAC	CGGCCGGTTC	GCCGAGCCCG	43740
GCGAACTGAC CGAGCCGGGC	TACTGGGCCG	AGCACGTGCG	GCGGCCGGTG	CGGTTCGCCG	43800
AGGGCGTCGC GGCCGCGACG	GAGTCCGGCG	GCTCGCTGTT	CGTGGAGCTC	GGGCCGGGGG	43860
CGGCGCTGAC CGCCCTCGTC	GAGGAGACGG	CCGAGGTCAC	CTGCGTCGCG	GCCCTGCGGG	43920
ACGACCGCCC GGAGGTCACC	GCGCTGATCA	CCGCGGTCGC	CGAGCTGTTC	GTCCGCGGGG	43980
TTGCGGTCGA TTGGCCGGCC	CTGCTGCCGC	CGGTCACCGG	GTTCGTCGAC	CTGCCGAAGT	44040
ACGCCTTCGA CCAGCAGCAC	TATTGGCTGC	AGCCCGCCGC	GCAGGCCACG	GACGCGGCCT	44100
CGCTCGGGCA GGTCGCGGCC	GACCACCCGC	TGCTGGGCGC	GGTGGTCCGG	CTGCCGCAGT	44160
CGGACGCCT GGTCTTCACC	TCGCGGCTGT	CATTGAAATC	GCACCCGTGG	CTGGCCGACC	44220
ACGTCATCGG CGGGGTGGTG	CTCGTCGCGG	GCACCGGGCT	CGTCGAGCTG	GCCGTCCGGG	44280
CCGGGGACGA GGCCGGCTGC	CCGGTCCTCG	AAGAACTCGT	CATCGAGGCT	CCGCTGGTCG	44340
TCCCCGACCA CGGCGGGGTC	CGGATCCAGG	TCGTCGTGGG	GGCACCGGGG	GAGACCGGTT	44400
CGCGCGCGGT CGAGGTGTAC	TCCCTGCGCG	AGGACGCCGG	TGCCGAAGTG	TGGGCCCGGC	44460
ACGCCACCGG GTTCCTGGCT	GCGACGCCGT	CGCAGCACAA	GCCGTTCGAC	TTCACCGCCT	44520
GGCCGCCGCC CGGCGTCGAG	CGCGTCGACG	TCGAGGACTT	CTACGACGGC	CTCGTCGACC	44580
GCGGGTACGC CTACGGGCCG	TCGTTCCGGG	GCCTGCGGGC	GGTGTGGCGG	CGCGGCGACG	44640
AAGTGTTCGC CGAGGTCGCC	CTGGCCGAGG	ACGACCGCGC	GCACGCGGCC	CGGTTCGGCA	44700
TCCACCCGG CCTGCTGGAC	GCCGCCCTGC	ACGCGGGCAT	GCCGGTGCC	ACCACCACGG	44760



AAGAGCCCGG CCGGCCGGTG CTGCCGTTCG CCTGGAACGG CCTGGTGCTG CACGCGGCCG 44820 GGGCGTCCGC GCTGCGGGTC CGGCTCGCCC CGAGCGGTCC GGACGCCCTG TCGGTCGAGG 44880 CCGCGGACGA GGCCGGCGGT CTCGTTGTGA CGGCGGACTC GCTGGTCTCC CGGCCGGTGT 44940 CGGCCGAACA GCTGGGCGCG GCGGCGAACC ACGACGCGTT GTTCCGCGTG GAGTGGACCG 45000 AGATTTCCTC GGCTGGAGAC GTTCCGGCGG ACCACGTCGA AGTGCTCGAA GCCGTCGGCG 45060 AGGATCCCCT GGAACTGACC GGCCGGGTCC TGGAGGCCGT GCAGACCTGG CTCGCCGACG 45120 CAGCCGACGA CGCTCGCCTG GTCGTGGTGA CCCGCGGCGC CGTCCACGAG GTGACTGACC 45180 45240 TCGTGCTCCT GGACACCGAC GGTGAAGTGC CGCTAGGCCG GGTGCTGGCC ACCGGCGAGC 45300 CCCAAACAGC CGTCCGAGGC GCCACGCTGT TCGCCCCGCG GCTGGCCCGC GCCGAGGCCG 45360 45420 CGGAGGCACC GGCAGTGACC GGCGGGACGG TCCTGATCTC GGGCGCCGGC TCGCTGGGCG CGCTCACCGC CCGGCACCTG GTCGCCCGGC ACGGAGTCCG GCGGCTGGTG CTCGTCAGCC 45480 GCCGTGGCCC CGACGCCGAC GGCATGGCCG AACTGACCGC TGAACTCATC GCTCAGGGCG 45540 CCGAGGTCGC CGTAGTCGCT TGCGACCTGG CCGACCGGGA CCAGGTCCGG GTACTGCTGG 45600 CCGAGCACCG CCCGAACGCC GTCGTGCACA CGGCCGGTGT TCTCGACGAC GGCGTCTTCG 45660 AGTCGCTGAC GCGGGAGCGG CTGGCCAAGG TCTTCGCGCC CAAAGTTACT GCTGCCAATC 45720 ACCTCGACGA GCTGACCCGC GAACTGGATC TTCGCGCGTT CGTCGTGTTC TCCTCCGCCT 45780 CCGGGGTCTT CGGCTCCGCC GGGCAGGGCA ACTACGCCGC TGCCAACGCC TACCTGGACG 45840 CCGTGGTCGC CAACCGCCGG GCCGCGGGCC TGCCCGGCAC ATCGCTGGCC TGGGGCCTGT 45900

.... ....





GGGAACAGAC CGACGGGATG ACCGCGCACC TCGGCGACGC CGACCAGGCG CGGGCGAGTC 45960 GCGCGGGGT CCTCGCCATC TCACCGCCG AAGGCATGGA GCTGTTCGAC GCAGCGCCGG 46020 ACCGCTCGT CGTCCCGGTC AAGCTGGACC TGCGCAAGAC CCGCGCGGC GGGACGGTGC 46080 CGCACCTGCT GCGCGGCCTG GTCCGCCCGG GACGCAGCA GGCCCGTCCG GCGTCCACTG 46140 TGGACAACGG ACTGGCCGGG CGACTCGCCG GGCTCGCGCC GGCGGAGCAG GAGGCGCTGC 46200 TGCTCGACGT CGTCCGCACG CAGGTCGCGC TGGTGCTCGG GCACGCCGGG CCGGAGGCCG 46260 TCCGCGCGGA CACGGCGTTC AAGGACACCG GCTTCGACTC GCTGACGTCG GTGGAACTGC 46320 GCAACCGGCT GCGCGAGGCG AGCGGGCTGA AGCTGCCCGC GACGCTCGTC TTCGACTACC 46380 CGACGCCGGT CGCGCTGGCC CGCTACCTGC GTGACGAACT CGGCGACACG GTGGCAACAA 46440 CTCCGGTGGC CACCGCGGCC GCAGCGGACG CCGGCGAGCC GATCGCCATC GTCGGCATGG 46500 CGTGCCGGCT GCCGGCGGG GTCACCGATC CCGAAGGCCT GTGGCGCCTG GTGCGCGACG 46560 GCCTCGAAGG GCTGTCTCCC TTCCCCGAGG ACCGGGGCTG GGACCTGGAG AACCTGTTCG 46620 ACGACGACCC CGACCGCTCC GGCACGACGT ACACCAGCCG GGGCGGGTTC CTCGACGGCG 46680 CCGGCCTGTT CGACGCGGC TTCTTCGGGA TTTCGCCGCG CGAGGCGCTG GCCATGGACC 46740 CGCAGCAGCG GCTGCTGCTC GAGGCGGCCT GGGAAGCCCT CGAAGGCACC GGTGTCGACC 46800 CGGGCTCGTT GAAGGGCGCC GACGTCGGGG TGTTCGCCGG GGTGTCCAAC CAGGGCTATG 46860 GGATGGGCGC GGATCCGGCC GAACTGGCGG GGTACGCGAG CACGGCGGGC GCTTCGAGCG 46920 TCGTCTCGGG CCGAGTCTCG TACGTCTTCG GGTTCGAAGG ACCGGCGGTC ACGATCGACA 46980



CGGCTTGCTC GTCGTCGCTG GTGGCGATGC ACCTGGCCGG GCAGGCGCTG CGGCAGGGCG 47040 AGTGCTCGAT GGCCCTGGCC GGTGGCGTCA CGGTGATGGG GACGCCCGGC ACGTTCGTGG 47100 AGTTCGCGAA GCAGCGCGC CTGGCCGGCG ACGGCCGGTG CAAGGCCTAC GCCGAAGGCG 47160 CGGACGCAC GGGCTGGCC GAGGGCGTCG GGGTCGTCGT GCTGGAGCGG CTGTCGGTGG 47220 CGCGCGAGCG CGGGCACCGG GTGCTGGCCG TGCTGCGCGG CAGCGCGGTC AACTCCGACG 47289 GCGCGTCCAA CGGCCTGACC GCCCCCAACG GGCCGTCGCA GCAACGGGTG ATCCGCCGGG 47340 CCCTGGCCGG CGCCGGCCTC GAACCGTCCG ATGTGGACAT CGTGGAAGGG CACGGCACCG 47400 GGACGCCCT GGCCGACCCG ATCGAGGCCC AGGCCCTGCT GGCCACCTAC GGCAAGGACC 47460 GCGACCCGGA GACGCCGTTG TGGCTGGGGT CGGTGAAGTC GAACTTCGGC CACACGCAGT 47520 CCGCGGCCGG CGTGGCCGGG GTGATCAAGA TGGTGCAGGC GCTGCGCCAC GGCGTCATGC 47580 CGCCCACCCT GCACGTGGAC CGGCCCACCA GCCAGGTCGA CTGGTCCGCG GGGGCCGTCG 47640 AAGTGCTGAC CGAGGCACGG GAGTGGCCGC GGAACGGCCG TCCGCGCCGG GCCGGGGTGT 47700 CCTCGTTCGG GATCAGCGGC ACGAACGCCC ACCTGATCAT CGAAGAAGCA CCGGCCGAGC 47760 CACAGCTTGC CGGACCACCG CCGGACGGCG GTGTGGTGCC GCTGGTCGTC TCGGCTCGCA 47820 GCCCCGGTGC CCTGGCCGGT CAGGCGCGTC GGCTGGCCAC GTTCCTCGGC GACGGGCCCC 47880 TTTCCGACGT CGCCGGTGCG CTGACGAGCC GCGCCCTGTT CGGCGAGCGC GCGGTCGTCG 47940 TGGCGGATTC GGCCGAGGAA GCCCGCGCCG GTCTGGGCGC ACTGGCCCGC GGCGAAGACG 48000 CGCCGGGCCT GGTCCGCGGC CGGGTGCCCG CGTCCGGCCT GCCGGGCAAG CTCGTGTGGG 48060 TGTTCCCCGG GCAGGGGACG CAGTGGGTGG GCATGGGCCG CGAACTCCTC GAAGAGTCTC 48120

WO 98/07868 PCT/EP97/04495

- 97 -



CGGTGTTCGC CGAGCGGATC GCCGAGTGTG CGGCCGCGCT GGAGCCGTGG ATCGGCTGGT 48180 CGCTGTTCGA CGTCCTCCGT GGCGACGGTG ACCTCGATCG GGTCGATGTG CTGCAGCCCG 48240 CGTGCTTTGC GGTGATGGTC GGCTTGGCCG CGGTGTGGTC CTCGGCCGGG GTGGTCCCCG 48300 ATGCGGTGCT CGGCCACTCC CAGGGTGAGA TCGCCGCGGC GTGCGTGTCG GGTGCGTTGT 48360 CGCTGGAGGA TGCGGCGAAG GTGGTTGCCC TGCGCAGCCA GGCCATCGCC GCGAAGCTCT 48420 CCGGCCGCGG CGGGATGCCT TCGGTCGCCT TGGGCGAAGC CGATGTGGTG TCGCGGCTGG 48480 CGGACGGGT CGAGGTGGCT GCCGTCAACG GTCCGGCGTC CGTGGTGATC GCGGGGGATG 48540 CCCAGGCCT CGACGAAACG CTGGAAGCGC TGTCCGGTGC GGGAATCCGG GCTCGGCGGG 48600 TGGCGGTGGA CTACGCCTCG CACACCGGC ACGTCGAAGA CATCGAAGAC ACCCTCGCCG 48660 AAGCGCTGGC CGGGATCGAC GCCCGGGCGC CGCTGGTGCC GTTCCTCTCC ACCCTCACCG 48720 CCGAGTGGAT CCGGGACGAG GCCGTCGTGG ACGCGGCCTA CTGGTACCGG AACCTGCGCG 48780 GCCGGGTGCG GTTCGGCCCG GCCGTCGAGG CGCTGCTGGC CCAGGGGCAC GGTGTTTCG 48840 TCGAGCTCAG CGCCCACCG GTGCTGGTCC AGCCGATCAC CGAGCTCACC GACGAAACCG 48900 CCGCCGTCGT CACCGCTTCG CTGCGCCGGG ACGACGGTGG CCTGCGCCGG CTGCTGACCT 48960 CGATGGCCGA GCTCTTCGTC CGTGGGGTCG AAGTGGACTG GACGTCGCTG GTGCCGCCGG 49020 CCCGGGCCGA CCTCCCGACG TACGCCTTCG ACCACGAGCA CTACTGGCTC CGCGCCGCG 49080 ACACCECTTC CGACGCCGTC TCGCTGGGGC TGGCCGGGGC GGACCACCCG CTGCTCGGCG 49140 CGGTCGTGCA GCTTCCGCAG TCCGACGCC TGGTCTTCAC TTCCCGGCTC TCCCTGCGCT 49200





CGCACCCTG GCTGGCCGAC CACGCGGTCC GGGACGTCGT GATCGTCCCC GGCACCGGGC 49260 TGGTCGAGCT GGCCGTGCGG GCCGGTGACG AAGCCGGCTG CCCGGTGCTC GACGAGCTGG 49320 TGATCGAGGC GCCGCTCGTG GTGCCCCGCC GCGGCGGGGT CCGCGTGCAG GTCGCCCTCG 49380 GCGGCCCCGC CGACGACGGT TCGCGCACGG TGGACGTCTT CTCCCTGCGC GAAGACGCGG 49440 ACAGCTGGCT CCGGCACGCC ACGGGCGTGC TGGTCCCGGA GAACCGGCCG CGGGGGACCG 49500 CCGCGTTCGA CTTCGCCGCC TGGCCGCCAC CGGAGGCGAA GCCCGTGGAC CTCACCGGTG 49560 CCTACGACGT GCTCGCGGAC GTCGGGTACG GCTACGGGCC CACGTTCCGG GCCGTGCGGG 49620 CCGTGTGGCG GCGCGCAGC GGGAACACCA CCGAGACCTT CGCCGAGATC GCCCTGCCCG 49680 AAGACGCCCG CGCGGAAGCC GGCCGGTTCG GCATCCACCC CGCGCTGCTG GACGCGGCCC 49740 TGCACTCGAC GATGGTCAGC GCCGCGGCGG ACACCGAGTC CTACGGCGAC GAAGTGCGGC 49800 TGCCGTTCGC GTGGAACGGG CTGCGGCTGC ACGCGGCCGG CGCCTCGGTG CTGCGGGTGC 49860 GCGTCGCCAA GCCCGAGCGG GACAGTCTGT CGCTGGAGGC CGTCGACGAG TCCGGCGGCC 49920 TEGTEGTGAE GETGGATTEE CTEGTEGGGE GECEGGTGTE GAACGACCAG ETGAEGAEGG 49980 CGGCGGGGCC GGCGGGCCC GGCTCGCTGT ACCGCGTGGA CTGGACGCCA TTGTCCTCAG 50040 TGGACACTTC GGGACGGGTG CCGTCCTGGC TTCCGGTCGC CACCGCGGAA GAGGTGGCGA 50100 CGCTGGCCGA CGACGTCCTG ACCGGCGCGA CCGAGGCGCC GGCGGTGGCC GTCATGGAGG 50160 CCGTCGCCGA CGAGGGTTCC GTGCTGGCGC TCACCGTCCG GGTGCTGGAC GTGGTCCAGT 50220 50280 TECCCECCE CGACGCGTG GTGCACGACC CGGCCGGGC CGCGGTGTGG GGGCTGGTCC 50340





GGGCCGCGCA GGCGGAGAAC CCGGACCGGA TCGTCCTCCT CGACGTCGAG CCGGAAGCCG 50400 ACGTACCGCC GCTGCTGGGT TCGGTGCTCG CCGACGGCGA GCCGCAGGTC GCGGTGCGCG 50460 GAACCACGCT GTCCATCCCC CGCCTCGCCC GCGCCGCCG GCCCGACCCG GCCGCCGGGT 50520 TCAAGACCCG GGGACCGGTG CTGGTCACCG GCGGGACCGG GTCGCTCGGC GGCCTGGTCG 50580 CCCGGCACCT GGTCGAGCGG CACGGCGTCC GGCAGCTGGT GCTGGCGAGT CGCCGGGGCC 50640 TGGACGCCGA AGGCGCGAAG GACCTGGTCA CCGACCTCAC CGCACTGGGG GCCGACGTCG 50700 CGGTCGCCCC TTGCGACGTC GCCGACCGGG ACCAGGTGGC GGCCCTGCTG ACCGAGCACC 50760 GGCCGTCCGC CGTGGTGCAC ACGGCCGGCG TCCCGGACGC CGGGGTGATC GGGACGGTGA 50820 CCCCGGACCG GCTGGCCGAG GTGTTCGCGC CCAAGGTCAC CGCGGCCCGG CACCTCGACG 50880 AGCTGACCCG CGACCTGGAC CTCGACAGTT TCGTCGTCTA CTCCTCGGTT TCCGCGGTGT 50940 TCATGGGCGC CGGCAGCGGC AGCTACGCCG CGGCGAACGC GTACCTGGAC GGGCTGATGG 51000 CCCACCGGCG CGCGCCGGC CTGCCGGGCC AGTCGCTGGC GTGGGGGCTG TGGGACCAGA 51060 CCACCGGGGG CATGGCGGCC GGGACCGACG AGGCCGGCCG GGCCCGGATG ACCCGGCGCG 51120 GCGCCTGGT CGCGATGAAA CCCGCCGCCG GACTGGACCT CTTCGACGCT GCCATCGGGT 51180 CCGGCGAGCC GCTGCTGGTG CCCGCCCAGC TCGACCTGCG GGGCCTGCGC GCCGAAGCGG 51240 CGGGCGGCAC CGAAGTGCCG CACCTGCTGC GCGGCCTGGT CCGCGCCGGA CGCCAGCAGG 51300 CCCGTGCGCC GTCCACTGTG GAGGAGAACT GGGCCGGCCG GCTGGCCGGG CTCGAGCCGG CCGAGCGGGG CCAGGTCCTC CTGGAACTGG TGCGCGCCCA GGTGGCAGGG GTCCTGGGCT 51420



ACCGCGCCGC CCACCAGGTC GACCCGGACC AGGGCCTGTT CGAGATCGGG TTCGACTCGC 51480 TCACCGCGAT CGAACTCCGC AACCGGCTGC GCGCCAGGAC CGAACGGAAG ATCTCGCCCG 51540 GTGTCGTCTT CGACCATCCC ACGCCGGCCC TGCTCGCCGC GCACTTGAAC GAGCTGCTCC 51600 GAAAGAAGGT GTGAACGTGT TCGACGTGGA GACCTACCTC CAGCGGATCG GCTGCGGCGG 51660 GGAAACCGGC GTGGACCTCG AAACGCTGGC GAAGCTGCAG AAGAGCCACC TGATGGCGAT 51720 CCCGTACAGC AGCCTCGCCT ACGAACTCCG GGACGCGGTG AACGTCGTCG ACCTCGACGA 51780 CCGGCTGTTC CACCGGCTCC TGACCGAACT CGGCTACGAC GTCACGCCGC TGGCCGGCAG 51900 CACCGCCGAA GGCCGGGAGA CCTTCGGCAC CGACGTCGAG CACATGTTCA ACCTGGTCAC 51960 CCTGGACGGC GCCGACTGGC TCGTGGACGT CGGCTACCCC GGCCCCACCT ACGTCGAGCC 52020 ACTGGCGGTC TCGCCCGCGG TGCAGACCCA GTACGGGAGC CAGTTCCGGT TGGTGGAACA 52080 GGAAACCGGT TATGCGCTGC AACGCCGGGG TGCGGTCACC CGCTGGAGCG TCGTCTACAC 52140 GTTCACGACG CAACCGCGTC AGTGGAGTGA CTGGAAGGAA CTGGAGGACA ACTTCCGGGC 52200 CCTCGTGGGG GACACCACCC GCACCGACAC GCAGGAAACC CTGTGCGGCC GCGCGTTCGC 52260 GAACGGCCAG GTCTTCCTGC GGCAGCGCCG CTACCTGACG GTCGAGAACG GCCGCGAGCA 52320 GGTGCGCACG ATCACCGACG ACGACGAGTT CCGGGCGCTG GTGTCCCGCG TGCTGTCCGG 52380 CGACCACGGC TGAACTGGCG AAAGGCACGA CGATGACGGA AAAAGCGGGC CTGCTGGCGA 52440 AGTTCGCCGG CCTCTGCAAA ACCGCCTACG AGCACCACTA CATCCCGTAC CTGCACTTCT 525c0 TCTACGGCGG CGAGTACCTC CACCACGGCA GCGAGCCGGT GTCCCGGATC GCGGACCTGC 52560





CGTACGTGAC CGTGCCGGAG CCGCGGAAGA AGGCGCCGTG AGGACGACGA TCCCGGTCCG CCTGGCGGAA CGGTCCTACG ACGTGCTCGT CGGCCCCGGG GTGCGGGCGG CGCTGCCCGA 52680 GGTCGTCCGG CGGCTCGCCG CGAGACGGCC CGTGGTCGTG TCGGCCCGGC CGGCGGACTG 52740 GGTGCCCGGC ACCGGCGTCG AGACCCTGCT GCTCCAGGCG CGCGACGGCG AGCCGACCAA 52800 GCGGCTGTCC ACAGTGGAGG AACTGTGCGG TGAGTTCGCG CGGTTCGGGC TCACCCGGTC 52860 CGACGTCGTG GTCTCCTGCG GCGGCGGCAC GACCACGGAC GTCGTCGGGC TCGCGGCCGC 52920 GCTGTACCAC CGGGGGGTCG CCGTGGTCCA CCTGCCCACG TCCCTGCTCG CCCAGGTCGA 52980 CGCCAGCGTC GGCGGGAAGA CCGCGGTGAA CCTGCCGGCG GGCAAGAACC TCGTCGGGGC 53040 GTACTGGCAG CCCAGCGCGG TGCTGTGCGA CACGGACTAC CTGACGACGC TGCCGCGGGG GGAGGTGCTG AACGGCCTCG GCGAGATCGC CCGCTGCCAC TTCATCGGCG CGCCGGACCT 53160 GCGGGGGGC TCGCGCCCGG AGCAGATCGC CGCCAGCGTC ACCCTCAAGG CGGGCATCGT 53220 CGCGCAGGAC GAGCGGGACA CCGGCCCGCG GCACCTGCTC AACTACGGCC ACACGCTGGG 5328C GCACGCGCTG GAGATCGCGA CCGGCTTCGC CCTGCGCCAC GGCGAGGCGG TGGCGATCGG 53340 CACGGTCTTC GCGGGCCGGC TGGCCGGCGC GCTCGGCCGC CTCGACCAGT CCGGTGTGGA 53400 CGAACACCTC GCCGTCGTCC GCCACTACGG CCTGCCCGCC GCGCTGCCCG CGGACGTCGA 53460 CCCGGCGGTG CTCGTCCGGC AGATGTACCG GGACAAGAAG GCGATCACCG GGCTCGCCTT 53520 CGTCCTGGCC GGGCCGGGG GCGCGGAGCT GGTGAGCGAC GTGCCGGCGC CGGTCGTCAC 53580 CGACGTCCTG GACCGGATGC CCCGCGACAG CCTGGAAAAC CTGGTGGGGA CGACGGAAGC 53640



GACGCCGACC GGCCGCCGA GCCGGACTTC GCGCCCCACG GCCGGGCGGT CGACCGGGTG 53700

CTGGCCGGCC GGCTGAGCGC GGCGCTGGCC CGCCGGCCG CGCAGCAGCC GGCTGGCCG 53760

GACGCCGAGC GGCGCCGA GGTGAATTC 53789

## (2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4572 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Phe Tyr Thr Ser Gly Thr Thr Gly Arg Pro Lys Gly Val Val Ser

1 10 15

Thr Gln Arg Asn Cys Leu Trp Ser Val Ala Ser Cys Tyr Val Pro Phe
20 25 30

Pro Gly Leu Ser Asp Gln Asp Arg Val Leu Trp Pro Leu Pro Leu Phe 35 40 45

His Ser Leu Ser His Ile Ala Cys Val Leu Ser Ala Thr Val Val Gly 50 55 60

Ala Ser Val Arg Ile Ala Asp Gly Ser Ser Ala Asp Asp Val Met Arg
65 70 75 80

DISCOUNTS AND DOCUMEN





Leu	Ile	Glu	Ala	Glu 85	Ser	Ser	Thr	Phe	Leu 90	Ala	Gly	Val	Pro	Thr 95	Thr
Tyr	His	His	Leu 100	Val	Arg	Ala	Ala	Arg 105	Gln	Arg	Gly	Phe	Ser 110	Ala	Pro
Ser	Leu	Arg 115	Ile	Gly	Leu	Ala	Gly 120	Gly	Ala	Val	Leu	Gly 125	Ala	Gly	Leu
Arg	Ser 130	Glu	Phe	Glu	Glu	Thr 135	Phe	Gly	Val	Pro	Leu 140	Ile	Asp	Ala	Tyr
Gly 145	Ser	Thr	Glu	Thr	Cys 150	Gly	Ala	Ile	Thr	Met 155	Asn	Pro	Pro	Asp	Gly 160
Ala	Arg	Val	Glu	Gly 165	Ser	Cys	Gly	Leu	Ala 170	Val	Pro	Gly	Val	Asp 175	Val
Arg	Val	Val	Asp 180	Pro	Asp	Thr	Gly	Leu 185	Asp	Val	Pro	Ala	Gly 190	Glu	Glu
Gly	Glu	Val 195	Trp	Val	Ser	Gly	Pro 200	Asn	Val	Met	Leu	Gly 205	Tyr	His	Asn
Ser	Pro 210	Glu	Ala	Thr	Ala	Ala 215	Ala	Met	Arg	Asp	Gly 220	Trp	Phe	Arg	Thr
Gl <u>y</u> 225	Asp	Leu	Ala	Arg	Arg 230	Asp	Asp	Ala	Gly	Туг 235	Phe	Thr	Ile	Cys	Gly 240
Arg	Ile	Lys	Glu	Leu 245	Ile	Ile	Arg	Gly	Gly <sub>.</sub> 250	Ala	Asn	Ile	His	Pro 255	Gly
Glu	Val	Glu	Ala 260	Val	Leu	Arg	Thr	Val 265	Asp	Gly	Val	Ala	Asp 270	Ala	Ala



- Val Gly Gly Val Pro His Asp Thr Leu Gly Glu Val Pro Val Ala Tyr 275 280 285
- Val Ile Pro Gly Pro Thr Gly Phe Asp Pro Ala Ala Leu Ile Glu Lys 290 295 300
- Cys Arg Glu Gln Leu Ser Ala Tyr Lys Val Pro Asp Arg Ile Leu Glu 305 310 315 320
- Val Ala His Ile Pro Arg Thr Ala Ser Gly Lys Ile Arg Arg Gly Leu
  325 330 335
- Leu Thr Asp Glu Pro Ala Gln Leu Arg Tyr Ala Ala Thr Glu His Glu 340 345 350
- Glu Gln Ser Arg His Ala Asp Glu Ser Val Ala Ala Ala Leu Arg Ala 355 360 365
- Arg Leu Ser Gly Leu Asp Glu Arg Ala Gln Cys Glu Leu Leu Glu Asp 370 375 380
- Leu Val Arg Thr Gln Ala Ala Asp Val Leu Gly Gln Pro Val Pro Asp 385 390 595 400
- Gly Arg Ala Phe Arg Asp Leu Gly Phe Thr Ser Leu Ala Ile Val Glu 405 410 415
- Leu Arg Asn Arg Leu Thr Glu His Thr Gly Leu Trp Leu Pro Ala Ser 420 425 430
- Ala Val Phe Asp His Pro Thr Pro Ala Ala Leu Ala Ala Arg Val Arg
  435 440 445
- Ala Glu Leu Leu Gly Ile Thr Gln Ala Val Ala Glu Pro Val Val Ala 450 455 460
- Ala Asp Pro Gly Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg Leu

- 105 -



Pro Gly Gly Val Ala Ser Pro Glu Asp Leu Trp Arg Leu Val Ala Glu Arg Val Asp Ala Val Ser Glu Phe Pro Gly Asp Arg Gly Trp Asp Leu Asp Ser Leu Ile Asp Pro Asp Arg Glu Arg Ala Gly Thr Ser Tyr Val Gly Gln Gly Gly Phe Leu His Asp Ala Gly Glu Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Val Ala Met Asp Pro Gln Gln Arg Leu Leu Glu Thr Ser Trp Glu Ala Leu Glu Asn Ala Gly Val Asp Pro Ile Ala Leu Lys Gly Thr Asp Thr Gly Val Phe Ser Gly Leu Met Gly Gln Gly Tyr Gly Ser Gly Ala Val Ala Pro Glu Leu Glu Gly Phe €05 Val Thr Thr Gly Val Ala Ser Ser Val Ala Ser Gly Arg Val Ser Tyr €20 Val Leu Gly Leu Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Gln Gly €50 Glu Cys Ser Met Ala Leu Ala Gly Gly Val Thr Val Met Ala Thr Pro



- Gly Ser Phe Val Glu Phe Ser Arg Gln Arg Ala Leu Ala Pro Asp Gly 675 680 685
- Arg Cys Lys Ala Phe Ala Ala Ala Ala Asp Gly Thr Gly Trp Ser Glu 690 695 700
- Gly Val Gly Val Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg 705 710 715 720
- Gly His Arg Ile Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp
  725 730 735
- Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Leu Ser Gln Gln Arg
  740 745 750
- Val Ile Arg Arg Ala Leu Ala Ala Ala Gly Leu Ala Pro Ser Asp Val 755 760 765
- Asp Val Val Glu Ala His Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile 770 775 780
- Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Glu Arg Lys Gln Pro 785 790 795 800
- Leu Trp Leu Gly Ser Leu Lys Ser Asn Ile Gly His Ala Gln Ala Ala 805 810 815
- Ala Gly Val Ala Gly Val Ile Lys Met Val Gln Ala Leu Arg His Glu 820 825 830
- Thr Leu Pro Pro Thr Leu His Val Asp Lys Pro Thr Leu Glu Val Asp 835 840 845
- Trp Ser Ala Gly Ala Ile Glu Leu Leu Thr Glu Ala Arg Ala Trp Pro 850 855 860



Arg Asn Gly Arg Pro Arg Ala Gly Val Ser Ser Phe Gly Val Ser 875 870 880 865 Gly Thr Asn Ala His Leu Ile Leu Glu Glu Ala Pro Ala Glu Glu Pro 890 895 885 Val Ala Ala Pro Glu Leu Pro Val Val Pro Leu Val Val Ser Ala Arg 900 905 910 Ser Thr Glu Ser Leu Ser Gly Gln Ala Glu Arg Leu Ala Ser Leu Leu 925 915 920

Glu Gly Asp Val Ser Leu Thr Glu Val Ala Gly Ala Leu Val Ser Arg 930 935 940

Arg Ala Val Leu Asp Glu Arg Ala Val Val Ala Gly Ser Arg Glu 945 950 955 960

Glu Ala Val Thr Gly Leu Arg Ala Leu Asn Thr Ala Gly Ser Gly Thr 965 970 975

Pro Gly Lys Val Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp Ala 980 985 990

Gly Met Gly Arg Glu Leu Leu Ala Glu Ser Pro Val Phe Ala Glu Arg 995 1000 1005

Ile Ala Glu Cys Ala Ala Leu Ala Pro Trp Ile Asp Trp Ser Leu 1010 1015 1020

Val Asp Val Leu Arg Gly Glu Gly Asp Leu Gly Arg Val Asp Val Leu 1025 1030 1035 1040

Gln Pro Ala Cys Phe Ala Val Met Val Gly Leu Ala Ala Val Trp Glu 1045 1050 1055

Ser Val Gly Val Arg Pro Asp Ala Val Val Gly His Ser Gln Gly Glu



1060 1065 1070

- Ile Ala Ala Cys Val Ser Gly Ala Leu Ser Leu Glu Asp Ala Ala 1075 1080 1085
- Lys Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Glu Leu Ser Gly
  1090 1095 1100
- Arg Gly Gly Met Ala Ser Val Ala Leu Gly Glu Asp Asp Val Val Ser 1105 1110 1115 1120
- Arg Leu Val Asp Gly Val Glu Val Ala Ala Val Asn Gly Pro Ser Ser 1125 1130 1135
- Val Val Ile Ala Gly Asp Ala His Ala Leu Asp Ala Thr Leu Glu Ile 1140 1145 1150
- Leu Ser Gly Glu Gly Ile Arg Val Arg Arg Val Ala Val Asp Tyr Ala 1155 1160 1165
- Ser His Thr Arg His Val Glu Asp Ile Arg Asp Thr Leu Ala Glu Thr 1170 1175 1180
- Leu Ala Gly Ile Ser Ala Gln Ala Pro Ala Val Pro Phe Tyr Ser Thr 1185 1190 1195 1200
- Val Thr Ser Glu Trp Val Arg Asp Ala Gly Val Leu Asp Gly Gly Tyr 1205 1216 1215
- Trp Tyr Arg Asn Leu Arg Asn Gln Val Arg Phe Gly Ala Ala Ala Thr 1220 1225 1230
- Ala Leu Leu Glu Gln Gly His Thr Val Phe Val Glu Val Ser Ala His 1235 1240 1245
- Pro Val Thr Val Gln Pro Leu Ser Glu Leu Thr Gly Asp Ala Ile Gly 1250 1255 1260



Thr Leu Arg Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Ala Ser Met 1265 1270 1275 1280

Gly Glu Leu Phe Val Arg Gly Ile Asp Val Asp Trp Thr Ala Met Val 1285 1290 1295

Pro Ala Ala Gly Trp Val Asp Leu Pro Thr Tyr Ala Phe Glu His Arg 1300 1305 1310

His Tyr Trp Leu Glu Pro Ala Glu Pro Ala Ser Ala Gly Asp Pro Leu 1315 1320 1325

Leu Gly Thr Val Val Ser Thr Pro Gly Ser Asp Arg Leu Thr Ala Val 1330 1335 1340

Ala Gln Trp Ser Arg Arg Ala Gln Pro Trp Ala Val Asp Gly Leu Val 1345 1350 1355 1360

Pro Asn Ala Ala Leu Val Glu Ala Ala Ile Arg Leu Gly Asp Leu Ala 1365 1370 1375

Gly Thr Pro Val Val Gly Glu Leu Val Val Asp Ala Pro Val Val Leu 1320 1385 1390

Pro Arg Arg Gly Ser Arg Glu Val Gln Leu Ile Val Gly Glu Pro Gly 1395 1400 1405

Glu Gln Arg Arg Pro Ile Glu Val Phe Ser Arg Glu Ala Asp Glu
1410 1415 1420

Pro Trp Thr Arg His Ala His Gly Thr Leu Ala Pro Ala Ala Ala 1425 1430 1435 1440

Val Pro Glu Pro Ala Ala Ala Gly Asp Ala Thr Asp Val Thr Val Ala 1445 1450 1455



Gly Leu Arg Asp Ala Asp Arg Tyr Gly Ile His Pro Ala Leu Leu Asp 1460 1465 1470

Ala Ala Val Arg Thr Val Val Gly Asp Asp Leu Leu Pro Ser Val Trp 1475 1480 1485

Thr Gly Val Ser Leu Leu Ala Ser Gly Ala Thr Ala Val Thr 1490 1495 1500

Pro Thr Ala Thr Gly Leu Arg Leu Thr Asp Pro Ala Gly Gln Pro Val 1505 1510 1515 1520

Leu Thr Val Glu Ser Val Arg Gly Thr Pro Phe Val Ala Glu Gln Gly
1525 1530 1535

Thr Thr Asp Ala Leu Phe Arg Val Asp Trp Pro Glu Ile Pro Leu Pro 1540 1545 1550

Thr Ala Glu Thr Ala Asp Phe Leu Pro Tyr Glu Ala Thr Ser Ala Glu 1555 1560 1565

Ala Thr Leu Ser Ala Leu Gln Ala Trp Leu Ala Asp Pro Ala Glu Thr 1570 1575 1580

Arg Leu Ala Val Val Thr Gly Asp Cys Thr Glu Pro Gly Ala Ala Ala 1585 1590 1595 1600

Ile Trp Gly Leu Val Arg Ser Ala Gln Ser Glu His Pro Gly Arg Ile 1605 1610 1615

Val Leu Ala Asp Leu Asp Asp Pro Ala Val Leu Pro Ala Val Val Ala 1620 1625 1630

Ser Gly Glu Pro Gln Val Arg Val Arg Asn Gly Val Ala Ser Val Pro 1635 1640 1645

Arg Leu Thr Arg Val Thr Pro Arg Gln Asp Ala Arg Pro Leu Asp Pro

- 111 -

Glu Gly Thr Val Leu Ile Thr Gly Gly Thr Gly Thr Leu Gly Ala Leu Thr Ala Arq His Leu Val Thr Ala His Gly Val Arg His Leu Val Leu Val Ser Arg Arg Gly Glu Ala Pro Glu Leu Gln Glu Leu Thr Ala Leu Gly Ala Ser Val Ala Ile Ala Ala Cys Asp Val Ala Asp Arg Ala Gln Leu Glu Ala Val Leu Arg Ala Ile Pro Ala Glu His Pro Leu Thr Ala Val Ile His Thr Ala Gly Val Leu Asp Asp Gly Val Val Thr Glu Leu Thr Pro Asp Arg Leu Ala Thr Val Arg Arg Pro Lys Val Asp Ala Ala Arg Leu Leu Asp Glu Leu Thr Arg Glu Ala Asp Leu Ala Ala Phe Val Leu Phe Ser Ser Ala Ala Gly Val Leu Gly Asn Pro Gly Gln Ala Gly Tyr Ala Ala Ala Asn Ala Glu Leu Asp Ala Leu Ala Arg Gln Arg Asn Ser Leu Asp Leu Pro Ala Val Ser Ile Ala Trp Gly Tyr Trp Ala 

Thr Val Ser Gly Met Thr Glu His Leu Gly Asp Ala Asp Leu Arg Arg

1850 -

- Asn Gln Arg Ile Gly Met Ser Gly Leu Pro Ala Asp Glu Gly Met Ala 1860 1865 1870
- Leu Leu Asp Ala Ala Ile Ala Thr Gly Gly Thr Leu Val Ala Ala Lys 1875 1880 1885
- Phe Asp Val Ala Ala Leu Arg Ala Thr Ala Lys Ala Gly Gly Pro Val 1890 1895 1900
- Pro Pro Leu Leu Arg Gly Leu Ala Pro Leu Pro Arg Arg Ala Ala Ala 1905 1910 1915 1920
- Lys Thr Ala Ser Leu Thr Glu Arg Leu Ala Gly Leu Ala Glu Thr Glu 1925 1930 1935
- Gln Ala Ala Leu Leu Asp Leu Val Arg Arg His Ala Ala Glu Val . 1940 1945 1950
- Leu Gly His Ser Gly Ala Glu Ser Val His Ser Gly Arg Thr Phe Lys 1955 1960 1965
- Asp Ala Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Leu 1970 1975 1980
- Ala Ala Ala Thr Gly Leu Thr Leu Ser Pro Ala Met Ile Phe Asp Tyr 1985 1990 1995 2000
- Pro Lys Pro Pro Ala Leu Ala Asp His Leu Arg Ala Lys Leu Phe Gly 2005 2010 2015
- Ser Ala Ala Asn Arg Pro Ala Glu Ile Gly Thr Ala Ala Ala Glu Glu 2020 2025 2030
- Pro Ile Ala Ile Val Ala Met Ala Cys Arg Phe Pro Gly Gly Val His 2035 2040 2045

DESCRICTOR INC. CONTRACT.

Ser	Pro	Glu	Asp	Leu	Trp	Arg	Leu	Val	Ala	Asp	Gly	Ala	Asp	Ala	Val
	2050		•			205	5				2060	)			

Thr Glu Phe Pro Ala Asp Arg Gly Trp Asp Thr Asp Arg Leu Tyr His 2065 2070 2075 2080

Glu Asp Pro Asp His Glu Gly Thr Thr Tyr Val Arg His Gly Ala Phe 2085 2090 2095

Leu Asp Asp Ala Ala Gly Phe Asp Ala Ala Phe Phe Gly Ile Ser Pro 2100 2105 2110

Asn Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Glu Thr 2115 2120 2125

Ser Trp Glu Leu Phe Glu Arg Ala Ala Ile Asp Pro Thr Thr Leu Ala 2130 2135 2140

Gly Gln Asp Ile Gly Val Phe Ala Gly Val Asn Ser His Asp Tyr Ser 2145 2150 2155 2160

Met Arg Met His Arg Ala Ala Gly Val Glu Gly Phe Arg Leu Thr Gly 2165 2170 2175

Gly Ser Ala Ser Val Leu Ser Gly Arg Val Ala Tyr His Phe Gly Val 2180 2185 2190

Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val 2195 2200 2205

Ala Leu His Met Ala Val Gln Ala Leu Gln Arg Gly Glu Cys Ser Met 2210 2225 2220

Ala Leu Ala Gly Gly Val Met Val Met Gly Thr Val Glu Thr Phe Val
2225 2230 2235 2240

Glu Phe Ser Arg Gln Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Ala

2250

- Phe Ala Asp Gly Ala Asp Gly Thr Gly Trp Ser Glu Gly Val Gly Leu 2260 2265 2270
- Leu Leu Val Glu Arg Leu Ser Glu Ala Gln Arg Arg Gly His Gln Val 2275 2280 2285
- Leu Ala Val Val Arg Gly Ser Ala Val Asn Ser Asp Gly Ala Ser Asn 2290 2295 2300
- Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Lys 2305 2310 2315 2320
- Ala Leu Ala Ala Gly Leu Ser Thr Ser Asp Val Asp Ala Val Glu 2325 2330 2335
- Ala His Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ala Glu Ala 2340 2345 2350
- Leu Leu Ala Thr Tyr Gly Cln Asn Arg Glu Thr Pro Leu Trp Leu Gly 2355 2360 2365
- Ser Val Lys Ser Asn Leu Gly His Thr Gln Ala Ala Ala Gly Val Ala 2370 2375 2380
- Gly Val Ile Lys Met Val Met Ala Met Arg His Gly Val Leu Pro Arg 2385 2390 2395 2400
- Thr Leu His Val Asp Arg Pro Ser Ser Tyr Val Asp Trp Ser Ala Gly
  2405 2410 2415
- Ala Val Glu Leu Thr Glu Ala Arg Asp Trp Val Ser Asn Gly His 2420 2425 2430
- Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Ile Gly Gly Thr Asn Ala 2435 2440 2445

His Val Val Leu Glu Glu Val Ala Ala Pro Ile Thr Thr Pro Gln Pro 2450 2455 2460

Glu Pro Ala Glu Phe Leu Val Pro Val Leu Val Ser Ala Arg Thr Ala 2465 2470 2475 2480

Ala Gly Leu Arg Gly Gln Ala Gly Arg Leu Ala Ala Phe Leu Gly Asp 2485 2490 2495

Arg Thr Asp Val Arg Val Pro Asp Ala Ala Tyr Ala Leu Ala Thr Thr 2500 2505 2510

Arg Ala Gln Leu Asp His Arg Ala Val Val Leu Ala Ser Asp Arg Ala 2515 2520 2525

Gln Leu Cys Ala Asp Leu Ala Ala Phe Gly Ser Gly Val Val Thr Gly 2530 2535 2540

Thr Pro Val Asp Gly Lys Leu Ala Val Leu Phe Thr Gly Gln Gly Ser 2545 2550 2555 2560

Gln Trp Ala Gly Met Gly Arg Glu Leu Ala Glu Thr Phe Pro Val Phe 2565 2570 2575

Arg Asp Ala Phe Glu Ala Ala Cys Glu Ala Val Asp Thr His Leu Arg 2580 2585 2590

Glu Arg Pro Leu Arg Glu Val Val Phe Asp Asp Ser Ala Leu Leu Asp 2595 2600 2605

Gln Thr Met Tyr Thr Gln Gly Ala Leu Phe Ala Val Glu Thr Ala Leu 2610 2615 2620

Phe Arg Leu Phe Glu Ser Trp Gly Val Arg Pro Gly Leu Leu Ala Gly 2625 2630 2635 2640

- His Ser Ile Gly Glu Leu Ala Ala Ala His Val Ser Gly Val Leu Asp 2655 2655
- Leu Ala Asp Ala Gly Glu Leu Val Ala Ala Arg Gly Arg Leu Met Gln 2660 2665 2670
- Ala Leu Pro Ala Gly Gly Ala Met Val Ala Val Gln Ala Thr Glu Asp 2675 2680 2685
- Glu Val Ala Pro Leu Leu Asp Gly Thr Val Cys Val Ala Ala Val Asn 2690 2695 2700
- Gly Pro Asp Ser Val Val Leu Ser Gly Thr Glu Ala Ala Val Leu Ala 2705 2710 2715 2720
- Val Ala Asp Glu Leu Ala Gly Arg Gly Arg Lys Thr Arg Arg Leu Ala 2725 2730 2735
- Val Ser His Ala Phe His Ser Pro Leu Met Glu Pro Met Leu Asp Asp 2740 2745 2750
- Phe Arg Ala Val Ala Glu Arg Leu Thr Tyr Arg Ala Gly Ser Leu Pro 2755 2760 2765
- Val Val Ser Thr Leu Thr Gly Glu Leu Ala Ala Leu Asp Ser Pro Asp 2770 2775 2780
- Tyr Trp Val Gly Gln Val Arg Asn Ala Val Arg Phe Ser Asp Ala Val 2785 2790 2795 2800
- Thr Ala Leu Gly Ala Gln Gly Ala Ser Thr Phe Leu Glu Leu Gly Pro 2805 2810 2815
- Gly Gly Ala Leu Ala Ala Met Ala Leu Gly Thr Leu Gly Gly Pro Glu 2820 2825 2830
- Gln Ser Cys Val Ala Thr Leu Arg Lys Asn Gly Ala Glu Val Pro Asp

-----

Val Leu Thr Ala Leu Ala Glu Leu His Val Arg Gly Val Gly Val Asp Trp Thr Thr Val Leu Asp Glu Pro Ala Thr Ala Val Gly Thr Val Leu Pro Thr Tyr Ala Phe Gln His Gln Arg Phe Trp Val Asp Val Asp Glu Thr Ala Ala Val Ser Val Thr Pro Pro Pro Ala Glu Pro Ile Val Asp Arg Pro Val Gln Asp Val Leu Glu Leu Val Arg Glu Ser Ala Ala Val Val Leu Gly His Arg Asp Ala Gly Ser Phe Asp Leu Asp Arg Ser Phe Lys Asp His Gly Phe Asp Ser Leu Ser Ala Val Lys Leu Arg Asn Arg. Leu Arg Asp Phe Thr Gly Val Glu Leu Pro Ser Thr Leu Ile Phe Asp Tyr Pro Asn Pro Ala Val Leu Ala Asp His Leu Arg Ala Glu Leu Leu Gly Glu Arg Pro Ala Ala Pro Ala Pro Val Thr Arg Asp Val Ser Asp Glu Pro Ile Ala Ile Val Gly Met Ser Thr Arg Leu Pro Gly Gly Ala 

Asp Ser Pro Glu Glu Leu Trp Lys Leu Val Ala Glu Gly Arg Asp Ala

**)** 

- Val Ser Gly Phe Pro Val Asp Arg Gly Trp Asp Leu Asp Gly Leu Tyr 3045 3050 3055
- His Pro Asp Pro Ala His Ala Gly Thr Ser Tyr Thr Arg Ser Gly Gly 3060 3065 3070
- Phe Leu His Asp Ala Ala Gln Phe Asp Ala Gly Leu Phe Gly Ile Ser 3075 3080 3085
- Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Glu 3090 3095 3100
- Thr Ser Trp Glu Ala Leu Glu Arg Ala Gly Val Asp Pro Leu Ser Ala 3105 3110 3115 3120
- Arg Gly Ser Asp Val Gly Val Phe Thr Gly Ile Val His His Asp Tyr 3125 3130 3135
- Val Thr Arg Leu Arg Glu Val Pro Glu Asp Val Gln Gly Tyr Thr Met 3140 3145 3150
- Thr Gly Thr Ala Ser Ser Val Ala Ser Gly Arg Val Ala Tyr Val Phe 3155 3160 3165
- Gly Phe Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser 3170 3175 3180
- Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Gln Gly Glu Cys 3185 3190 3195 3200
- Ser Met Ala Leu Ala Gly Gly Ala Thr Val Met Ala Ser Pro Asp Ala 3205 3210 3215
- Phe Leu Glu Phe Ser Arg Gln Arg Gly Leu Ser Ala Asp Gly Arg Cys 3220 3225 3230

Lys	Ala	Tyr	Ala	Glu	Gly	Ala	Asp	Gly	Thr	Gly	Trp	Ala	Glu	Gly	Val
	3235						3240	)				3245	5		

- Gly Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His 3250 3255 3260
- Arg Val Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala 3265 3270 3275 3280
- Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile 3285 3290 3295
- Arg Gly Ala Leu Ala Ser Ala Gly Leu Ala Pro Ser Asp Val Asp Val 3300 3305 3310
- Val Glu Gly His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Val 3315 3320 3325
- Gln Ala Leu Leu Ala Thr Tyr Gly Gln Glu Arg Glu Gln Pro Leu Trp 3330 3340
- Leu Gly Ser Leu Lys Ser Asn Leu Gly His Thr Gln Ala Ala Gly
  3345 3350 3355 3360
- Val Val Gly Val Ile Lys Met Ile Met Ala Met Arg His Gly Val Met 3365 3370 3375
- Pro Ala Thr Leu His Val Asp Glu Arg Thr Ser Gln Val Asp Trp Ser 3380 3385 3390
- Ala Gly Ala Ile Glu Val Leu Thr Glu Ala Arg Glu Trp Pro Arg Thr 3395 3400 3405
- Gly Arg Pro Arg Ala Gly Val Ser Ser Phe Gly Ala Ser Gly Thr 3410 3415 3420
- Asn Ala His Leu Ile Ile Glu Glu Gly Pro Ala Glu Glu Ala Val Asp

Glu Glu Val Ala Ser Val Val Pro Leu Val Val Ser Ala Arg Ser Ala Gly Ser Leu Ala Gly Gln Ala Gly Arg Leu Ala Ala Val Leu Glu Asn Glu Ser Leu Ala Gly Val Ala Gly Ala Leu Val Ser Gly Arg Ala Thr Leu Asn Glu Arg Ala Val Val Ile Ala Gly Ser Arg Asp Glu Ala Gln Asp Gly Leu Gln Ala Leu Ala Arg Gly Glu Asn Ala Pro Gly Val Val Thr Gly Thr Ala Gly Lys Pro Gly Lys Val Val Trp Val Phe Pro Gly Gln Gly Ser Gln Trp Met Gly Met Gly Arg Asp Leu Leu Asp Ser Ser Pro Val Phe Ala Ala Arg Ile Lys Glu Cys Ala Ala Ala Leu Glu Gln Trp Thr Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Asp Ala Asp Leu Leu Asp Arg Val Asp Val Val Gln Pro Ala Ser Phe Ala Met Met Val Gly Leu Ala Ala Val Trp Thr Ser Leu Gly Val Thr Pro Asp Ala Val 

Leu Gly His Ser Gln Gly Glu Ile Ala Ala Cys Val Ser Gly Ala

- Leu Ser Leu Asp Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala 3635 3640 3645
- Ile Ala Gly Glu Leu Ala Gly Arg Gly Gly Met Ala Ser Val Ala Leu 3650 3655 3660
- Ser Glu Glu Asp Ala Val Ala Arg Leu Thr Pro Trp Ala Asn Arg Val 3665 3670 3675 3680
- Glu Val Ala Ala Val Asn Ser Pro Ser Ser Val Val Ile Ala Gly Asp 3695 3690 3695
- Ala Gln Ala Leu Asp Glu Ala Leu Glu Ala Leu Ala Gly Asp Gly Val 3700 3705 3710
- Arg Val Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val 3715 3720 3725
- Glu Ala Ile Ala Glu Thr Leu Ala Lys Thr Leu Ala Gly Ile Asp Ala 3730 3735 3740
- Arg Val Pro Ala Ile Pro Phe Tyr Ser Thr Val Leu Gly Thr Trp Ile 3745 3750 3755 3760
- Glu Gln Ala Val Val Asp Ala Gly Tyr Trp Tyr Arg Asn Leu Arg Gln
  3765 3770 3775
- Gln Val Arg Phe Gly Pro Ser Val Ala Asp Leu Ala Gly Leu Gly His 3780 3795 3790
- Thr Val Phe Val Glu Ile Ser Ala His Pro Val Leu Val Gln Pro Leu 3795 3800 3805
- Ser Glu Ile Ser Asp Asp Ala Val Val Thr Gly Ser Leu Arg Arg Asp 3810 3815 3820

Asp Gly Gly Leu Arg Arg Leu Leu Ala Ser Ala Ala Glu Leu Tyr Val 3825 3830 3835 3840

Arg Gly Val Ala Val Asp Tro Thr Ala Ala Val Pro Ala Ala Gly Tro
3845 3850 3855

Val Asp Leu Pro Thr Tyr Ala Phe Asp Arg Arg His Phe Trp Leu His 3860 3865 3870

Glu Ala Glu Thr Ala Glu Ala Ala Glu Gly Met Asp Gly Glu Phe Trp 3875 3880 3885

Thr Ala Ile Glu Gln Ser Asp Val Asp Ser Leu Ala Glu Leu Leu Glu 3890 3895 3900

Leu Val Pro Glu Gln Arg Gly Ala Leu Ser Thr Val Val Pro Val Leu 3905 3910 3915 3920

Ala Gln Trp Arg Asp Arg Arg Glu Arg Ser Thr Ala Glu Lys Leu
3925 3930 3935

Arg Tyr Gln Val Thr Trp Gln Pro Leu Glu Arg Glu Ala Ala Gly Val

Pro Gly Gly Arg Trp Leu Ala Val Val Pro Ala Gly Thr Thr Asp Ala 3955 3965

Leu Leu Lys Glu Leu Thr Gly Gln Gly Leu Asp Ile Val Arg Leu Glu 3970 3975 3980

Ile Glu Glu Ala Ser Arg Ala Gln Leu Ala Glu Gln Leu Arg Asn Val 3985 3990 3995 4000

Leu Ala Glu His Asp Leu Thr Gly Val Leu Ser Leu Leu Ala Leu Asp
4005 4010 4015

Gly Gly Pro Ala Asp Ala Ala Glu Ile Thr Ala Ser Thr Leu Ala Leu

PHENOCIN, AND DESTROY

4020 4025 4030

Val Gln Ala Leu Gly Asp Thr Thr Thr Ser Ala Pro Leu Trp Cys Leu 4035 4040 4045

Thr Ser Gly Ala Val Asn Ile Gly Ile Gln Asp Ala Val Thr Ala Pro 4050 4055 4060

Ala Gln Ala Ala Val Trp Gly Leu Gly Arg Ala Val Ala Leu Glu Arg
4065 4070 4075 4080

Leu Asp Arg Trp Gly Gly Leu Val Asp Leu Pro Ala Ala Ile Asp Ala 4085 4090 4095

Arg Thr Ala Gln Ala Leu Leu Gly Val Leu Asn Gly Ala Ala Gly Glu 4100 4105 4110

Asp Gln Leu Ala Val Arg Arg Ser Gly Val Tyr Arg Arg Arg Leu Val 4115 4120 4125

Arg Lys Pro Val Pro Glu Ser Ala Thr Ser Arg Trp Glu Pro Arg Gly
4130 4135 4140

Thr Val Leu Val Thr Gly Gly Ala Glu Gly Leu Gly Arg His Ala Ser 4145 4150 4155 4160

Val Trp Leu Ala Gln Ser Gly Ala Glu Arg Leu Ile Val Thr Gly Thr 4165 4170 4175

Asp Gly Val Asp Glu Leu Thr Ala Glu Leu Ala Glu Phe Gly Thr Thr 4180 4185 4190

Val Glu Phe Cys Ala Asp Thr Asp Arg Asp Ala Ile Ala Gln Leu Val 4195 4200 4205

Ala Asp Ser Glu Val Thr Ala Val Val His Ala Ala Asp Ile Ala Gln 4210 4215 4220 Thr Ser Ser Val Asp Asp Thr Gly Val Ala Asp Leu Asp Glu Val Phe 4225 4230 4235 4240

Ala Ala Lys Val Thr Thr Ala Val Trp Leu Asp Gln Leu Phe Glu Asp 4245 4250 4255

Thr Pro Leu Asp Ala Phe Val Val Phe Ser Ser Ile Ala Gly Ile Trp
4260 4265 4270

Gly Gly Gly Gln Gly Pro Ala Gly Ala Ala Asn Ala Val Leu Asp 4275 4280 4285

Ala Leu Val Glu Trp Arg Arg Ala Arg Gly Leu Lys Ala Thr Ser Ile 4290 4295 4300

Ala Trp Gly Ala Leu Asp Gln Ile Gly Ile Gly Met Asp Glu Ala Ala 4305 4310 4315 4320

Leu Ala Gln Leu Arg Arg Gly Val Ile Pro Met Ala Pro Pro Leu 4325 4330 4335

Ala Val Thr Ala Met Val Gln Ala Val Ala Gly Asn Glu Lys Ala Val
4340 4345 4350

Ala Val Ala Asp Met Asp Trp Ala Ala Phe Ile Pro Ala Phe Thr Ser 4355 4360 4365

Val Arg Pro Ser Pro Leu Phe Ala Asp Leu Pro Glu Ala Lys Ala Ile 4370 4375 4380

Leu Arg Ala Ala Gln Asp Asp Gly Glu Asp Gly Asp Thr Ala Ser Ser 4385 4390 4395 4400

Leu Ala Asp Ser Leu Arg Ala Val Pro Asp Ala Glu Gln Asn Arg Ile 4405 4410 4415 Leu Leu Lys Leu Val Arg Gly His Ala Ser Thr Val Leu Gly His Ser 4420 4425 4430

Gly Ala Glu Gly Ile Gly Pro Arg Gln Ala Phe Gln Glu Val Gly Phe 4435 4440 4445

Asp Ser Leu Ala Ala Val Asn Leu Arg Asn Ser Leu His Ala Ala Thr 4450 4455 4460

Gly Leu Arg Leu Pro Ala Thr Leu Ile Phe Asp Tyr Pro Thr Pro Glu 4465 4470 4475 4480

Ala Leu Val Gly Tyr Leu Arg Val Glu Leu Leu Arg Glu Ala Asp Asp 4485 4490 4495

Gly Leu Asp Gly Arg Glu Asp Asp Leu Arg Arg Val Leu Ala Ala Val 4500 4505 4510

Pro Phe Ala Arg Phe Lys Glu Ala Gly Val Leu Asp Thr Leu Leu Gly
4515 4520 4525

Leu Ala Asp Thr Gly Thr Glu Pro Gly Thr Asp Ala Glu Thr Thr Glu 4530 4535 4540

Ala Ala Pro Ala Ala Asp Asp Ala Glu Leu Ile Asp Ala Leu Asp Ile 4545 4550 4555 4560

Ser Gly Leu Val Gln Arg Ala Leu Gly Gln Thr Ser 4565 4570

## (2) INFORMATION FOR SEQ ID NO: 5:

...... ...

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5069 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

: }

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Met Ala Asn Gln Ser Trp Arg Lys Asn Met Ser Ala Pro Asn Glu Gln
1 5 10 15

Ile Val Asp Ala Leu Arg Ala Ser Leu Lys Glu Asn Val Arg Leu Gln
20 25 30

Gln Glu Asn Ser Ala Leu Ala Ala Ala Ala Ala Glu Pro Val Ala Ile 35 40 45

Val Ser Met Ala Cys Arg Tyr Ala Gly Gly Ile Arg Gly Pro Glu Asp 50 55 60

Phe Trp Arg Val Val Ser Glu Gly Ala Asp Val Tyr Thr Gly Phe Pro 65 70 75 80

Glu Asp Arg Gly Trp Asp Val Glu Gly Leu Tyr His Pro Asp Pro Asp 85 90 95

Asn Pro Gly Thr Thr Tyr Val Arg Glu Gly Ala Phe Leu Gln Asp Ala 100 105 110

Ala Gln Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu 115 120 125

Ala Met Asp Pro Gln Gln Arg Gln Leu Leu Glu Val Ser Trp Glu Thr
130 135 140

Leu Glu Arg Ala Gly Ile Asp Pro His Ser Val Arg Gly Ser Asp Ile 145 150 155 160

Gly	Val	Tyr	Ala	Gly	Val	Val	His	Gln	Asp	Tyr	Ala	Pro	Asp	Leu	Ser
٠				165					170					175	

- Gly Phe Glu Gly Phe Met Ser Leu Glu Arg Ala Leu Gly Thr Ala Gly
  180 185 190
- Gly Val Ala Ser Gly Arg Val Ala Tyr Thr Leu Gly Leu Glu Gly Pro 195 200 205
- Ala Val Thr Val Asp Thr Met Cys Ser Ser Ser Leu Val Ala Ile His 210 215 220
- Leu Ala Ala Gln Ala Leu Arg Arg Gly Glu Cys Ser Met Ala Leu Ala 225 230 235 240
- Gly Gly Ser Thr Val Met Ala Thr Pro Gly Gly Phe Val Gly Phe Ala 245 250 255
- Arg Glm Arg Ala Leu Ala Phe Asp Gly Arg Cys Lys Ser Tyr Ala Ala 260 265 270
- Ala Ala Asp Gly Ser Gly Trp Ala Glu Gly Val Gly Val Leu Leu Leu 275 280 285
- Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Gln Val Leu Ala Val
  290 295 300
- Ile Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr 305 310 315 320
- Ala Pro Asn Gly Pro Ala Gln Gln Arg Val Ile Arg Lys Ala Leu Ala 325 330 335
- Ser Ala Gly Leu Thr Pro Ser Asp Val Asp Thr Val Glu Gly His Gly 340 345 350

- Thr Gly Thr Val Leu Gly Asp Pro Ile Glu Val Gln Ala Leu Leu Ala 355 360 365
- Thr Tyr Gly Gln Gly Arg Asp Pro Gln Gln Pro Leu Trp Leu Gly Ser 370 375 380
- Val Lys Ser Val Val Gly His Thr Gln Ala Ala Ser Gly Val Ala Gly
  385 390 395 400
- Val Ile Lys Met Val Gln Ser Leu Arg His Gly Gln Leu Pro Ala Thr 405 410 415
- Gln His Val Asp Ala Pro Thr Pro Gln Val Asp Trp Ser Ala Gly Ala 420 425 430
- Ile Glu Leu Leu Ala Glu Gly Arg Glu Trp Pro Arg Asn Gly His Pro
  435 440 445
- Arg Arg Gly Gly Ile Ser Ser Phe Gly Ala Ser Gly Thr Asn Ala His 450 455 460
- Met Ile Leu Glu Glu Ala Pro Glu Asp Glu Pro Val Thr Glu Ala Pro 465 470 475 480
- Ala Pro Thr Gly Val Val Pro Leu Val Val Ser Ala Ala Thr Ala Ala 485 490 495
- Ser Leu Ala Ala Gln Ala Gly Arg Leu Ala Glu Val Gly Asp Val Ser 500 505 510
- Leu Ala Asp Val Ala Gly Thr Leu Val Ser Gly Arg Ala Met Leu Ser 515 520 525
- Glu Arg Ala Val Val Ala Gly Ser His Glu Glu Ala Val Thr Gly
  530 535 540
- Leu Arg Ala Leu Ala Arg Gly Glu Ser Ala Pro Gly Leu Leu Ser Gly

545					550					555					560
Arg	Gly	Ser	Gly	Val 565	Pro	Gly	Lys	Val	Val 570	Trp	Val	Phe	Pro	Gly 575	Gln
Gly	Thr	Gln	Trp 580	Ala	Gly	Met	Gly	Arg 585	Glu	Leu	Leu	Asp	Ser 590	Ser	Glu
Val	Phe	Ala 595	Ala	Arg	Ile	Ala	Glu 600	Cys	Glu	Thr	Ala	Leu 605	Gly	Arg	Trp
Val	Asp 610	Trp	Ser	Leu	Thr	Asp 615	Val	Leu	Arg	Gly	Glu 620	Ala	Asp	Leu	Leu
Asp 625	Arg	Val	Asp	Val	Val 630	Gln	Pro	Ala	Ser	Phe 635	Ala	Val	Met	Val	Gly 640
Leu	Ala	Ala	Val	Trp 645	Ala	Ser	Leu	Gly	Val 650	Glu	Pro	Glu	Ala	Val 655	Val
Gly	P.is	Ser	Gln 660	Gly	Glu	Ile	Ala	<u>Ala</u> 665	Ala	Cys	Val	Ser	Gly 670	Ala	Leu
Ser	Leu	Glu 675	Asp	Ala	Alz	īys	Val 680	Val	Ala	Leu	Arg	Ser 685	Gln	Ala	Ile
Ala	Ala 690	Ser	Leu	Ala	Gly	Arg 695	Gly	Gly	Met	Ala	Ser 700	Val	Ala	Leu	Ser
Glu 705	Glu	Asp	Ala	<u> ጥ</u> ኮድ	Ala 710	Arg	Leu	Glu	Pro	Trp 715	Ala	Gly	Arg	Val	Glu 720
Val	Ala	Ala	Val	Asn 725	Gly	Pro	Thr	Ser	Val 730	Val	Ile	Ala	Gly	Asp 735	Ala
Glu	Ala	Leu	Asp 740	Glu	Ala	Leu	ązA	Ala 745	Leu	Asp	Asp	Gln	Gly 750	Val	Arg

- Ile Arg Arg Val Ala Val Asp Tyr Ala Ser His Thr Arg His Val Glu
  755 760 765
- Ala Ala Arg Asp Ala Leu Ala Glu Met Leu Gly Gly Ile Arg Ala Gln
  770 780
- Ala Pro Glu Val Pro Phe Tyr Ser Thr Val Thr Gly Gly Trp Val Glu
  785 790 795 800
- Asp Ala Gly Val Leu Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Arg 805 810 815
- Gln Val Arg Phe Gly Pro Ala Val Ala Glu Leu Ile Glu Gln Gly His 820 825 830
- Arg Val Phe Val Glu Val Ser Ala His Pro Val Leu Val Gln Pro Ile 835 840 845
- Asn Glu Leu Val Asp Asp Thr Glu Ala Val Val Thr Gly Thr Leu Arg 850 855 860
- Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Ala Ser Ala Ala Glu Leu 865 870 875 880
- Phe Val Arg Gly Val Thr Val Asp Trp Ser Gly Val Leu Pro Pro Ser 885 890 895
- Arg Arg Val Glu Leu Pro Thr Tyr Ala Phe Asp His Gln His Tyr Trp 900 905 910
- Leu Gln Met Gly Gly Ser Ala Thr Asp Ala Val Ser Leu Gly Leu Ala 915 920 925
- Gly Ala Asp His Pro Leu Leu Gly Ala Val Val Pro Leu Pro Gln Ser 930 935 940

-------

Asp	Gly	Leu	Val	Phe	Thr	Ser	Arg	Leu	Ser	Leu	Lys	Ser	His	Pro	Trp
945					950					955					960

- Leu Ala Gly His Ala Ile Gly Gly Val Val Leu Ile Pro Gly Thr Val 965 970 975
- Tyr Val Asp Leu Ala Leu Arg Ala Gly Asp Glu Leu Gly Phe Gly Val 980 985 990
- Leu Glu Glu Leu Val Ile Glu Ala Pro Leu Val Leu Gly Glu Arg Gly 995 1000 1005
- Gly Val Arg Val Gln Val Ala Val Ser Gly Pro Asn Glu Thr Gly Ser 1010 1015 1020
- Arg Ala Val Asp Val Phe Ser Met Arg Glu Asp Gly Asp Glu Trp Thr .

  1025 1030 1035 1040
- Arg His Ala Thr Gly Leu Leu Gly Ala Ser Thr Ser Arg Glu Pro Ser 1045 1050 1055
- Arg Phe Asp Phe Ala Ala Trp Pro Pro Ala Gly Ala Glu Pro Ile Asp 1060 1065 1076
- Val Glu Asn Phe Tyr Thr Asp Leu Thr Glu Arg Gly Tyr Ala Tyr Ser 1075 1080 1085
- Gly Ala Phe Gln Gly Met Arg Ala Val Trp Arg Arg Gly Asp Glu Val 1090 1095 1100
- Phe Ala Glu Val Ala Leu Pro Asp Asp His Arg Glu Asp Ala Gly Lys
  1105 1110 1115 1120
- Phe Gly Leu His Pro Ala Leu Leu Asp Ala Ala Leu His Thr Asn Ala 1125 1130 1135
- Phe Ala Asn Pro Asp Asp Asp Asp Ser Val Leu Pro Phe Ala Trp Asn

1140 1145 1150

Gly Leu Val Leu His Ala Val Gly Ala Ser Ala Leu Arg Val Arg Val 1155 1160 1165

- Ala Pro Gly Gly Pro Asp Ala Leu Thr Phe Gln Ala Ala Asp Glu Thr 1170 1175 1180

Gly Gly Leu Val Val Thr Met Asp Ser Leu Val Ser Arg Glu Val Ser 1185 1190 1195 1200

Ala Ala Gln Leu Glu Thr Ala Ala Gly Glu Glu Arg Asp Ser Leu Phe 1205 1210 1215

Gln Val Asp Trp Ile Glu Val Pro Ala Thr Glu Thr Ala Ala Thr Glu 1220 1225 1230

His Ala Glu Val Leu Glu Ala Phe Gly Glu Ala Ala Pro Leu Glu Leu 1235 1240 1245

Thr Ser Arg Val Leu Glu Ala Val Gln Ser Trp Leu Ala Asp Ala Ala 1250 1255 1260

Asp Glu Ala Arg Leu Val Val Val Thr Arg Gly Ala Val Arg Glu Val 1265 1270 1275 1280

Thr Asp Pro Ala Gly Ala Ala Val Trp Gly Leu Val Arg Ala Ala Gln 1285 1290 1295

Ala Glu Asn Pro Gly Arg Ile Ile Leu Val Asp Thr Asp Gly Asp Val 1300 1305 1310

Pro Leu Gly Ala Val Leu Ala Ser Gly Glu Pro Gln Leu Ala Val Arg 1315 1320 1325

Gly Asn Ala Phe Ser Val Pro Arg Leu Ala Arg Ala Thr Gly Glu Val 1330 1335 1340 Pro Glu Ala Pro Ala Val Phe Ser Pro Glu Gly Thr Val Leu Leu Thr 1345 1350 1355 1360

Gly Gly Thr Gly Ser Leu Gly Gly Leu Val Ala Lys His Leu Val Ala 1365 1370 1375

Arg His Gly Val Arg Arg Leu Val Leu Ala Ser Arg Arg Gly Val Ala 1380 1385 1390

Ala Glu Asp Leu Val Thr Glu Leu Thr Glu Gln Gly Ala Thr Val Ser 1395 1400 1405

Val Val Ala Cys Asp Val Ser Asp Arg Asp Gln Val Ala Ala Leu Leu 1410 1415 1420

Ala Glu His Arg Pro Thr Gly Ile Val His Leu Ala Gly Leu Leu Asp 1425 1430 1435 1440

Asp Gly Val Ile Gly Ala Leu Asn Arg Glu Arg Leu Ala Gly Val Phe 1445 1450 1455

Ala Pro Lys Val Asp Ala Val Gln His Leu Asp Glu Leu Thr Arg Asp 1460 1465 1470

Leu Gly Leu Asp Ala Phe Val Val Phe Ser Ser Ala Ala Ala Leu Met 1475 . 1480 1485

Gly Ser Ala Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Phe Leu Asp 1490 1495 1500

Gly Leu Met Ala Gly Arg Arg Ala Ala Gly Leu Pro Gly Val Ser Leu 1505 1510 1515 1520

Ala Trp Gly Leu Trp Glu Gln Ala Asp Gly Leu Thr Ala Asn Leu Ser 1525 1530 1535

- Ala Thr Asp Gln Ala Arg Met Ser Arg Gly Gly Val Leu Pro Met Thr 1540 1545 1550
- Pro Ala Glu Ala Leu Asp Ile Phe Asp Ile Gly Leu Ala Ala Glu Gln 1555 1560 1565
- Ala Leu Leu Val Pro Ile Lys Leu Asp Leu Arg Thr Leu Arg Gly Gln 1570 1575 1580
- Ala Thr Ala Gly Gly Glu Val Pro His Leu Leu Arg Gly Leu Val Arg 1585 1590 1595 1600
- Ala Ser Arg Arg Val Thr Arg Thr Ala Ala Ala Ser Gly Gly Gly Gly 1605 1615
- Leu Val His Lys Leu Ala Gly Arg Pro Ala Glu Glu Glu Glu Ala Val 1620 1635 1630
- Leu Leu Gly Ile Val Gln Ala Glu Ala Ala Ala Val Leu Gly Phe Asn 1635 1640 1645
- Ala Pro Glu Leu Ala Gln Gly Thr Arg Gly Phe Ser Asp Leu Gly Phe 1650 1655 1660
- Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Leu Ser Ala Ala Thr 1665 1670 1675 1680
- Gly Val Lys Leu Pro Ala Thr Leu Val Phe Asp Tyr Pro Thr Pro Val 1685 1690 1695
- Ala Leu Ala Arg His Leu Arg Glu Glu Leu Gly Glu Thr Val Ala Gly
  1700 1705 1710
- Ala Pro Ala Thr Pro Val Thr Thr Val Ala Asp Ala Gly Glu Pro Ile 1715 1720 1725
- Ala Ile Val Gly Met Ala Cys Arg Leu Pro Gly Gly Val Met Ser Pro

Asp Asp Leu Trp Arg Met Val Ala Glu Gly Arg Asp Gly Met Ser Pro Phe Pro Gly Asp Arg Gly Trp Asp Leu Asp Gly Leu Phe Asp Ser Asp Pro Glu Arg Pro Gly Thr Ala Tyr Ile Arg Gln Gly Gly Phe Leu His Glu Ala Ala Leu Phe Asp Pro Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Leu Leu Glu Ala Ser Tro Glu Ala Leu Glu Arg Ala Gly Ile Asp Pro Thr Lys Ala Arg Gly Asp Ala Val Gly Val Phe Ser Gly Val Ser Ile His Asp Tyr Leu Glu Ser Leu Ser Asn Met Pro Ala Glu Leu Glu Gly Phe Val Thr Thr Ala Thr Ala Gly Ser Val Ala Ser Gly Arg Val Ser Tyr Thr Phe Gly Phe Glu . Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala Ala Gln Ala Leu Arg Gln Gly Glu Cys Thr Met Ala 

Leu Ala Gly Gly Val Ala Val Met Gly Ser Pro Ile Gly Val Ile Gly

- Met Ser Arg Gln Arg Gly Met Ala Glu Asp Gly Arg Val Lys Ala Phe 1940 1945 1950
- Ala Asp Gly Ala Asp Gly Thr Val Leu Ser Glu Gly Val Gly Ile Val 1955 1960 1965
- Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Val Leu 1970 1975 1980
- Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly
  1985 1990 1995 2000
- Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Ser Ala 2005 2010 2015
- Leu Ala Gly Ala Gly Leu Gln Pro Ser Glu Val Asp Val Val Glu Ala 2020 2025 2030
- His Gly Thr Gly Thr Ala Leu Gly Glu Pro Ile Glu Ala Gln Ala Leu 2035 2040 2045
- Leu Ala Thr Tyr Gly Lys Ser Arg Glu Thr Pro Leu Trp Leu Gly Ser 2050 2055 2060
- Leu Lys Ser Asn Ile Gly His Thr Gln Ala Ala Gly Val Ala Ala 2065 2070 2075 2080
- Val Ile Lys Met Val Gln Ala Leu Arg Gln Asp Thr Leu Pro Pro Thr 2085 2090 2095
- Leu His Val Gln Glu Pro Thr Lys Gln Val Asp Trp Ser Ala Gly Ala 2100 2105 2110
- Val Glu Leu Leu Thr Glu Gly Arg Glu Trp Ala Arg Asn Gly His Pro 2115 2120 2125

- Arg Arg Ala Gly Val Ser Ser Phe Gly Ile Ser Gly Thr Asn Ala His 2130 2135 2140
- Leu Ile Leu Glu Glu Ala Pro Ala Asp Asp Thr Ala Glu Ala Asp Val 2145 2150 2155 2160
- Pro Asp Ala Val Val Pro Val Val Ile Ser Ala Arg Ser Thr Gly Ser 2165 2170 2175
- Leu Ala Gly Gln Ala Gly Arg Leu Ala Ala Phe Leu Asp Gly Asp Val 2180 2185 2190
- Pro Leu Thr Arg Val Ala Gly Ala Leu Leu Ser Thr Arg Ala Thr Leu 2195 2200 2205
- Thr Asp Arg Ala Val Val Ala Gly Ser Ala Glu Glu Ala Arg Ala 2210 2215 2220
- Gly Leu Thr Ala Leu Ala Arg Gly Glu Ser Ala Ser Gly Leu Val Thr
  2225 2230 2235 2240
- Gly Thr Ala Gly Met Pro Gly Lys Thr Val Trp Val Phe Pro Gly Gln
  2245 2250 2255
- Gly Thr Gln Trp Ala Gly Met Gly Arg Glu Leu Leu Glu Ala Ser Pro 2260 2265 2270
- Val Phe Ala Glu Arg Ile Glu Glu Cys Ala Ala Ala Leu Gln Pro Trp 2275 2280 2285
- Ile Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Glu Gly Glu Leu Asp 2290 2295 2300
- Arg Val Asp Val Leu Gln Pro Ala Cys Phe Ala Val Met Val Gly Leu 2305 2310 2315 2320
- Ala Ala Val Trp Ala Ser Val Gly Val Val Pro Asp Ala Val Leu Gly

2325 2330 2335

His Ser Gln Gly Glu Ile Ala Ala Cys Val Ser Gly Ala Leu Ser 2340 2345 2350

Leu Glu Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala Ile Ala 2355 2360 2365

Ala Glu Leu Ser Gly Arg Gly Gly Met Ala Ser Ile Gln Leu Ser His 2370 2375 2380

Asp Glu Val Ala Ala Arg Leu Ala Pro Trp Ala Gly Arg Val Glu Ile 2385 2390 2395 2400

Ala Ala Val Asn Gly Pro Ala Ser Val Val Ile Ala Gly Asp Ala Glu 2405 2410 2415

Ala Leu Thr Glu Ala Val Glu Val Leu Gly Gly Arg Arg Val Ala Val 2420 2425 2430

Asp Tyr Ala Ser His Thr Arg His Val Glu Asp Ile Gln Asp Thr Leu 2435 2440 2445

Ala Glu Thr Leu Ala Gly Ile Asp Ala Gln Ala Pro Val Val Pro Phe 2450 2455 2460

Tyr Ser Thr Val Ala Gly Glu Trp Ile Thr Asp Ala Gly Val Val Asp
2465 2470 2475 2480

Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn Gln Val Gly Phe Gly Pro 2485 2490 2495

Ala Val Ala Glu Leu Ile Glu Gln Gly His Gly Val Phe Val Glu Val
2500 2505 2510

Ser Ala His Pro Val Leu Val Gln Pro Ile Ser Glu Leu Thr Asp Ala 2515 2520 2525 Val Val Thr Gly Thr Leu Arg Arg Asp Asp Gly Gly Val Arg Arg Leu 2530 2535 2540

Leu Thr Ser Met Ala Glu Leu Phe Val Arg Gly Val Pro Val Asp Trp 2545 2550 2555 2560

Ala Thr Met Ala Pro Pro Ala Arg Val Glu Leu Pro Thr Tyr Ala Phe 2565 2570 2575

Asp His Gln His Phe Trp Leu Ser Pro Pro Ala Val Ala Asp Ala Pro 2580 2585 2590

Ala Leu Gly Leu Ala Gly Ala Asp His Pro Leu Leu Gly Ala Val Leu 2595 2600 2605

Pro Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Val 2610 2615 2620

Arg Thr His Pro Trp Leu Ala Asp Gly Val Pro Ala Ala Ala Leu Val 2625 2630 2635 2640

Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys Pro Val Leu Ala 2655 2650 2655

Asp Leu Thr Val Glu Lys Leu Leu Val Leu Pro Glu Ser Gly Gly Leu 2660 2665 2670

Arg Val Gln Val Ile Val Ser Gly Glu Arg Thr Val Glu Val Tyr Ser 2675 2680 2685

Gln Leu Glu Gly Ala Glu Asp Trp Ile Arg Asn Ala Thr Gly His Leu 2690 2695 2700

Ser Ala Thr Ala Pro Ala His Glu Ala Phe Asp Phe Thr Ala Trp Pro 2705 2710 2715 2720

- Pro Ala Gly Ala Gln Gln Val Asp Gly Leu Trp Arg Arg Gly Asp Glu 2725 2730 2735
- Ile Phe Ala Glu Val Ala Leu Pro Glu Glu Leu Asp Ala Gly Ala Phe 2740 2745 2750
- Gly Ile His Pro Phe Leu Leu Asp Ala Ala Val Gln Pro Val Leu Ala 2755 2760 2765
- Asp Asp Glu Gln Pro Ala Glu Trp Arg Ser Leu Val Leu His Ala Ala 2770 2775 2780
- Gly Ala Ser Ala Leu Arg Val Arg Leu Val Pro Gly Gly Ala Leu Gln 2785 2790 2795 2800
- Ala Ala Asp Glu Thr Gly Gly Leu Val Leu Thr Ala Asp Ser Val Ala 2805 2810 2815
- Gly Arg Glu Leu Ser Ala Gly Lys Thr Arg Ala Gly Ser Leu Tyr Arg 2820 2825 2830
- Val Asp Trp Thr Glu Val Ser Ile Ala Asp Ser Ala Val Pro Ala Asn 2835 2840 2845
- Ile Glu Val Val Glu Ala Pne Gly Glu Glu Pro Leu Glu Leu Thr Gly 2850 2855 2860
- Arg Val Leu Glu Ala Val Gln Thr Trp Leu Val Thr Ala Ala Asp Asp 2865 2870 2875 2880
- Ala Arg Leu Val Val Val Thr Arg Gly Ala Val Arg Glu Val Thr Asp 2885 2890. 2895
- Pro Ala Gly Ala Ala Val Trp Gly Leu Val Arg Ala Ala Gln Ala Glu 2900 2905 2910
- Asn Pro Gly Arg Ile Phe Leu Ile Asp Thr Asp Gly Glu Ile Pro Ala

2915 2920 2925

Leu Thr Gly Asp Glu Pro Glu Ile Ala Val Arg Gly Gly Lys Phe Phe 2930 2935 2940

Val Pro Arg Ile Thr Arg Ala Glu Pro Ser Gly Ala Ala Val Phe Arg 2945 2950 2955 2960

Pro Asp Gly Thr Val Leu Ile Ser Gly Ala Gly Ala Leu Gly Gly Leu 2965 2970 2975

Val Ala Arg Arg Leu Val Glu Arg His Gly Val Arg Lys Leu Val Leu 2980 2985 2990

Ala Ser Arg Arg Gly Arg Asp Ala Asp Gly Val Ala Asp Leu Val Ala 2995 3000 3005

Asp Leu Ala Ala Asp Val Ser Val Val Ala Cys Asp Val Ser Asp Arg 3010 3015 3020

Ala Gln Val Ala Ala Leu Leu Asp Glu His Arg Pro Thr Ala Val Val 3025 3030 3035 3040

His Thr Ala Gly Val Ile Asp Ala Gly Val Ile Glu Thr Leu Asp Arg 3045 3050 3055

Asp Arg Leu Ala Thr Val Phe Ala Pro Lys Val Asp Ala Val Arg His . 3060 3065 3070

Leu Asp Glu Leu Thr Arg Asp Arg Asp Leu Asp Ala Phe Val Val Tyr 3075 3080 3085

Ser Ser Val Ser Ala Val Phe Met Gly Ala Gly Ser Gly Ser Tyr Ala 3090 3095 3100

Ala Ala Asn Ala Phe Leu Asp Gly Leu Met Ala Asn Arg Arg Ala Ala 3105 3110 3115 3120

- Gly Leu Pro Gly Leu Ser Leu Ala Trp Gly Leu Trp Asp Gln Ser Thr 3125 3130 3135
- Gly Met Ala Ala Gly Thr Asp Glu Ala Thr Arg Ala Arg Met Ser Arg 3140 3145 3150
- Arg Gly Gly Leu Gln Ile Met Thr Gln Ala Glu Gly Met Asp Leu Phe 3155 3160 3165
- Asp Ala Ala Leu Ser Ser Ala Glu Ser Leu Leu Val Pro Ala Lys Leu 3170 3180
- Asp Leu Arg Gly Val Arg Ala Asp Ala Ala Gly Gly Val Val Pro 3185 3190 3195 3200
- His Met Leu Arg Gly Leu Val Arg Ala Gly Arg Ala Gln Ala Arg Ala 3205 3210 3215
- Ala Ser Thr Val Asp Asn Gly Leu Ala Gly Arg Leu Ala Gly Leu Ala 3220 3225 3230
- Pro Ala Asp Gln Leu Thr Leu Leu Leu Asp Leu Val Arg Ala Gln Val
  3235 3240 3245
- Ala Ala Val Leu Gly His Ala Asp Ala Ser Ala Val Arg Val Asp Thr 3250 3255 3260
- Ala Phe Lys Asp Ala Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg 3265 3270 3275 3280
- Asn Arg Met Arg Th: Ala Thr Gly Leu Lys Leu Pro Ala Thr Leu Val 3285 3290 3295
- Phe Asp Tyr Pro Asn Pro Gln Ala Leu Ala Arg His Leu Arg Asp Glu 3300 3305 3310

- Leu Gly Gly Ala Ala Gln Thr Pro Val Thr Thr Ala Ala Ala Lys Ala 3315 3320 3325
- Asp Leu Asp Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg Leu Pro 3330 3335 3340
- Gly Gly Val Ala Gly Pro Glu Asp Leu Trp Arg Leu Val Ala Glu Gly
  3345 3350 3355 3360
- Arg Asp Ala Val Ser Ser Phe Pro Thr Asp Arg Gly Trp Asp Thr Asp 3365 3370 3375
- Ser Leu Tyr Asp Pro Asp Pro Ala Arg Pro Gly Lys Thr Tyr Thr Arg 3380 3385 3390
- His Gly Gly Phe Leu His Glu Ala Gly Leu Phe Asp Ala Gly Phe Phe 3395 3400 3405
- Gly Ile Ser Pro Arg Glu Ala Val Ala Met Asp Pro Gln Gln Arg Leu 3410 3415 3420
- Leu Leu Glu Ala Ser Trp Glu Ala Met Glu Asp Ala Gly Val Asp Pro 3425 3430 3435 3440
- Leu Ser Leu Lys Gly Asn Asp Val Gly Val Phe Thr Gly Met Phe Gly 3445 3450 3455
- Gln Gly Tyr Val Ala Pro Gly Asp Ser Val Val Thr Pro Glu Leu Glu 3460 3465 3470
- Gly Phe Ala Gly Thr Gly Gly Ser Ser Ser Val Ala Ser Gly Arg Val 3475 3480 3485
- Ser Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Ser Ala 3490 3495 3500
- Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ser Leu Arg

Gln Gly Glu Cys Ser Met Ala Leu Ala Gly Gly Ala Thr Val Met Ala Asn Prc Gly Ala Phe Val Glu Phe Ser Arg Gln Arg Gly Leu Ala Val Asp Gly Arg Cys Lys Ala Phe Ala Ala Ala Ala Asp Gly Thr Gly Trp Ala Glu Gly Val Gly Val Val Ile Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Ile Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Arg Ala Leu Val Ser Ala Gly Leu Ala Pro Ser Asp Val Asp Val Val Glu Ala His Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Lys Asp Arg Glu Ser Pro Leu Tro Leu Gly Ser Leu Lys Ser Asn Ile Gly His Ala Gln Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln Ala Leu Arg

His Glu Val Leu Pro Pro Thr Leu His Val Asp Arg Pro Thr Pro Glu

- Val Asp Trp Ser Ala Gly Ala Val Glu Leu Leu Thr Glu Ala Arg Glu 3715 3720 3725
- Trp Pro Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly 3730 3735 3740
- Val Ser Gly Thr Asn Ala His Leu Ile Leu Glu Glu Ala Pro Ala Glu 3745 3750 3755 3760
- Glu Pro Val Pro Thr Pro Glu Val Pro Leu Val Pro Val Val Val Ser 3765 3770 3775
- Ala Arg Ser Arg Ala Ser Leu Ala Gly Gln Ala Gly Arg Leu Ala Gly 3780 3785 3790
- Phe Val Ala Gly Asp Ala Ser Leu Ala Gly Val Ala Arg Ala Leu Val 3795 3800 3805
- Thr Asn Arg Ala Ala Leu Thr Glu Arg Ala Val Met Val Val Gly Ser 3810 3815 3820
- Arg Glu Glu Ala Val Thr Asn Leu Glu Ala Leu Ala Arg Gly Glu Asp 3825 3830 3835 3840
- Pro Ala Ala Val Val Thr Gly Arg Ala Gly Ser Pro Gly Lys Leu Val 3845 3850 3855
- Trp Val Phe Pro Gly Gln Gly Ser Gln Trp Ile Gly Met Gly Arg Glu 3860 3865 3870
- Leu Leu Asp Ser Ser Pro Val Phe Ala Glu Arg Val Ala Glu Cys Ala 3875 3890 3885
- Ala Ala Leu Glu Pro Trp Ile Asp Trp Ser Leu Leu Asp Val Leu Arg 3890 3895 3900

- Gly Glu Ser Asp Leu Leu Asp Arg Val Asp Val Val Gln Pro Ala Ser 3905 3910 3915 3920
- Phe Ala Met Met Val Gly Leu Ala Ala Val Trp Gln Ser Val Gly Val
  3925 3930 3935
- Arg Pro Asp Ala Val Val Gly His Ser Gln Gly Glu Ile Ala Ala 3940 3945 3950
- Cys Val Ser Gly Ala Leu Ser Leu Gln Asp Ala Ala Lys Val Val Ala 3955 3960 3965
- Leu Arg Ser Gln Ala Ile Ala Thr Arg Leu Ala Gly Arg Gly Gly Met 3970 3980
- Ala Ser Val Ala Leu Ser Glu Glu Asp Ala Thr Ala Trp Leu Ala Pro 3985 3990 3995 4000
- Trp Ala Asp Arg Val Gln Val Ala Ala Val Asn Ser Pro Ala Ser Val
  4005 4010 4015
- Val Ile Ala Gly Glu Ala Gln Ala Leu Asp Glu Val Val Asp Ala Leu 4020 4025 4030
- Ser Gly Gln Glu Val Arg Val Arg Val Ala Val Asp Tyr Gly Ser 4035 4040 4045
- His Thr Asn Gln Val Glu Ala Ile Glu Asp Leu Leu Ala Glu Thr Leu 4050 4060
- Ala Gly Ile Glu Ala Gln Ala Pro Lys Val Pro Phe Tyr Ser Thr Leu 4065 4070 4075 4080
- Ile Gly Asp Trp Ile Arg Asp Ala Gly Ile Val Asp Gly Gly Tyr Trp
  4085 4090 4095
- Tyr Arg Asn Leu Arg Asn Gln Val Gly Phe Gly Pro Ala Val Ala Glu

4100 4105 4110

Leu Val Arg Gln Gly His Gly Val Phe Val Glu Val Ser Ala His Pro 4115 4120 4125

Val Leu Val Gln Pro Leu Ser Glu Leu Ser Asp Asp Ala Val Val Thr 4130 4135 4140

Gly Ser Leu Arg Arg Glu Asp Gly Gly Leu Arg Arg Leu Leu Thr Ser 4145 4150 4155 4160

Met Ala Glu Leu Tyr Val Gln Gly Val Pro Leu Asp Trp Thr Ala Val
4165 4170 4175

Leu Pro Arg Thr Gly Arg Val Asp Leu Pro Lys Tyr Ala Phe Asp His
4190 4185 4190

Arg His Tyr Trp Leu Arg Pro Ala Glu Ser Ala Thr Asp Ala Ala Ser 4195 4200 4205

Leu Gly Cln Ala Ala Ala Asp His Pro Leu Leu Gly Ala Val Val Glu 4210 4215 4220

Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Val Arg
4225 4230 4235 4240

Thr His Pro Trp Leu Ala Asp His Ala Val Gly Gly Val Val Ile Leu 4245 4250 4255

Pro Gly Ser Gly Leu Ala Glu Leu Ala Val Arg Ala Gly Asp Glu Ala 4260 4265 4270

Gly Cys Thr Ala Leu Asp Glu Leu Ile Ile Glu Ala Pro Leu Val Val 4275 4280 4285

Pro Ala Gln Gly Ala Val Arg Val Gln Val Ala Leu Ser Gly Pro Asp 4290 4295 4300 Glu Thr Gly Ser Arg Thr Val Asp Leu Tyr Ser Gln Arg Asp Gly Gly
4305 4310 4315 4320

Ala Gly Thr Trp Thr Arg His Ala Thr Gly Val Leu Ser Thr Ala Pro 4325 4330 4335

Ala Gln Glu Pro Glu Phe Asp Phe His Ala Trp Pro Pro Ala Asp Ala 4340 4345 4350

Glu Arg Ile Asp Val Glu Thr Phe Tyr Thr Asp Leu Ala Glu Arg Gly
4355 4360 4365

Tyr Gly Tyr Gly Pro Ala Phe Gln Gly Leu Gln Ala Val Trp Arg Arg 4370 4375 4380

Asp Gly Asp Val Phe Ala Glu Val Ala Leu Pro Glu Asp Leu Arg Lys
4395 4390 4395 4400

Asp Ala Gly Arg Phe Gly Val His Pro Ala Leu Leu Asp Ala Ala Leu 4405 4410 4415

Gln Ala Ala Thr Ala Val Gly Gly Asp Glu Pro Gly Gln Pro Val Leu
4420 4425 4430

Ala Phe Ala Trp Asn Gly Leu Val Leu His Ala Ala Gly Ala Ser Ala 4435 4440 4445

Leu Arg Val Arg Leu Ala Pro Ser Gly Pro Asp Thr Leu Ser Val Ala 4450 4455 4460

Ala Ala Asp Glu Thr Gly Gly Leu Val Leu Thr Met Glu Ser Leu Val
4465 4470 4475 4480

Ser Arg Pro Val Ser Ala Glu Gln Leu Gly Ala Ala Ala Asp Ala Gly
4485 4490 4495

- His Asp Ala Met Phe Arg Val Asp Trp Thr Glu Leu Pro Ala Val Pro 4500 4505 4510
- Arg Ala Glu Leu Pro Pro Trp Val Arg Ile Asp Thr Ala Asp Asp Val 4515 4520 4525
- Ala Ala Leu Ala Glu Lys Ala Asp Ala Pro Pro Val Val Trp Glu 4530 4535 4540
- Ala Ala Gly Gly Asp Pro Ala Leu Ala Val Ser Ser Arg Val Leu Glu 4545 4550 4555 4560
- Ile Met Gln Ala Trp Leu Ala Ala Pro Ala Phe Glu Glu Ala Arg Leu
  4565 4570 4575
- Val Val Thr Thr Arg Gly Ala Val Pro Ala Gly Gly Asp His Thr Leu 4580 4585 4590
- Thr Asp Pro Ala Ala Ala Ala Val Trp Gly Leu Val Arg Ser Ala Gln 4595 4600 4605
- Ala Glu His Pro Asp Arg Val Val Leu Leu Asp Thr Asp Gly Glu Val
  4610 4615 4620
- Pro Leu Gly Ala Val Leu Ala Ser Gly Glu Pro Gln Leu Ala Val Arg 4625 4630 4635 4640
- Gly Thr Thr Phe Phe Val Pro Arg Leu Ala Arg Ala Thr Arg Leu Ser 4645 4650 4655
- Asp Ala Pro Pro Ala Phe Asp Pro Asp Gly Thr Val Leu Val Ser Gly
  4660 4665 4670
- Ala Gly Ser Leu Gly Thr Leu Val Ala Arg His Leu Val Thr Arg His 4675 4680 4685
- Gly Val Arg Arg Val Val Leu Ala Ser Arg Gln Gly Arg Asp Ala Glu

4690 4695 4700

Gly Ala Gln Asp Leu Ile Thr Glu Leu Thr Gly Glu Gly Ala Asp Val 4705 4710 4715 4720

Ser Phe Val Ala Cys Asp Val Ser Asp Arg Asp Gln Val Ala Ala Leu 4725 4730 4735

Leu Ala Gly Leu Pro Asp Leu Thr Gly Val Val His Thr Ala Gly Val
4740 4745 4750

Phe Glu Asp Gly Val Ile Glu Ala Leu Thr Pro Asp Gln Leu Ala Asn 4755 4760 4765

Val Tyr Aia Ala Lys Val Thr Ala Ala Met His Leu Asp Glu Leu Thr 4770 4775 4780

Arg Asp Arg Asp Leu Gly Ala Phe Val Val Phe Ser Ser Val Ala Gly
4785 4790 4795 4800

Val Met Gly Gly Gly Gln Gly Pro Tyr Ala Ala Ala Asn Ala Phe 4805 4810 4815

Leu Asp Ala Ala Met Ala Ser Arg Gln Ala Ala Gly Leu Pro Gly Leu 4820 4825 4830

Ser Leu Ala Trp Gly Leu Trp Glu Arg Ser Ser Gly Met Ala Ala His 4835 4840 4845

Leu Ser Glu Val Asp His Ala Arg Ala Ser Arg Asn Gly Val Leu Glu
4850 4860

Leu Thr Arg Ala Glu Gly Leu Ala Leu Phe Asp Leu Gly Leu Arg Met 4865 4870 4875 4880

Ala Glu Ser Leu Leu Val Pro Ile Lys Leu Asp Leu Ala Ala Met Arg
4885 4890 4895

Ala Ser Thr Val Pro Val Leu Phe Arg Gly Leu Val Arg Pro Ser Arg
4900 4905 4910

Thr Gln Ala Arg Thr Ala Ser Thr Val Asp Arg Gly Leu Ala Gly Arg
4915 4920 4925

Leu Ala Gly Leu Pro Val Ala Glu Arg Ala Ala Val Leu Val Asp Leu 4930 4940

Val Arg Gly Gln Val Ala Val Leu Gly Tyr Asp Gly Pro Glu Ala 4945 4950 4955 4960

Val Arg Pro Asp Thr Ala Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr
4965 4970 4975

Ser Val Glu Leu Arg Asn Arg Leu Arg Glu Ala Thr Gly Leu Lys Leu 4980 4985 4990

Pro Ala Thr Leu Val Phe Asp Tyr Pro Asn Pro Leu Ala Val Ala Arg 4995 5000 5005

Tyr Leu Gly Ala Arg Leu Val Pro Asp Gly Thr Ala Asn Gly Asn Gly 5010 5020

Asn Gly Asn Gly His Ser Glu Asp Asp Arg Leu Arg His Ala Leu Ala 5025 5030 5035 5040

Ala Ile Ala Ala Glu Asp Ala Gly Glu Glu Arg Ser Ile Ala Asp Leu 5045 5050 5055

Gly Val Asp Asp Leu Val Gln Leu Ala Phe Gly Asp Glu
5060 5065

- (2) INFORMATION FOR SEQ ID NO: 6:
  - (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1721 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Ala Cys Arg Leu Pro Gly Gly Val Thr Gly Pro Gly Asp Leu Trp

1 5 10 15

Arg Leu Val Ala Glu Gly Gly Asp Ala Val Ser Gly Phe Pro Thr Asp
20 25 30

Arg Cys Trp Asp Leu Asp Thr Leu Phe Asp Pro Asp Pro Asp His Ala 35 40 45

Gly Thr Ser Tyr Thr Asp Gln Gly Gly Phe Leu His Asp Ala Ala Leu 50 55 60

Phe Asp Pro Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met 70 75 80

Asp Pro Gln Gln Arg Leu Leu Leu Glu Ala Ser Trp Glu Ala Leu Glu 85 90 95

Gly Val Gly Leu Asp Pro Ala Ser Leu Gln Gly Thr Asp Val Gly Val

Phe Thr Gly Ala Gly Gly Ser Gly Tyr Gly Gly Gly Leu Thr Gly Pro

Glu Met Gln Ser Phe Ala Gly Thr Gly Leu Ala Ser Ser Val Ala Ser

Gly Arg Val Ser Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Gln Gly Asp Cys Ser Met Ala Leu Ala Gly Gly Ala Met Val Met Ser Gly Pro Asp Ser Phe Val Val Phe Ser Arg Gln Arg Gly Leu Ala Thr Asp Gly Arg Cys Lys Ala Phe Ala Ser Gly Ala Asp Gly Met Val Leu Ala Glu Gly Ile Ser Val Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Val Leu Ala Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Ala Ala Leu Ala Asn Ala Gly Ile. Gly Pro Ser Asp Val Asp Leu Val Glu Ala His Gly Thr Gly Thr Ser Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Asp Arg Glu Thr Pro Leu Trp Leu Gly Ser Leu Lys Ser Asn Ile Gly 

- His Thr Gln Ala Ala Gly Val Ala Ser Val Ile Lys Val Val Gln 340 345 350
- Ala Leu Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Glu Pro 355 360 365
- Ser Ser Gln Val Asp Trp Ser Glu Gly Ala Val Glu Leu Leu Thr Gly 370 375 380
- Ser Arg Asp Trp Pro Arg Gly Asp Arg Pro Arg Arg Ala Gly Val Ser 385 390 395 400
- Ser Phe Gly Val Ser Gly Thr Asn Val His Leu Ile Ile Glu Glu Ala 405 410 415
- Pro Glu Glu Pro Ala Ala Ala Val Pro Thr Ser Ala Asp Val Val Pro 420 425 430
- Leu Val Val Ser Ala Arg Ser Thr Gly Ser Leu Ala Gly Gln Ala Asp 435 440 445
- Arg Leu Thr Glu Val Asp Val Pro Leu Gly His Leu Ala Gly Ala Leu 450 455 460
- Val Ala Gly Arg Ala Val Leu Glu Glu Arg Ala Val Val Ala Gly
  465 470 475 480
- Ser Ala Glu Glu Ala Arg Ala Gly Leu Gly Ala Leu Ala Arg Gly Glu 485 490 495
- Ala Ala Pro Gly Val Val Thr Gly Thr Ala Gly Lys Pro Gly Lys Val
- Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp Val Gly Met Gly Arg
  515 520 525

- Glu Leu Leu Asp Ala Ser Pro Val Phe Ala Glu Arg Ile Lys Glu Cys 530 535 540
- Ala Ala Leu Asp Gln Trp Thr Asp Trp Ser Leu Leu Asp Val Leu 545 550 555 560
- Arg Gly Asp Gly Asp Leu Asp Ser Val Glu Val Leu Gln Pro Ala Cys 565 570 575
- Phe Ala Val Met Val Gly Leu Ala Ala Val Trp Glu Ser Ala Gly Val
  580 585 590
- Arg Pro Asp Ala Val Val Gly His Ser Gln Gly Glu Ile Ala Ala 595 600 605
- Cys Val Ser Gly Ala Leu Thr Leu Asp Asp Ala Ala Lys Val Val Ala 610 620
- Leu Arg Ser Gln Ala Ile Ala Ala Arg Leu Ser Gly Arg Gly Met 625 630 635 640
- Ala Ser Val Ala Leu Ser Glu Asp Glu Ala Asn Ala Arg Leu Gly Leu 645 650 655
- Trp Asp Gly Arg Ile Glu Val Ala Ala Val Asn Gly Pro Ala Ser Val
  660 665 670
- Val Ile Ala Gly Asp Ala Gln Ala Leu Asp Glu Ala Leu Glu Val Leu 675 680 685
- Ala Gly Asp Gly Val Arg Val Arg Gln Val Ala Val Asp Tyr Ala Ser 690 695 . 700
- His Thr Arg His Val Glu Asp Ile Arg Asp Thr Leu Ala Glu Thr Leu 705 710 715 720
- Ala Gly Ile Thr Ala Gln Ala Pro Asp Val Pro Phe Arg Ser Thr Val

Thr Gly Gly Trp Val Arg Asp Ala Asp Val Leu Asp Gly Gly Tyr Trp Tyr Arg Asn Leu Arg Asn Gln Val Arg Phe Gly Pro Ala Val Ala Glu Leu Leu Glu Gln Gly His Gly Val Phe Val Glu Val Ser Ala His Pro Val Leu Val Gln Pro Ile Ser Glu Leu Thr Asp Ala Val Val Thr Gly Thr Leu Arg Arg Asp Asp Gly Gly Leu Arg Arg Leu Leu Thr Ser Met Ala Glu Leu Phe Val Arg Gly Val Arg Val Asp Trp Ala Thr Leu Val Pro Pro Ala Arg Val Asp Leu Pro Thr Tyr Ala Phe Asp His Gln His Phe Trp Leu Arg Pro Ala Ala Gin Ala Asp Ala Val Ser Leu Gly Gln Ala Ala Ala Glu His Pro Leu Leu Gly Ala Val Val Arg Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Arg Thr His Pro Trp Leu Ala Asp His Thr Ile Gly Gly Val Val Leu Phe Pro Gly Thr 

Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys Pro

- Val Leu Asp Glu Leu Val Thr Glu Ala Pro Leu Val Val Pro Gly Gln 930 935 940
- Gly Gly Val Asn Val Gln Val Thr Val Ser Gly Pro Asp Gln Asn Gly 945 950 955 960
- Leu Arg Thr Val Asp Ile His Ser Gln Arg Asp Asp Val Trp Thr Arg
- His Ala Thr Gly Thr Val Ser Ala Thr Pro Ala Ser Ser Pro Gly Phe 980 985 990
- Asp Phe Thr Ala Trp Pro Pro Pro Asp Gly Gln Arg Val Glu Ile Gly 995 1000 1005
- Asp Phe Tyr Ala Asp Leu Ala Glu Arg Gly Tyr Ala Tyr Gly Pro Leu 1010 1015 1020
- Phe Gln Gly Val Arg Ala Val Trp Gln Arg Gly Glu Asp Val Phe Ala 1025 1030 1035 1040
- Glu Val Ala Leu Pro Glu Asp Arg Glu Asp Ala Ala Arg Phe Gly
  1045 1050 1055
- Leu His Pro Ala Leu Leu Asp Ala Ala Leu Gln Thr Gly Thr Ile Ala 1060 1065 1070
- Ala Ala Ser Gly Gln Pro Gly Lys Ser Val Met Pro Phe Ser Trp 1075 1080 1085
- Asn Arg Leu Ala Leu His Ala Val Gly Ala Ala Gly Leu Arg Val Arg 1090 1095 1100
- Val Ala Pro Gly Gly Pro Asp Ala Leu Thr Val Glu Ala Ala Asp Glu 1105 1116 1115 1120

ونند

- Thr Gly Ala Pro Val Leu Thr Met Asp Ser Leu Ile Leu Arg Glu Val 1125 1130 1135
- Ala Leu Asp Gln Leu Asp Thr Ala Arg Ala Gly Ser Leu Tyr Arg Val 1140 1145 1150
- Asp Trp Thr Pro Leu Pro Thr Val Asp Ser Ala Val Pro Ala Gly Arg 1155 1160 1165
- Ala Glu Val Leu Glu Ala Phe Gly Glu Glu Pro Leu Asp Leu Thr Gly
  1170 1180
- Arg Val Leu Ala Ala Leu Gln Ala Trp Leu Ser Asp Ala Ala Glu Glu 1185 1190 1195 1200
- Ala Arg Leu Val Val Val Thr Arg Gly Ala Val Pro Ala Gly Asp Gly
  1205 1210 1215
- Val Val Ser Asp Pro Ala Gly Ala Ala Val Trp Gly Leu Val Arg Ala 1220 1225 1230
- Ala Gln Ala Glu Asn Pro Asp Arg Phe Val Leu Leu Asp Thr Asp Gly
  1235 1240 1245
- Glu Val Pro Leu Glu Ala Val Leu Ala Thr Gly Glu Pro Gln Leu Ala 1250 1255 1260
- Leu Arg Gly Thr Thr Phe Ser Val Pro Arg Leu Ala Arg Val Thr Glu 1265 1270 1275 1280
- Pro Ala Glu Ala Pro Leu Thr Phe Arg Pro Asp Gly Thr Val Leu Val 1285 1290 1295
- Ser Gly Ala Gly Thr Leu Gly Ala Leu Ala Ala Arg Asp Leu Val Thr 1300 1305 1310
- Arg His Gly Val Arg Arg Leu Val Leu Ala Ser Arg Arg Gly Arg Ala

1315 1320 1325

Ala Glu Gly Ile Asp Asp Leu Val Ala Glu Leu Thr Gly His Gly Ala 1330 1335 1340

Glu Val Thr Val Ala Ala Cys Asp Val Ser Asp Arg Asp Gln Val Ala 1345 1350 1355 1360

Ala Leu Leu Lys Glu His Ala Leu Thr Ala Val Val His Thr Ala Gly
1365 1370 1375

Val Phe Asp Ala Gly Val Thr Gly Ala Leu Thr Arg Glu Arg Leu Ala 1380 1385 1390.

Lys Val Phe Ala Pro Lys Val Asp Ala Ala Asn His Leu Asp Glu Leu 1395 1400 1405

Thr Arg Asp Leu Asp Leu Asp Ala Phe Ile Val Tyr Ser Ser Ala Ser
1410 1415 1420

Ser Ile Phe Met Gly Ala Gly Ser Gly Gly Tyr Ala Ala Ala Asn Ala 1425 1430 1435 1440

Tyr Leu Asp Gly Leu Met Ala Ala Arg Arg Ala Ala Gly Leu Pro Gly
1445 1450 1455

Leu Ser Leu Ala Trp Gly Pro Trp Glu Gln Leu Thr Gly Met Ala Asp 1460 1465 1470

Thr Ile Asp Asp Leu Thr Leu Ala Arg Met Ser Arg Arg Glu Gly Arg 1475 1480 1485

Gly Gly Val Arg Ala Leu Gly Ser Ala Asp Gly Met Glu Leu Phe Asp 1490 1495 1500

Ala Ala Leu Ala Ala Gly Gln Ala Leu Leu Val Pro Ile Glu Leu Asp 1505 1510 1515 1520

- Leu Arg Glu Val Arg Ala Asp Ala Ala Gly Gly Gly Thr Val Pro Eis 1525 1530 1535
- Leu Leu Arg Gly Leu Val Arg Ala Gly Arg Gln Ala Ala Arg Thr Ala 1540 1545 1550
- Ala Thr Glu Asp Gly Gly Leu Glu Arg Arg Leu Ala Gly Leu Thr Val 1555 1560 1565
- Ala Glu Gln Glu Ala Leu Leu Leu Asp Leu Val Arg Gly Gln Val Ala 1570 1575 1580
- Val Val Leu Gly His Ala Asp Ser Ser Gly Val Arg Ala Asp Ala Ala 1585 1590 1595 1600
- Phe Lys Asp Ala Gly Phe Asp Ser Leu Thr Ser Val Glu Leu Arg Asn 1605 1610 1615
- Arg Leu Arg Glu Thr Thr Gly Leu Lys Leu Pro Ala Thr Leu Val Phe 1620 1625 1630
- Asp His Pro Asn Pro Leu Ala Leu Ala Arg His Leu Arg Ala Glu Leu 1635 1640 1645
- Ala Val Asp Glu Ala Ser Pro Ala Asp Ala Val Leu Ala Gly Leu Ala 1650 1655 1660
- Gly Leu Glu Ala Ala Ile Ala Ala Ala Gly Ala Pro Asp Gly Asp Arg 1665 1670 1675 1680
- Ile Thr Ala Arg Leu Arg Glu Leu Leu Lys Ala Ala Glu Ala Glu 1685 1690 1695
- Ala Arg Pro Gly Thr Ser Gly Asp Leu Asp Thr Ala Ser Asp Glu Glu 1700 1705 1710

Leu Phe Ala Leu Val Asp Gly Leu Asp 1715 1720

- (2) INFORMATION FOR SEQ ID NO: 7:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1688 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: peptide
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Met Ala Cys Arg Tyr Pro Gly Gly Val Ser Ser Pro Glu Asp Leu Trp

1 5 10 15

Arg Leu Val Ala Glu Gly Thr Asp Ala Val Ser Ala Phe Pro Gly Asp
20 25 30

Arg Gly Trp Asp Val Asp Gly Leu Val Asp Pro Asp Pro Asp Arg Pro 35 40 45

Gly Thr Thr Tyr Thr Asp Gln Gly Gly Phe Leu His Glu Ala Gly Leu 50 55 60

Phe Asp Ala Gly Phe Phe Gly Ile Ser Pro Arg Glu Ala Val Ala Met 55 70 75 80

Asp Pro Gln Gln Arg Leu Leu Clu Thr Ser Trp Glu Ala Ile Glu 85 90 95

Arg Thr Gly Thr Asp Pro Leu Ser Leu Lys Gly Ser Asp Ile Gly Val

1.03

Phe Thr Gly Val Ala Ser Met Gly Tyr Gly Ala Gly Gly Val Val Ala Pro Glu Leu Glu Gly Phe Val Gly Thr Gly Ala Ala Pro Cys Ile Ala Ser Gly Arg Val Ser Tyr Val Leu Gly Phe Glu Gly Pro Ala Val Thr Val Asp Thr Gly Cys Ser Ser Ser Leu Val Ala Met His Leu Ala Ala Gln Ala Leu Arg Arg Gly Glu Cys Ser Met Ala Leu Ala Gly Gly Ala Met Val Met Ala Gln Pro Gly Ser Phe Val Ser Phe Ser Arg Gln Arg Gly Leu Ala Leu Asp Gly Arg Cys Lys Ala Phe Ser Asp Ser Ala Asp Gly Met Gly Leu Ala Glu Gly Val Gly Val Ile Ala Leu Glu Arg Leu Ser Val Ala Arg Glu Arg Gly His Arg Val Leu Ala Val Leu Arg Gly Ile Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Ala Ala Leu Ala Glu Ala Gly Leu Ser Pro Ser Asp Val Asp Ala Val Glu Gly His Gly Thr Gly

Thr 305	Thr	Leu	Gly	Asp	Pro 310	Ile	Glu	Ala	Gln	Ala 315	Leu	Leu	Ala	Thr	Tyr 320
Gly	Lys	Gly	Arg	Asp 325	Pro	Glu	Lys	Pro	Leu 330	Trp	Leu	Gly	Ser	Val 335	Lys
Ser	Asn	Leu	Gly 340	His	Thr	Gln	Ala	Ala 345	Ala	Gly	Val	Ala	Ser 350	Val	Ile
Lys	Met	Val 355	Gln	Ala	Leu	Arg	His 360	Gly	Val	Leu	Pro	Pro 365	Thr	Leu	His
Val	Asp 370	Arg	Pro	Ser	The	Glu 375	Val	Asp	Trp	Ser	Ala 380	Gly	Ala	Val	Ser
Leu 385	Leu	Thr	Glu	Ala	Arg 390	Glu	Trp	Pro	Arg	Glu 395	Gly	Arg	Pro	Arg	Arg 400
- רמ	Clar	1751	Ser	Ser	Phe	Glv	Tle	Ser	Glv	Thr	Asn	Ala	His	Leu	Ile

Leu Glu Glu Ala Pro Glu Glu Glu Pro Pro Val Ala Glu Ala Pro Ser 420 425 430

405

410

Ala Gly Val Val Pro Val Val Val Ser Ala Arg Gly Ala Leu Ala Gly
435 440 445

Gln Ala Gly Arg Leu Ala Ala Phe Leu Glu Ala Ser Asp Glu Pro Leu 450 455 460

Val Thr Val Ala Gly Ala Leu Ile Cys Gly Arg Ser Arg Phe Gly Asp 465 470 475 480

Arg Ala Val Val Ala Gly Thr Arg Ala Glu Ala Thr Ala Gly Leu 485 490 495

- Ala Ala Leu Ala Arg Gly Glu Ser Ala Ala Asp Val Val Thr Gly Thr 500 505 510
- Val Ala Ala Ser Gly Val Pro Gly Lys Leu Val Trp Val Phe Pro Gly 515 520 525
- Gln Gly Ser Gln Trp Val Gly Met Gly Arg Glu Leu Leu Glu Ala Ser 530 535 540
- Pro Val Phe Ala Ala Arg Ile Ala Glu Cys Ala Ala Ala Leu Glu Pro 545 550 555 560
- Trp Ile Asp Trp Ser Leu Leu Asp Val Leu Arg Gly Glu Gly Asp Leu 565 570 575
- Asp Arg Val Asp Val Val Gln Pro Ala Ser Phe Ala Val Met Val Gly 580 585 590
- Leu Ala Ala Val Trp Ser Ser Val Gly Val Val Pro Asp Ala Val Leu 595 600 605
- Gly His Ser Gln Gly Glu Ile Ala Ala Ala Cys Val Ser Gly Ala Leu 610 615 620
- Ser Leu Gln Asp Ala Ala Lys Val Val Ala Leu Arg Ser Gln Ala Ile 625 630 635 640
- Ala Ala Lys Leu Ala Gly Arg Gly Gly Met Ala Ser Val Ala Leu Ser 655
- Glu Glu Asp Ala Val Ala Arg Leu Arg His Trp Ala Asp Arg Val Glu 660 665 · 670
- Val Ala Ala Val Asn Ser Pro Ser Ser Val Val Ile Ala Gly Asp Ala 675 680 695
- Glu Ala Leu Asp Gln Ala Leu Glu Ala Leu Thr Gly Gln Asp Ile Arg

	690					695					700					
Val 705	Arg	Arg	Val	Ala	Val 710	Asp	Tyr	Ala	Ser	His 715	Thr	Arg	His	Val	Glu 720	
Asp	Ile	Gln	Glu	Pro 725	Leu	Ala	Glu	Ala	Leu 730	Ala	Gly	Ile	Glu	Ala 735	His	
Ala	Prc	Thr	Leu 740	Pro	Phe	Phe	Ser	Thr 745	Leu	Thr	Gly	Asp	Trp 750	Ile	Arg	
Glu	Ala	Gly 755	Val	Val	qzA	Gly	Gly 760	Tyr	Trp	Tyr	Arg	Asn 765	Leu	Arg	Asn	
Gln	Val 770	Gly	Phe	Gly	Pro	Ala 775	Val	Ala	Glu	Leu	Leu 780	Gly	Leu	Gly	His	
Arg 785	Val	Phe	Val	Glu	Val 790	Ser	Ala	His	Pro	Val 795	Leu	Val	Gln	Ala	Ile 800	
Ser	Ala	Ile	Ala	<b>qzA</b> 208	Asp	Thr	Asp	Ala	Val 210	Val	Thr	Gly	Ser	Leu 815	Arg	
Arg	Glu	Glu	Gly 820	Gly	Leu	Arg	Arg	Leu 825	Leu	Thr	Ser	Met	Ala 830	Glu	Leu	
Phe	Val	Arg 835	Gly	Val	Asp	Val	Asp 840	Trp	Ala	Thr	Met	Val 845	Pro	Pro	Ala	
Arg	Val 250	Asp	Leu	Pro	Thr	Tyr 855	Ala	Phe	Asp	His	Gln 860	His	Tyr	Trp	Leu	
Arg 865	Tyr	Val	Glu	Thr	Ala 870	Thr	Asp	Ala	Ala	Gly 875	Pro	Val	Val	Arg	Leu 880	
Pro	Gln	Thr	Gly	Gly	Leu	Val	Phe	Thr	Thr	Glu	Trp	Ser	Leu	Lys	Ser	

885

- Gln Pro Trp Leu Ala Glu His Thr Leu Glu Asp Leu Val Val Pro 900 905 910
- Gly Ala Ala Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly
  915 920 925
- Thr Pro Val Leu Asp Glu Leu Val Ile Glu Thr Pro Leu Val Val Pro 930 935 940
- Glu Arg Gly Ala Ile Arg Val Gln Val Thr Val Ser Gly Pro Asp Asp 945 950 955 960
- Gly Thr Arg Thr Leu Glu Val His Ser Gln Pro Glu Asp Ala Thr Asp 965 970 975
- Glu Trp Thr Arg His Ala Thr Gly Thr Leu Ser Ala Thr Pro Asp Glu 980 985 990
- Ser Ser Gly Phe Asp Phe Thr Ala Trp Pro Pro Pro Gly Ala Arg Gln 995 1000 1005
- Leu Asp Gly Val Pro Ala Ile Trp Arg Ala Gly Asp Glu Ile Phe Ala 1010 1015 1020
- Glu Val Ser Leu Pro Asp Asp Ala Asp Ala Glu Ala Phe Gly Ile His
  1025 1030 1035 1040
- Pro Ala Leu Leu Asp Ala Ala Leu His Pro Ala Leu Pro Gly Asp Asp 1045 1050 1055
- Gly Leu Thr Gln Pro Met Glu Trp Arg Gly Leu Thr Leu His Ala Ala 1060 1065 1070
- Gly Ala Ser Thr Leu Arg Val Arg Leu Val Pro Gly Gly Phe Leu Glu 1075 1080 1085

Ala Ala Asp Gly Ala Gly Ser Leu Val Val Thr Ala Lys Glu Val Ala 1090 1095 1100

Leu Arg Pro Val Thr Ile Ala Arg Ser Arg Thr Thr Thr Arg Asp Ser 1105 1110 1115 1120

Leu Phe Gln Leu Asn Trp Ile Glu Leu Pro Glu Ser Gly Val Val Ala 1125 1130 1135

Ala Ala Asp Asp Thr Glu Val Leu Glu Val Pro Ala Gly Asp Ser Pro 1140 1145 1150

Leu Ala Ala Thr Ser Arg Val Leu Glu Arg Leu Gln Thr Trp Leu Thr 1155 1160 1165

Glu Pro Glu Ala Glu Gln Leu Val Val Thr Arg Gly Ala Val Pro 1170 1175 1180

Ala Gly Asp Thr Pro Val Thr Asp Pro Ala Ala Ala Ala Val Trp Gly
1185 1190 1195 1200

Leu Val Arg Ser Ala Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu 1205 1210 1215

Asp Thr Asp Gly Glu Val Pro Leu Gly Ala Val Leu Ala Gly Glu 1220 1225 1230

Pro Gln Val Ala Val Arg Gly Thr Ala Leu Tyr Val Pro Arg Leu Ala 1235 1240 1245

Arg Ala Asp Ala Ala Pro Val Ser Gly Leu His Gly Thr Val Leu Val 1250 1255 1260

Ser Gly Ala Gly Val Leu Gly Glu Ile Val Ala Arg His Leu Val Thr 1265 1270 1275 1280

Arg His Gly Val Arg Lys Leu Val Leu Ala Ser Arg Arg Gly Leu Asp

1290

- Ala Asp Gly Ala Lys Asp Leu Val Thr Asp Leu Thr Gly Glu Gly Ala 1300 1305 1310
- Asp Val Ser Val Val Ala Cys Asp Leu Ala Asp Arg Asn Gln Val Ala 1315 1320 1325
- Ala Leu Leu Ala Asp His Arg Pro Ala Ser Val Ile His Thr Ala Gly
  1330 1335 1340
- Val Leu Asp Asp Gly Val Ile Gly Thr Leu Thr Pro Glu Arg Leu Ala 1345 1350 1355 1360
- Lys Val Phe Ala Pro Lys Val Asp Ala Val Arg His Leu Asp Glu Leu 1365 1370 1375
- Thr Arg Asp Leu Asp Leu Asp Ala Phe Val Val Phe Ser Ser Gly Ser 1380 1385 1390
- Gly Val Phe Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala 1395 1400 1405
- Phe Leu Asp Ala Ala Met Ala Ser Arg Arg Ala Ala Gly Leu Pro Gly 1410 1415 1420
- Leu Ser Leu Ala Trp Gly Leu Trp Glu Gln Ala Thr Gly Met Thr Ala 1425 1430 1435 1440
- His Leu Gly Gly Thr Asp Gln Ala Arg Met Ser Arg Gly Gly Val Arg 1445 1450 1455
- Pro Ile Thr Ala Glu Glu Gly Met Ala Leu Phe Asp Thr Ala Leu Gly
  1460 1465 1470
- Ala Gln Pro Ala Leu Leu Val Pro Val Lys Leu Asp Leu Arg Glu Val 1475 1480 1485



Arg Ala Gly Gly Ala Val Pro His Leu Leu Arg Gly Leu Val Arg Ala 

Gly Arg Arg Gln Ala Gln Ala Ala Ser Thr Val Asp Asn Gln Leu Leu 

Gly Arg Leu Ala Gly Leu Gly Ala Pro Glu Gln Glu Ala Leu Leu Val 

Asp Leu Val Arg Gly Gln Val Ala Ala Val Leu Gly His Ala Gly Pro 

Asp Ala Val Arg Ala Asp Thr Ala Phe Lys Asp Ala Gly Phe Asp Ser 

Leu Thr Ser Val Asp Leu Arg Asn Arg Leu Arg Glu Ser Thr Gly Leu 

Lys Leu Pro Ala Thr Leu Ala Phe Asp Tyr Pro Thr Pro Leu Val Leu 

Ala Arg His Leu Arg Asp Glu Leu Gly Ala Gly Asp Asp Ala Leu Ser 

Val Val His Ala Arg Leu Glu Asp Val Glu Ala Leu Leu Gly Gly Leu 

Arg Leu Asp Glu Ser Thr Lys Thr Gly Leu Thr Leu Arg Leu Gln Gly 

Leu Val Ala Arg Cys Asn Gly Val Asn Asp Gln Thr Gly Glu Thr 

Leu Ala Asp Arg Leu Glu Ala Ala Ser Ala Asp Glu Val Leu Asp Phe 

Ile Asp Glu Glu Leu Gly Leu Thr 1685

## (2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3413 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Ala Thr Asp Glu Lys Leu Leu Lys Tyr Leu Lys Arg Val Thr Ala 1 5 10 15

Glu Leu His Ser Leu Arg Lys Gln Gly Ala Arg His Ala Asp Glu Pro 20 25 30

Leu Ala Val Val Gly Met Ala Cys Arg Phe Pro Gly Gly Val Ser Ser 35 40 45

Pro Glu Asp Leu Trp Gln Leu Val Ala Gly Gly Val Asp Ala Leu Ser 50 55 50

Asp Phe Pro Asp Asp Arg Gly Trp Glu Leu Asp Gly Leu Phe Asp Pro 65 70 75 80

Asp Pro Asp His Pro Gly Thr Ser Tyr Thr Ser Gln Gly Gly Phe Leu 95 90 95

Arg Gly Ala Gly Leu Phe Asp Ala Gly Leu Phe Gly Ile Ser Pro Arg

- 171 -

100 105 110

Glu Ala Leu Val Met Asp Pro Gln Gln Arg Val Leu Leu Glu Thr Ser 115 120 125

Trp Glu Ala Leu Glu Asp Ala Gly Val Asp Pro Leu Ser Leu Lys Gly
130 135 140

Ser Asp Val Gly Val Phe Ser Gly Val Phe Thr Gln Gly Tyr Gly Ala 145 150 155 160

Gly Ala Ile Thr Pro Asp Leu Glu Ala Phe Ala Gly Ile Gly Ala Ala 165 170 175

Ser Ser Val Ala Ser Gly Arg Val Ser Tyr Val Phe Gly Leu Glu Gly 180 185 190 "

Pro Ala Val Thr Ile Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile
195 200 205

His Leu Ala Ala Gln Ala Leu Arg Ala Gly Glu Cys Ser Met Ala Leu 210 215 220

Ala Gly Gly Ala Thr Val Met Pro Thr Pro Gly Thr Phe Val Ala Phe 225 230 235 240

Ser Arg Gln Arg Val Leu Ala Ala Asp Gly Arg Ser Lys Ala Phe Ser 245 250 255

Ser Thr Ala Asp Gly Thr Gly Trp Ala Glu Gly Ala Gly Val Leu Val
260 265 270

Leu Glu Arg Leu Ser Val Ala Gln Glu Arg Gly His Arg Ile Leu Ala 275 280 285

Val Leu Arg Gly Ser Ala Val Asn Gln Asp Gly Ala Ser Asn Gly Leu 290 295 300 Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Lys Ala Leu Ala Gly Ala Gly Leu Val Ala Ser Asp Val Asp Val Val Glu Ala His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Gln Gly Arg Glu Arg Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly His Thr Gln Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln Ala Leu Arg His Gly Ala Met Pro Pro Thr Leu His Val Ala Glu Pro Thr Pro Glu Val Asp Trp Ser Ala Gly Ala Val Glu Leu Leu Thr Glu Pro Arg Glu Trp Pro Ala Gly Asp Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Ile Ser Gly Thr Asn Ala His Leu Ile Leu Glu Glu Ala Pro Pro Ala Asp Ala Val Ala Glu Glu Pro Glu Phe Lys Gly Pro Val Pro Leu Val Val Ser Ala Gly Ser Pro Thr Ser Leu Ala Gln Ala Gly Arg Leu Ala Glu Val Leu Ala Ser Gly Gly 



Val Ser Arg Ala Arg Leu Ala Ser Gly Leu Leu Ser Gly Arg Ala Leu
500 505 510

Leu Gly Asp Arg Ala Val Val Ala Gly Thr Asp Glu Asp Ala Val
515 520 525

Ala Gly Leu Arg Ala Leu Ala Arg Gly Asp Arg Ala Pro Gly Val Leu 530 540

Thr Gly Ser Ala Lys His Gly Lys Val Val Tyr Val Phe Pro Gly Gln 545 550 555 560

Gly Ser Gln Arg Leu Gly Met Gly Arg Glu Leu Tyr Asp Arg Tyr Pro
565 570 575

Val Phe Ala Thr Ala Phe Asp Glu Ala Cys Glu Gln Leu Asp Val Cys
580 585 590

Leu Ala Gly Arg Ala Gly His Arg Val Arg Asp Val Val Leu Gly Glu
595 600 605

Val Pro Ala Glu Thr Gly Leu Leu Asn Gln Thr Val Phe Thr Gln Ala 610 615 620

Gly Leu Phe Ala Val Glu Ser Ala Leu Phe Arg Leu Ala Glu Ser Trp 625 630 635 640

Gly Val Arg Pro Asp Val Val Leu Gly His Ser Ile Gly Glu Ile Thr
645 650 655

Ala Ala Tyr Ale Ala Gly Val Phe Ser Leu Pro Asp Ala Ala Arg Ile 660 665 670

Val Ala Arg Gly Arg Leu Met Gln Ala Leu Ala Pro Gly Gly Ala 675 680 685

Met Val Ala Val Ala Ala Ser Glu Ala Glu Val Ala Glu Leu Leu Gly

Asp Gly Val Glu Leu Ala Ala Val Asn Gly Pro Ser Ala Val Val Leu Ser Gly Asp Ala Asp Ala Val Val Ala Ala Ala Arg Met Arg Glu Arg Gly His Lys Thr Lys Gln Leu Lys Val Ser His Ala Phe His Ser Ala Arg Met Ala Pro Met Leu Ala Glu Phe Ala Ala Glu Leu Ala Gly Val Thr Trp Arg Glu Pro Glu Ile Pro Val Val Ser Asn Val Thr Gly Arg Phe Ala Glu Pro Gly Glu Leu Thr Glu Pro Gly Tyr Trp Ala Glu His Val Arg Pro Val Arg Phe Ala Glu Gly Val Ala Ala Ala Thr Glu Ser Gly Gly Ser Leu Phe Val Glu Leu Gly Pro Gly Ala Ala Leu Thr Ala Leu Val Glu Glu Thr Ala Glu Val Thr Cys Val Ala Ala Leu Arg Asp Asp Arg Pro Glu Val Thr Ala Leu Ile Thr Ala Val Ala Glu Leu Phe Val Arg Gly Val Ala Val Asp Trp Pro Ala Leu Leu Pro Pro 

Val Thr Gly Phe Val Asp Leu Pro Lys Tyr Ala Phe Asp Gln Gln His



Tyr Trp Leu Gln Pro Ala Ala Gln Ala Thr Asp Ala Ala Ser Leu Gly 900 905 910

Gln Val Ala Ala Asp His Pro Leu Leu Gly Ala Val Val Arg Leu Pro 915 920 925

Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu Lys Ser His 930 935 940

Pro Trp Leu Ala Asp His Val Ile Gly Gly Val Val Leu Val Ala Gly 945 950 955 960

Thr Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu Ala Gly Cys 965 970 975

Pro Val Leu Glu Glu Leu Val Ile Glu Ala Pro Leu Val Val Pro Asp 980 985 990

His Gly Gly Val Arg Ile Gln Val Val Gly Ala Pro Gly Glu Thr 995 1000 1005

Gly Ser Arg Ala Val Glu Val Tyr Ser Leu Arg Glu Asp Ala Gly Ala 1010 1015 1020

Glu Val Trp Ala Arg His Ala Thr Cly Phe Leu Ala Ala Thr Pro Ser 1025 1030 1035 1040

Gln His Lys Pro Phe Asp Phe Thr Ala Trp Pro Pro Pro Gly Val Glu 1045 1050 1055

Arg Val Asp Val Glu Asp Phe Tyr Asp Gly Leu Val Asp Arg Gly Tyr
1060 1065 1070

Ala Tyr Gly Pro Ser Phe Arg Gly Leu Arg Ala Val Trp Arg Arg Gly
1075 1080 1085

٠,

Asp Glu Val Phe Ala Glu Val Ala Leu Ala Glu Asp Asp Arg Ala Asp 1090 1095 1100

Ala Ala Arg Phe Gly Ile His Pro Gly Leu Leu Asp Ala Ala Leu His
1105 1110 1115 1120

Ala Gly Met Ala Gly Ala Thr Thr Glu Glu Pro Gly Arg Pro Val 1125 1130 1135

Leu Pro Phe Ala Trp Asn Gly Leu Val Leu His Ala Ala Gly Ala Ser 1140 1145 1150

Ala Leu Arg Val Arg Leu Ala Pro Ser Gly Pro Asp Ala Leu Ser Val 1155 1160 1165

Glu Ala Ala Asp Glu Ala Gly Gly Leu Val Val Thr Ala Asp Ser Leu 1170 1175 1180

Val Ser Arg Pro Val Ser Ala Glu Gln Leu Gly Ala Ala Ala Asn His 1185 1190 1195 1200

Asp Ala Leu Phe Arg Val Glu Trp Thr Glu Ile Ser Ser Ala Gly Asp 1205 1210 1215

Val Pro Ala Asp His Val Glu Val Leu Glu Ala Val Gly Glu Asp Pro 1220 1225 1230

Leu Glu Leu Thr Gly Arg Val Leu Glu Ala Val Gln Thr Trp Leu Ala 1235 1240 1245

Asp Ala Ala Asp Asp Ala Arg Leu Val Val Val Thr Arg Gly Ala Val 1250 1255 1260

His Glu Val Thr Asp Pro Ala Gly Ala Ala Val Trp Gly Leu Ile Arg 1265 1270 1275 1280

Ala Ala Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu Asp Thr Asp



1285 1290 1295

- Gly Glu Val Pro Leu Gly Arg Val Leu Ala Thr Gly Glu Pro Gln Thr 1300 1305 1310
- Ala Val Arg Gly Ala Thr Leu Phe Ala Pro Arg Leu Ala Arg Ala Glu 1315 1320 1325
- Ala Ala Glu Ala Pro Ala Val Thr Gly Gly Thr Val Leu Ile Ser Gly
  1330 1335 1340
- Ala Gly Ser Leu Gly Ala Leu Thr Ala Arg His Leu Val Ala Arg His 1345 1350 1355 1360
- Gly Val Arg Arg Leu Val Leu Val Ser Arg Arg Gly Pro Asp Ala Asp 1365 1370 1375
- Gly Met Ala Glu Leu Thr Ala Glu Leu Ile Ala Gln Gly Ala Glu Val 1380 1385 1390
- Ala Val Val Ala Cys Asp Leu Ala Asp Arg Asp Gln Val Arg Val Leu 1395 1400 1405
- Leu Ala Glu His Arg Pro Asn Ala Val Val His Thr Ala Gly Val Leu 1410 1415 1420
- Asp Asp Gly Val Phe Glu Ser Leu Thr Arg Glu Arg Leu Ala Lys Val 1425 1430 1435 1440
- Phe Ala Pro Lys Val Thr Ala Ala Asn His Leu Asp Glu Leu Thr Arg 1445 1450 1455
- Glu Leu Asp Leu Arg Ala Phe Val Val Phe Ser Ser Ala Ser Gly Val 1460 1465 1470
- Phe Gly Ser Ala Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Tyr Leu 1475 1480 1485

Asp Ala Val Val Ala Asn Arg Arg Ala Ala Gly Leu Pro Gly Thr Ser 1490 1495 1500

Leu Ala Trp Gly Leu Trp Glu Gln Thr Asp Gly Met Thr Ala His Leu 1505 1510 1515 1520

Gly Asp Ala Asp Gln Ala Arg Ala Ser Arg Gly Gly Val Leu Ala Ile 1525 1530 1535

Ser Pro Ala Glu Gly Met Glu Leu Phe Asp Ala Ala Pro Asp Gly Leu 1540 1545 1550

Val Val Pro Val Lys Leu Asp Leu Arg Lys Thr Arg Ala Gly Gly Thr 1555 1560 1565

Val Pro His Leu Leu Arg Gly Leu Val Arg Pro Gly Arg Gln Gln Ala 1570 1575 1580

Arg Pro Ala Ser Thr Val Asp Asn Gly Leu Ala Gly Arg Leu Ala Gly
1585 1590 1595 1600

Leu Ala Pro Ala Glu Gln Glu Ala Leu Leu Leu Asp Val Val Arg Thr 1605 1610 1615

Gln Val Ala Leu Val Leu Gly His Ala Gly Pro Glu Ala Val Arg Ala 1620 1625 1630

Asp Thr Ala Phe Lys Asp Thr Gly Phe Asp Ser Leu Thr Ser Val Glu 1635 1640 1645

Leu Arg Asn Arg Leu Arg Glu Ala Ser Gly Leu Lys Leu Pro Ala Thr 1650 1655 1660

Leu Val Phe Asp Tyr Pro Thr Pro Val Ala Leu Ala Arg Tyr Leu Arg 1665 1670 1675 1680 WO 98/07868

- 179 -

Asp Glu Leu Gly Asp Thr Val Ala Thr Thr Pro Val Ala Thr Ala Ala 1685 1690 1695

Ala Ala Asp Ala Gly Glu Pro Ile Ala Ile Val Gly Met Ala Cys Arg 1700 1705 1710

Leu Pro Gly Gly Val Thr Asp Pro Glu Gly Leu Trp Arg Leu Val Arg 1715 1720 1725

Asp Gly Leu Glu Gly Leu Ser Pro Phe Pro Glu Asp Arg Gly Trp Asp 1730 1735 1740

Leu Glu Asn Leu Phe Asp Asp Asp Pro Asp Arg Ser Gly Thr Thr Tyr 1745 1750 1755 1760

Thr Ser Arg Gly Gly Phe Leu Asp Gly Ala Gly Leu Phe Asp Ala Gly 1765 1770 1775

Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln 1780 1785 1790

Arg Leu Leu Glu Ala Ala Trp Glu Ala Leu Glu Gly Thr Gly Val 1795 1800 1805

Asp Pro Gly Ser Leu Lys Gly Ala Asp Val Gly Val Phe Ala Gly Val 1810 1815 1820

Ser Asn Gln Gly Tyr Gly Met Gly Ala Asp Pro Ala Glu Leu Ala Gly 1825 1830 1835 1840

Tyr Ala Ser Thr Ala Gly Ala Ser Ser Val Val Ser Gly Arg Val Ser 1845 1850 1855

Tyr Val Phe Gly Phe Glu Gly Pro Ala Val Thr Ile Asp Thr Ala Cys 1860 1865 1870

Ser Ser Ser Leu Val Ala Met His Leu Ala Gly Gln Ala Leu Arg Gln

( ) 

- 180 -

1875 1880

Gly Glu Cys Ser Met Ala Leu Ala Gly Gly Val Thr Val Met Gly Thr 1890 1895 1900

Pro Gly Thr Phe Val Glu Phe Ala Lys Gln Arg Gly Leu Ala Gly Asp 1905 1910 1915 1920

Gly Arg Cys Lys Ala Tyr Ala Glu Gly Ala Asp Gly Thr Gly Trp Ala 1925 1930 1935

Glu Gly Val Gly Val Val Leu Glu Arg Leu Ser Val Ala Arg Glu 1940 1945 1950

Arg Gly His Arg Val Leu Ala Val Leu Arg Gly Ser Ala Val Asn Ser 1955 1960 1965

Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln 1970 1975 1980

Arg Val Ile Arg Arg Ala Leu Ala Gly Ala Gly Leu Glu Pro Ser Asp 1985 1990 1995 2000

Val Asp Ile Val Glu Gly His Gly Thr Gly Thr Ala Leu Gly Asp Pro 2005 2010 2015

Ile Glu Ala Gln Ala Leu Leu Ala Thr Tyr Gly Lys Asp Arg Asp Pro 2020 2025 2030

Glu Thr Pro Leu Trp Leu Gly Ser Val Lys Ser Asn Phe Gly His Thr 2035 2040 2045

Gln Ser Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln Ala Leu 2050 2055 2060

Arg His Gly Val Met Pro Pro Thr Leu His Val Asp Arg Pro Thr Ser
2065 2070 2075 2080

• 



- Gln Val Asp Trp Ser Ala Gly Ala Val Glu Val Leu Thr Glu Ala Arg
  2085 2090 2095
- Glu Trp Pro Arg Asn Gly Arg Pro Arg Arg Ala Gly Val Ser Ser Phe 2100 2105 2110
- Gly Ile Ser Gly Thr Asn Ala His Leu Ile Ile Glu Glu Ala Pro Ala 2115 2120 2125
- Glu Pro Gln Leu Ala Gly Pro Pro Pro Asp Gly Gly Val Val Pro Leu 2130 2135 2140
- Val. Val Ser Ala Arg Ser Pro Gly Ala Leu Ala Gly Gln Ala Arg Arg 2145 2150 2155 2160
- Leu Ala Thr Phe Leu Gly Asp Gly Pro Leu Ser Asp Val Ala Gly Ala 2165 2170 2175
- Leu Thr Ser Arg Ala Leu Phe Gly Glu Arg Ala Val Val Ala Asp 2180 2185 2190
- Ser Ala Glu Glu Ala Arg Ala Gly Leu Gly Ala Leu Ala Arg Gly Glu 2195 2200 2205
- Asp Ala Pro Gly Leu Val Arg Gly Arg Val Pro Ala Ser Gly Leu Pro 2210 2215 2220
- Gly Lys Leu Val Trp Val Phe Pro Gly Gln Gly Thr Gln Trp Val Gly
  2225 2230 2235 2240
- Met Gly Arg Glu Leu Leu Glu Glu Ser Pro Val Phe Ala Glu Arg Ile
  2245 2250 2255
- Ala Glu Cys Ala Ala Ala Leu Glu Pro Trp Ile Gly Trp Ser Leu Phe 2260 2265 2270

			1		•		
			- .a -				
	N						
				*			
u		-		v			Iz
-			· y				
**		м	* *	, ,			
· ·						i Di	ار بر
×			e e				
* *			• (1)				
·*	Χ						
*							
	1.						
h <u>i</u>				* . * *			
					*		

- 182 -

Asp Val Leu Arg Gly Asp Gly Asp Leu Asp Arg Val Asp Val Leu Gln 2275 2280 2285

Pro Ala Cys Phe Ala Val Met Val Gly Leu Ala Ala Val Trp Ser Ser 2290 2295 2300

Ala Gly Val Val Pro Asp Ala Val Leu Gly His Ser Gln Gly Glu Ile 2305 2310 2315 2320

Ala Ala Cys Val Ser Gly Ala Leu Ser Leu Glu Asp Ala Ala Lys 2325 2330 2335

Val Val Ala Leu Arg Ser Gln Ala Ile Ala Ala Lys Leu Ser Gly Arg 2340 2345 2350

Gly Gly Met Ala Ser Val Ala Leu Gly Glu Ala Asp Val Val Ser Arg 2355 2360 2365

Leu Ala Asp Gly Val Glu Val Ala Ala Val Asn Gly Pro Al Ser Val 2370 2375 2380

Val Ile Ala Gly Asp Ala Gln Ala Leu Asp Glu Thr Leu Glu Ala Leu 2385 2390 2395 2400

Ser Gly Ala Gly Ile Arg Ala Arg Arg Val Ala Val Asp Tyr Ala Ser 2405 2410 2415

His Thr Arg His Val Glu Asp Ile Glu Asp Thr Leu Ala Glu Ala Leu 2420 2425 2430

Ala Gly Ile Asp Ala Arg Ala Pro Leu Val Pro Phe Leu Ser Thr Leu 2435 2440 2445

Thr Gly Glu Trp Ile Arg Asp Glu Gly Val Val Asp Gly Gly Tyr Trp
2450 2455 2460

Tyr Arg Asn Leu Arg Gly Arg Val Arg Phe Gly Pro Ala Val Glu Ala



2465 2470 2475 2480

Leu Leu Ala Gln Gly His Gly Val Phe Val Glu Leu Ser Ala His Pro 2485 2490 2495

- Val Leu Val Gln Pro Ile Thr Glu Leu Thr Asp Glu Thr Ala Ala Val 2500 2505 2510
- Val Thr Gly Ser Leu Arg Arg Asp Asp Gly Gly Leu Arg Arg Leu Leu 2515 2520 2525
- Thr Ser Met Ala Glu Leu Phe Val Arg Gly Val Glu Val Asp Trp Thr 2530 2535 2540
- Ser Leu Val Pro Pro Ala Arg Ala Asp Leu Pro Thr Tyr Ala Phe Asp 2545 2550 2555 2560
- His Glu His Tyr Trp Leu Arg Ala Ala Asp Thr Ala Ser Asp Ala Val 2565 2570 2575
- Ser Leu Gly Leu Ala Gly Ala Asp His Pro Leu Leu Gly Ala Val Val 2580 2585 2590
- Gin Leu Pro Gln Ser Asp Gly Leu Val Phe Thr Ser Arg Leu Ser Leu 2595 2600 2605
- Arg Ser His Pro Trp Leu Ala Asp His Ala Val Arg Asp Val Val Ile 2610 2615 2620
- Val Pro Cly Thr Gly Leu Val Glu Leu Ala Val Arg Ala Gly Asp Glu 2625 2630 2635 2640
- Ala Gly Cys Pro Val Leu Asp Glu Leu Val Ile Glu Ala Pro Leu Val 2645 2650 2655
- Val Pro Arg Gly Gly Val Arg Val Gln Val Ala Leu Gly Gly Pro 2660 2665 2670

WO 98/07868

- 184 -

Ala Asp Asp Gly Ser Arg Thr Val Asp Val Phe Ser Leu Arg Glu Asp
2675 2680 2685

Ala Asp Ser Trp Leu Arg His Ala Thr Gly Val Leu Val Pro Glu Asn 2690 2695 2700

Arg Pro Arg Gly Thr Ala Ala Phe Asp Phe Ala Ala Trp Pro Pro Pro 2705 2710 2715 2720

Glu Ala Lys Pro Val Asp Leu Thr Gly Ala Tyr Asp Val Leu Ala Asp 2725 2730 2735

Val Gly Tyr Gly Pro Thr Phe Arg Ala Val Arg Ala Val Trp
2740 2745 2750

Arg Arg Gly Ser Gly Asn Thr Thr Glu Thr Phe Ala Glu Ile Ala Leu 2755 2760 2765

Pro Glu Asp Ala Arg Ala Glu Ala Gly Arg Phe Gly Ile His Pro Ala 2770 2775 2780


Leu Leu Asp Ala Ala Leu His Ser Thr Met Val Ser Ala Ala Ala Asp 2785 2790 2795 2800

Thr Glu Ser Tyr Gly Asp Glu Val Arg Leu Pro Phe Ala Trp Asn Gly
2805 2810 2815

Leu Arg Leu His Ala Ala Gly Ala Ser Val Leu Arg Val Arg Val Ala 2820 2825 2830

Lys Pro Glu Arg Asp Ser Leu Ser Leu Glu Ala Val Asp Glu Ser Gly
2835 2840 2845

Gly Leu Val Val Thr Leu Asp Ser Leu Val Gly Arg Pro Val Ser Asn 2850 2855 2860





Asp Gln Leu Thr Thr Ala Ala Gly Pro Ala Gly Ala Gly Ser Leu Tyr 2865 2870 2875 2880

Arg Val Asp Trp Thr Pro Leu Ser Ser Val Asp Thr Ser Gly Arg Val 2885 2890 2895

Pro Ser Trp Leu Pro Val Ala Thr Ala Glu Glu Val Ala Thr Leu Ala 2900 2905 2910

Asp Asp Val Leu Thr Gly Ala Thr Glu Ala Pro Ala Val Ala Val Met 2915 2920 2925

Glu Ala Val Ala Asp Glu Gly Ser Val Leu Ala Leu Thr Val Arg Val
2930 2935 2940

Leu Asp Val Val Gln Cys Trp Leu Ala Gly Gly Gly Leu Glu Gly Thr
2945 2950 2955 2960

Lys Leu Ala Ile Val Thr Arg Gly Ala Val Pro Ala Gly Asp Gly Val 2965 2970 2975

Val His Asp Pro Ala Ala Ala Ala Val Trp Gly Leu Val Arg Ala Ala 2980 2985 2990

Gln Ala Glu Asn Pro Asp Arg Ile Val Leu Leu Asp Val Glu Pro Glu 2995 3000 3005

Ala Asp Val Pro Pro Leu Leu Gly Ser Val Leu Ala Asp Gly Glu Pro 3010 3015 3020

Gln Val Ala Val Arg Gly Thr Thr Leu Ser Ile Pro Arg Leu Ala Arg 3025 3030 3035 3040

Ala Ala Arg Pro Asp Pro Ala Ala Gly Phe Lys Thr Arg Gly Pro Val

Leu Val Thr Gly Gly Thr Gly Ser Leu Gly Gly Leu Val Ala Arg His

( · -alika erati erati. \* Tali #0 x . 7 . 4

- 186 -

3060 3065 3070

Leu Val Glu Arg His Gly Val Arg Gln Leu Val Leu Ala Ser Arg Arg 3075 3080 3085

Gly Leu Asp Ala Glu Gly Ala Lys Asp Leu Val Thr Asp Leu Thr Ala 3090 3095 3100

Leu Giy Ala Asp Val Ala Val Ala Ala Cys Asp Val Ala Asp Arg Asp 3105 3110 3115 3120.

Gln Val Ala Ala Leu Leu Thr Glu His Arg Pro Ser Ala Val Val His 3125 3130 3135

Thr Ala Gly Val Pro Asp Ala Gly Val Ile Gly Thr Val Thr Pro Asp 3140 3145 3150

Arg Leu Ala Glu Val Phe Ala Pro Lys Val Thr Ala Ala Arg His Leu 3155 3160 3165

Asp Glu Leu Thr Arg Asp Leu Asp Leu Asp Ser Phe Val Val Tyr Ser 3170 3175 3180


Ser Val Ser Ala Val Phe Met Gly Ala Gly Ser Gly Ser Tyr Ala Ala 3185 3190 3195 3200

Ala Asn Ala Tyr Leu Asp Gly Leu Met Ala His Arg Arg Ala Ala Gly
3205 3210 3215

Leu Pro Gly Gln Ser Leu Ala Trp Gly Leu Trp Asp Gln Thr Thr Gly 3220 3225 3230

Gly Met Ala Ala Gly Thr Asp Glu Ala Gly Arg Ala Arg Met Thr Arg 3235. 3240 3245

Arg Gly Gly Leu Val Ala Met Lys Pro Ala Ala Gly Leu Asp Leu Phe 3250 3255 3260



WO 98/07868

- 187 -

Asp Ala Ala Ile Gly Ser Gly Glu Pro Leu Leu Val Pro Ala Gln Leu 3265 3270 3275 3280

Asp Leu Arg Gly Leu Arg Ala Glu Ala Ala Gly Gly Thr Glu Val Pro 3285 3290 3295

His Leu Leu Arg Gly Leu Val Arg Ala Gly Arg Gln Gln Ala Arg Ala 3300 3305 3310

Ala Ser Thr Val Glu Glu Asn Trp Ala Gly Arg Leu Ala Gly Leu Glu
3315 3320 3325

Pro Ala Glu Arg Gly Gln Val Leu Leu Glu Leu Val Arg Ala Gln Val 3330 3335 3340

Ala Gly Val Leu Gly Tyr Arg Ala Ala His Gln Val Asp Pro Asp Gln 3345 3350 3355 3360

Gly Leu Phe Glu Ile Gly Phe Asp Ser Leu Thr Ala Ile Glu Leu Arg 3365 3370 3375

Asn Arg Leu Arg Ala Arg Thr Glu Arg Lys Ile Ser Pro Gly Val Val 3380 3385 3390

Phe Asp His Pro Thr Pro Ala Leu Leu Ala Ala His Leu Asn Glu Leu 3395 3400 3405

Leu Arg Lys Lys Vai 3410

## (2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 226 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

• ·· · · · · 

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Met Ala Ile Pro Tyr Ser Ser Leu Ala Tyr Glu Leu Arg Asp Ala Val 1 5 10 15

Asn Val Val Asp Leu Asp Glu Asp Asp Val Phe Val Thr Ser Ile Ala 20 25 30

Glu Gly Gln Gly Gly Ala Cys Tyr His Leu Asn Arg Leu Phe His Arg 35 40 45

Leu Leu Thr Glu Leu Gly Tyr Asp Val Thr Pro Leu Ala Gly Ser Thr 50 55 60

Ala Glu Gly Arg Glu Thr Phe Gly Thr Asp Val Glu His Met Phe Asn 65 70 75 80

Leu Val Thr Leu Asp Gly Ala Asp Trp Leu Val Asp Val Gly Tyr Pro
85 90 95

Gly Pro Thr Tyr Val Glu Pro Leu Ala Val Ser Pro Ala Val Gln Thr 100 105 110

Gln Tyr Gly Ser Gln Phe Arg Leu Val Glu Gln Glu Thr Gly Tyr Ala 115 120 125

Leu Gln Arg Arg Gly Ala Val Thr Arg Trp Ser Val Val Tyr Thr Phe 130 135 140

Thr Thr Gln Pro Arg Gln Trp Ser Asp Trp Lys Glu Leu Glu Asp Asn

• ٠. 

- 189 -

 145
 150
 155
 160

 Phe Arg Ala Leu Val 165
 Gly Asp Thr Thr Arg Thr Arg Thr 170
 Thr 170
 Thr 175
 Thr 175

 Leu Cys Gly Arg Ala 180
 Phe Ala Asn Gly Gln Val Phe Leu Arg Gln Arg 190
 190
 Thr 175

 Arg Tyr Leu Thr Val Glu Asn Gly Arg Glu Gln Val Arg Thr Ile Thr

Asp Asp Glu Phe Arg Ala Leu Val Ser Arg Val Leu Ser Gly Asp 210 215 220

200

His Gly 225

.Fol • 

Ciba-Geigy AG CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. IDENTII	FICATION OF THE MICROORGANISM	
Identificati	on reference given by the DEPOSITOR-	Accession number given by the
pRi7-	3	INTERNATIONAL DEPOSITARY AUTHORITY:
		DSM 11114
II. SCIEN	TIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DES	IGNATION
The micros	organism identified under 1, above was accompanied by	
	(X ) a scientific description	
	(X ) a proposed taxonomic designation	
(Mark with	a cross where applicable).	
III. RECEII	PT AND ACCEPTANCE	
This Internal (Date of the	ational Depositary Authority accepts the microorganism identified u e original deposit) <sup>1</sup> .	inder I. above, which was received by it on 1996-08-10
IV. RECEI	PT OF REQUEST FOR CONVERSION	
The microo and a reque for convers	organism identified under I above was received by this International est to convert the original deposit to a deposit under the Budapest Tition).	Depositary Authority on (date of original deposit) realy was received by it on (date of receipt of request
V. INTERN	NATIONAL DEPOSITARY AUTHORITY	
Name:	DENT DELITED TO THE HOLE	
1 - 20 10-2	DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):
Address:	Mascheroder Weg 1b	
	D-38124 Braunschweig	U. Weiles
		Date: 1996-08-14

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the stants of international depositary authority was acquired.

. . . . .. -. -



Ciba-Geigy AG CH-4002 Basel

VIABILITY STATEMENT
ISSUED pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
Identified at the bottom of this page

I. DEPOSI	TOR	II. IDENTIFICATION OF THE MICROORGANISM
	Ciba-Geigy AG CH-4002 Basel	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY  DSM 11114  Usic of the deposit or the transfer  1996-08-10
III. VIABII	LITY STATEMENT	
On that dat  (X	ty of the microorganism identified under II above was tested on 1 see, the said microorganism was  1) viable  1) no longer viable  ITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PER	
V. INTERN	NATIONAL DEPOSITARY AUTHORITY	
Name: Address:	DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)  Date: 1996-08-14

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

Fill in if the information has been requested and if the results of the test were negative.

Form DSMZ-BP/9 (sole page) 0196



Novartis AG

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. IDENTIFICATION OF THE NECROORGANISM

Identification reference given by the DEPOSITOR.

pRi44-2

Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY

DSM 11655

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I, above was accompanied by:

(X) a scientific description

(X) a proposed taxonomic designation

(Mark with a cross where applicable).

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under 1. above, which was received by it on 1997-07-14 (Date of the original deposit).

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to conven the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name:

DSMZ-DEUTSCHE SAMMLUNG VON

MIKROORGANISMEN UND ZELLKULTUREN GmbH

Address:

Mascheroder Weg 1b

D-38124 Braunschweig

Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)

U. Weils

Date 1997-07-15

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

Novartis AG CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

	TOR	
	Novartis AG CH-4002 Basel	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 11655  Date of the deposit or the transfer'  1997-07-14
III. VIABII	LITY STATEMENT	
The viabili On that da	ry of the microorganism identified under II above was tested on e, the said microorganism was	1997-07-14 <sup>3</sup> .
(X	')' viable	
,	) no longer viable	
	ITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN F	ERFORMED'
IV. COND		ERFORMED'
IV. COND	ITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN F	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

Fill in if the information has been requested and if the results of the test were negative.

Form DSMZ-BP/9 (sole page) 0196

		f	•	
				",
	**************************************	·		
	·			
14)	es es		»·	
		•		
	*			
w).				
	- m -			
	-he			
	<i>A</i>	25.00		•
	and the second s		· · ·	
		,		
•		•		
		•		
	% <u>.</u>			
				· · · · · · · · · · · · · · · · · · ·
				المري الأساد
				*
	*	7.		•
	(A)			ď.
				.ស.វិ - 0
		× ×		
		e Year		
		A STATE OF THE STA		- 15
and the second second				
:			. 0.	
			•	•
-				
				e to
				أَنْ اللهِ
			**************************************	
		•••	· ·	*
			- 1	
			(A)	5 .
				- 3
				Te-
	e	т и		10
•	V s.	** \(\frac{1}{2} \)	* 1	
	•			
	•			
	91 - FF			
			· ·	
are.	* . *			Ψ.
is the second second	(C)			
14.				-3.
- 1 mm	The state of the s	_ S		

14 C C C

4

Novartis AG

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Signature(s) of person(s) having the power to represent the

International Depositary Authority or of authorized official(s).

U Weils

Date. 1997-07-15

I. IDENTIFICATION OF THE MICROORGANISM Identification reference given by the DEPOSITOR: Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY pNE95 DSM 11656 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I above was accompanied by: (X) a scientific description (X) a proposed taxonomic designation (Mark with a cross where applicable). III. RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1997-07-14 (Date of the original deposit). IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion). V. INTERNATIONAL DEPOSITARY AUTHORITY

Form DSMZ-BP/4 (sole page) 0196

Mascheroder Weg 1b

D-38124 Braunschweig

DSMZ-DEUTSCHE SAMMLUNG VON

MIKROORGANISMEN UND ZELLKULTUREN GmbH

Name:

Address:

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

Novartis AG

CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bonom of this page

Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY  DSM 11656  Date of the deposit or the transfer 1997-07-14
DSM 11656  Date of the deposit or the transfer!  1997-07-14
1997-07-14
997-07-14 '
997-07 <b>-14</b> '.
RFORMED'
Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)
U. We's
Date: 1997-07-15

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

Fill in if the information has been requested and if the results of the test were negative.

Form DSMZ-BP/9 (sole page) 0196

-Υ<sub>0</sub> 

Novartis AG

CH-4002 Basel

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

Date: 1997-07-15

I. IDENTIFICATION OF THE MICROORGANISM Identification reference given by the DEPOSITOR: Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: pNE112 DSM 11657 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION The microorganism identified under I. above was accompanied by: (X) a scientific description (X) a proposed taxonomic designation (Mark with a cross where applicable). III. RECEIPT AND ACCEPTANCE This International Depositary Authority accepts the microorganism identified under 1, above, which was received by it on 1997-07-14 (Date of the original deposit)1. IV. RECEIPT OF REQUEST FOR CONVERSION The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion). V. INTERNATIONAL DEPOSITARY AUTHORITY Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s). MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b U. Wals D-38124 Braunschweig

Form DSMZ-BP/4 (sole page) 0196

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

Ċ. . . . . 

.

Novartis AG

CH-4002 Basel

VIABILITY STATEMENT issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name Novartis AG Address. CH-4002 Basel	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY  DSM 11657  Date of the deposit or the transfer 1997-07-14
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on On that date, the said microorganism was  (X) <sup>3</sup> viable  ( ) <sup>1</sup> no longer viable	1997-07-14 1.
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN I	PERFORMED'
V. INTERNATIONAL DEPOSITARY AUTHORITY	·
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg Ib D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s)  Date: 1997-07-15

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

Fill in if the information has been requested and if the results of the test were negative.

Form DSMZ-BP/9 (sole page) 0196

			an an	
s w			-	
			· ,	
	e english			
	e english			
	e english			

## What is claimed is:

- 1. A DNA fragment from the genome of Amycolatopsis mediterranei which comprises a DNA region which is involved directly or indirectly in the gene cluster responsible for rifamycin synthesis, including the adjacent DNA regions to the right and left which, by reason of their function in connection with rifamycin biosynthesis, qualify as constituent of this rifamycin gene cluster; and functional fragments, derivatives or constituents thereof.
- 2. A DNA fragment according to claim 1, which is directly or indirectly involved in the gene cluster responsible for rifamycin synthesis.
- 3. A DNA fragment according to claim 1, which comprises sequence portions which code for a polyketide synthase or an enzymatically active domain thereof.
- 4. A DNA fragment according to claim 1, which comprises SEQ ID NO 1 or SEQ ID NO 3 or at least 15 consecutive nucleotides therefrom.
- 5. A DNA fragment according to claim 1, wherein said fragment comprises one or more of the partial nucleotide sequences depicted in SEQ ID NOS 1 and/or 3, or functional fragments thereof, and all other DNA sequences in the vicinity of this sequence which can, by reason of homologies which are present, be regarded as structural or functional equivalents and are therefore able to hybridize with this sequence.
- 6. A DNA fragment according to claim 1, wherein said fragment comprises a nucleotide sequence selected from the group consisting of ORF A, B, C, D, E and F or functional fragments thereof, or encodes one or more of the proteins or polypeptides, or functional derivatives thereof, depicted in SEQ ID NOS 4 to 9.
- 7. A method for identifying, isolating and cloning a DNA fragment according to claim 1.

.

·

- 8. A method according to claim 7, which comprises the following steps:
  - setting up of a genomic gene bank,
  - screening of this gene bank with the assistance of the DNA sequences according to the invention, and
  - isolation of the clones identified as positive.
- 9. The use of a DNA fragment according to claim 1 in the production of ansamycins or precursors thereof; including those in which the aliphatic bridge is connected only at one end to the aromatic nucleus.
- 10. The use of a DNA fragment according to claim 1 in the production of rifamycin, rifamycin analogues or precursors thereof.
- 11. The use of a DNA fragment according to claim 1 for inactivating or modifying genes of ansamycin biosynthesis.
- 12. The use of a DNA fragment according to claim 1 for inactivating or modifying genes of rifamycin biosynthesis, or the biosynthesis of rifamycin analogues.
- 13. The use of a DNA fragment according to claim 1 for constructing mutated actinomycetes strains from which the natural rifamycin or ansamycin biosynthesis gene cluster in the chromosome has been partly or completely deleted.
- 14. The use of DNA fragments according to claim 1 for assembling a library of polyketide synthases.
- 15. The use of the polyketide synthases according to claim 14 for assembling a library of polyketides.
- 16. A polyketide synthase from *Amycolatopsis mediterranei* which is directly or indirectly involved in rifamycin synthesis; and functional constituents or domains thereof.

- 17. The use of the polyketide synthase according to claim 16 for synthesizing ansamycins.
- 18. The use of polyketide synthases according to claim 14 for synthesizing a library of ansamycins.
- 19. A hybrid vector comprising a DNA fragment according to claim 1.
- 20. A hybrid vector comprising an expression vector comprising a DNA fragment according to claim 1.
- 21. A host organism comprising a hybrid vector according to claim 19.
- 22. A hybridization probe comprising a DNA fragment according to claim 1.
- 23. The use of the hybridization probe according to claim 22 for identifying DNA fragments involved in the biosynthesis of ansamycins.

. .. . 

A. CLASSIFICATION OF SUBJECT IPC 6 C12N15/52 C12N15/70

TION OF SUBJECT TER 12N15/52 C12P17/18 12N15/70 C1201/68

C12P17/10

C12N97-00

C12N1/21

-----

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum decumentation searched relassification system followed by classification symbols: IPC 6 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical search terms used)

Calegory	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	LAL, R. ET AL: "Rifamycins: strain improvement program" CRIT. REV. MICROBIOL. (1995), 21(1), 19-30 CODEN: CRVMAC;ISSN: 1040-841X, XP000615990 see the whole document	1
Y	MADON J ET AL: "TRANSFORMATION SYSTEM FOR AMYCOLATOPSIS -MEDITERRANEI DIRECT TRANSFORMATION OF MYCELIUM WITH PLASMID DNA."  J BACTERIOL 173 (20). 1991. 6325-6331. CODEN: JOBAAY ISSN: 0021-9193. XP000615993 see the whole document	1
<b>A</b>	WO 87 03907 A (LUBRIZOL GENETICS INC) 2 July 1987 see claims	1

Special categories of cried documents  "A" document defining the general state of the art which is not considered to be of particular relevance.	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.		
"E" earlier document but published on or after the international thing date "L" document which may throw doubts on priority claim(s) or	X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taxen alone.		
which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance, the claimed invertion cannot be considered to involve an inventive step when the		
<ul> <li>"O" document reterring to an oral disclosure, use, exhibition or other means.</li> </ul>	document is combined with one or more other such docu- ments, such combination being obvious to a person skilled in the art.		
"P" document published prior to the international filing date but later than the priority data claimed	"3" document member of the same patent family		
Oate of the actual completion of theinlernational search	Date of mailing of the international search report		
7 January 1998	13/01/1998		
Name and mailing address of the ISA	Authorized officer		
European Patent Office P B 5818 Patentiaan 2 NL - 2280 HV Rijswijk Feit (+31-70) 340-2040. Tx 31 651 epo ni Fax (+31-70) 340-3016	Delanghe, L		

1

Y Further documents are listed in the continuation of box C

Patent family members are fisted in annex

Information on patent family members

PCT/FP	97/04495
FUI/EF	7// 04473

Patent document cited in search report	Publication gate	Patent fa	Publication date
WO 8703907 A	02-07-87	AU 598516 B AU 6835487 A EP 0262154 A EP 0463707 A	28-06-90 15-07-87 06-04-88 02-01-92
WO 9508548 A	30-03-95	US 5672491 A AU 678058 B AU 7731794 A CA 2171629 A EP 0725778 A JP 9505983 T	30-09-97 15-05-97 10-04-95 30-03-95 14-08-96 17-06-97

## INTERNATIONAL SEARCH REPORT

tr. ational Application No

Catagory	Citation of document, with indication where appropriate, of the relevant passages	Refevant to claim No
Α	WO 95 08548 A (UNIV LELAND STANFORD JUNIOR ; JOHN INNES CENTRE (GB)) 30 March 1995 see claims	1

